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The fetal heart rate has been utilized as a method of determination of
fetal well-being since the late 19th century, both antenatally as well as
intrapartum. Prenatal detection of disorders in fetal heart rhythm
should be examined in a specialized center as they may be life-threate-
ning. Methods for detailed examination of the fetal heart rhythm
include Doppler and M-mode echocardiography and fetal magnetocar-
diography (FMCG). These methods are described in Part I of this thesis
for the purpose of the detailed diagnosis of fetal tachycardia. Aspects
of the consequences of fetal tachycardia, the necessity for prenatal
treatment and the choice of specific drugs are discussed in Part I.
Evaluation of the fetal heart rhythm by means of a direct electrode is
possible during labour through an electrode attached to the presen-
ting fetal part. A single lead fetal ECG (FECG) is derived and specific
intervals on the ECG can be investigated. Changes in RR intervals and
in T waves are used clinically to detect fetal hypoxia and asphyxia. The
QT interval, a measure of repolarization and cardiac electrical stability,
may provide additional information on the physiology and condition of
the fetal myocardium. The influence of intrapartum hypoxia on the QT
interval of the FECG is presented in Part II of this thesis.
Part I
Fetal Tachycardia
The normal fetal heart rate ranges are approximately 120-160 bpm at
30 weeks and 110-150 bpm at term 1, 2. Frequencies up to 170 bpm are
considered mildly abnormal, whereas overt tachycardia is usually defi-
ned as a heart rate exceeding 170 bpm 1 or 180 bpm 3. Fetal tachycardia
was first recognized in 1930 by Hyman et al. 4 and is a condition that
occurs in 0,4-0,6 % of all pregnancies 5.
In the extrauterine situation, rhythm disorders are usually detected by
a surface ECG. Atrial depolarization, resulting in atrial contraction, is
shown as the P wave on the ECG. The electrical impulse is delayed in
the atrioventricular (AV) node and consequently conducted to the ven-
tricles, where the depolarization of the ventricles results in the QRS
complex. Repolarization of the ventricles results in the T wave.
However, attempts to derive an adequate fetal ECG have thusfar failed,
due to interference from the maternal ECG. In the absence of a reliable
fetal ECG, other modes of investigating the fetal cardiac rhythm are
being used. The development of Doppler and M-mode echocardiogra-
phy have greatly improved the knowledge on rhythm disorders in the
fetus 6-9. The real time image of the fetal heart, motions of the cardiac
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chambers and flow dynamics can actually be considered a mechanical
and dynamic ECG 3. Fetal tachycardias are thus divided by M-mode
echocardiography in supraventricular tachycardia (SVT), atrial flutter
(AF) and ventricular tachycardia (VT), depending on the site of origin.
This will be further discussed in chapter 2 and 3. A detailed examina-
tion of the M-mode echocardiography however, can result in further
differentiation in type of tachycardia.
Aim 1 
Further delineation of fetal tachycardia by detailed examination of M-
mode echocardiography: diagnosis of persistent junctional reciprocating
tachycardia in the fetus (Chapter 3)
The development of new techniques in the diagnosis of fetal tachycar-
dia is ongoing, with fetal magnetocardiography as its most recent and
promising addition. Fetal magnetocardiography is a technique that
records the magnetic field generated by the electrical activity of the
fetal heart 10. Detection occurs non-invasively by sensors cooled by
liquid helium positioned several centimeters above the maternal
abdomen in a magnetically shielded room. As the maternal heart
generates magnetic activity as well, a maternal ECG is recorded simul-
taneously and substracted from the FMCG. This way, an averaged one
lead FMCG is obtained which allows for a more detailed differentiation
of the type of tachycardia 10-12.
Aim 2
Diagnosis of specific types of fetal tachycardia by fetal magnetocardio-
graphy (Chapter 2)
Consequences of fetal tachycardia
Fetal tachycardia may hemodynamically compromise the fetus,
through ventricular dysfunction and dilatation, secondary atrioventri-
cular valve regurgitation and fetal hydrops. This may ultimately lead to
fetal death. Congestive heart failure is usually defined if fluid accumu-
lation exists in the fetal body, such as pericardial effusion, pleural effu-
sion, ascites or skin edema. Fetal hydrops is usually defined if fluid
accumulation exists in 2 or more of these compartments. It is unclear
which factors play a role in the occurrence of hydrops and it is difficult,
if not impossible, to determine the likelihood of the development of
hydrops in a particular case. These factors and their possible use in cli-
nical practice will be discussed in more detail in chapter 4 and 5.
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Fluid accumulation occurs in the amniotic fluid compartment as well,
resulting in polyhydramnios. This predisposes the fetus to preterm deli-
very and neonatal complications of prematurity 13.
Fetal tachycardia may also result in neurological damage 14-17. The
cerebrovascular autoregulation that ensures adequate cerebral perfu-
sion during postnatal life does not function adequately in the distres-
sed newborn and most probably also not in distressed fetuses. A dis-
turbance in rhythm resulting in hemodynamic compromise predisposes
the fetus to cerebral ischemia in periods of moderate hypotension and
to intracranial hemorrhage in periods of moderate hypertension 15.
Although this has been described in several case-reports, little is
known on the outcome of the group hydropic fetuses as a whole.
Aim 3
Neurological follow-up of children who were treated for fetal tachycar-
dia complicated by hydrops (Chapter 4)
Treatment
The decision to initiate pharmacological intervention in the case of
fetal tachycardia depends on several factors and must be weighed
against possible maternal and/or fetal adverse effects inherent to the
use of antiarrhythmics. Although prenatal treatment in advanced cases
of fetal tachycardia is widely accepted, the necessity for treatment in
milder cases is still a point of discussion 18, 19. The necessity for treat-
ment will be discussed in chapter 5. However, in the absence of reliable
predictors of adverse outcome of fetuses, most centers have opted for
initiation of treatment as soon as the diagnosis of fetal tachycardia
has been established.
Several treatment protocols have been developed, in which different
modes of pharmacological intervention, indirect (transplacental,
through oral or intravenous maternal therapy) or direct (intra-umbili-
cal, intra-amniotic, intra-peritoneal and intra-muscular fetal therapy)
have been proposed.
Aim 4
Review of the literature on pharmacological intervention of fetal tachy-
cardia (Chapter 5)
The optimal treatment protocol however, has not yet been designed
and the search for other effective drugs continues. Sotalol is a potent
Bèta-blocking agent with additional class III antiarrhythmic properties
and a mild to absent negative inotropic effect 20, 21. It has proven to be
12
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safe and efficacious in the treatment of tachycardia in adulthood 22, 23
and infancy 24-26. Based on these findings, we hypothesized that sota-
lol could be a safe and effective antiarrhythmic agent for the treat-
ment of various forms of fetal tachycardia. The success of transplacen-
tal treatment of fetal tachycardia depends largely on the transplacen-
tal passage, maternal pharmacokinetics and pharmacodynamics of the
administered drug, influenced by various physiologic changes in preg-
nancy. These properties of sotalol are therefore also investigated.
Aim 5
To investigate the transplacental pharmacokinetics, pharmacodynamics,
effectiveness and safety of sotalol in the treatment of fetal tachycardia
(Chapter 6 and 7)
Part II
Fetal ECG in labour, aspects of the intrapartum QT interval
The evaluation of the electrophysiology of the fetal heart through a
direct electrode is for the first time feasible during labour. Fetal ECG
(FECG) analysis has formed the basis for electronic fetal monitoring for
decades. So far the FECG assessment has been limited to RR interval
measurements only. Among other time constants, the relationship
between PR and RR intervals has also been extensively investigated. A
PR shortening with RR lengthening is present during clinical FHR dece-
lerations and bradycardia 27 and experimental hypoxia 28. Clinically,
these measurements are not of additional value 29. The morphology of
the FECG including the ST segment and T wave configuration has been
shown to provide specific and clinically useful information of fetal car-
diovascular adaptation to experimental hypoxia and as an adjunct to
standard FHR monitoring in labour 30-32.
The last interval of the ECG complex, the QT interval, has been the sub-
ject of many studies in the neonate, during infancy and adulthood, as a
prolonged QT interval, either genetic or acquired, predisposes to ventri-
cular tachycardia and to recurrent (pre-) syncope or sudden cardiac
death 33-36. The genetic origin of this arrhythmia lies in malfunctioning
myocardial ion channels as a result of mutations in genes encoding
these ion channels. The aqcuired form may be the result of drug thera-
py, myocardial infarction or cardiomyopathy. The QT interval is a dyna-
mic parameter and is subject to different physiological processes.
Many studies have shown changes in its properties in situations of
13
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exercise, stress, infection and heart failure among others 37-43. The
dynamics of the QT interval during labour are unknown as the techno-
logy to measure this interval was not available until recently. The deve-
lopment of the STAN® technology, designed to perform analysis of the
fetal ST waveform to improve fetal surveillance, has provided us with
the means of evaluation of specific features on the fetal ECG, including
the QT interval. We hypothesized that the QT interval on the FECG,
representive of repolarization, could provide information on the phy-
siology of the fetal myocardium and may provide additional informa-
tion on the fetal myocardial adaptation to the ultimate stress of 
labour 44.
Aim 6
The evaluation of the effects of hypoxia and asphyxia on the fetal QT
interval (Chapter 9 and 10)
14
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Introduction
Fetal tachycardia, first recognized in 1930 by Hyman et al 1, is a condi-
tion occurring in approximately 0,4-0,6% of all pregnancies 2. The
necessity of therapeutic intervention in this condition is still a matter
of discussion focused on the natural history of the disease. The spec-
trum of opinions varies from non-intervention 3-5 based on a number
of cases in which the tachycardia subsided spontaneously 6, to aggres-
sive pharmacotherapeutic intervention 7, 8 based on reports of deterio-
ration of the fetal condition ultimately ending in significant neurologi-
cal morbidity 9-11 or fetal demise 12-14. Prenatal treatment through
indirect, maternally administered drug therapy seems to be the prefe-
rence of most centers 15-21.
The choice of the specific pharmacotherapeutic agents and the chan-
ces on success of therapy depend largely on the type of tachycardia.
The determination of the type of tachycardia is therefore of the
utmost importance 20, 22, however, the available diagnostic armamen-
tarium is limited. The most widely used method of diagnosis of fetal
tachycardia, M-mode echocardiography, provides a time related docu-
mentation of function of the various cardiac structures. The current
subdivision in supraventricular tachycardia (SVT), atrial flutter (AF) and
ventricular tachycardia (VT) derived from M-mode echocardiography is
not sufficient enough for differentiation according to the electrophy-
siologic mechanism. Several attempts have been made in the last years
to increase the accuracy and reliability of M-mode echocardiography by
measurement of atrioventricular (AV) and ventriculoatrial (VA) inter-
vals 23, 24 and the addition of Doppler echocardiography 25. New
methods registrating the actual electrophysiologic events in the fetus
are in development including noninvasive techniques such as
magnetocardiography 26 and direct intrapartum techniques such as
the ST-analyzer (STAN®, Neoventa Medical, Gothenburg, Sweden) 27, 28.
Characteristics of the most common types of fetal tachycardia are
described and examples of M-mode echocardiography and FMCG are
presented.
22
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Definitions of tachycardia
The normal fetal heart rate ranges are approximately 120-160 bpm at
30 weeks and 110-150 bpm at term 29, 30. Frequencies up to 170 bpm
are considered mildly abnormal, whereas overt tachycardia is usually
defined as a heart rate exceeding 170 bpm 29 or 180 bpm 22. These
rhythm abnormalities of the fetus are usually noticed at routine prena-
tal visits. Fetal echocardiography is used to exclude structural cardiac
and used to position the M-mode sampling line to intercept both the
atrial and ventricular walls. The relationship between peak atrial and
ventricular systolic excursions currently provides a division in SVT, AF
and VT.
Fetal magnetocardiography, a technique recording the magnetic field
generated by the electrical activity of the fetal heart 26, offers a more
precise delineation of the fetal electrophysiology. Detection occurs
non-invasively by sensors cooled by liquid helium positioned several
centimeters above the maternal abdomen in a magnetically shielded
room. As the maternal heart generates magnetic activity as well, a
maternal ECG is recorded simultaneously and substracted from the
fetal MCG. This way, an averaged one lead fetal MCG is obtained and
allows for a more detailed differentiation of the type of tachycardia.
Premature Atrial Contractions
Premature atrial contractions (PAC’s) do not qualify as a form of fetal
tachycardia, and are associated with good outcome. However, in
approximately 0,4 % of cases, it may progress to runs of tachycardia
and even become persistent. It is therefore recommended that these
patients are monitored weekly by doptone to exclude the presence of
runs of tachycardia 12, 16. M-mode echocardiography will show prema-
ture atrial contractions not followed by a ventricular contraction and a
subsequent ‘drop’ in heart rate (Figure 1).
23
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Figure 1
M-mode echocardiography of a premature atrial contraction (PAC).
The FMCG will show a premature P-wave not followed by a QRS com-
plex (Figure 2).
Figure 2
FMCG of a PAC (black arrow).
Atrial Flutter 
AF is a condition that accounts for approximately 21 – 50 % of fetal
tachycardia and may be associated with structural abnormalities 14, 21,
31. It is defined as an atrial rate ranging from 250 up to 500 bpm with a
fixed or variable AV block, as the AV-node is not able to conduct every
24
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contraction of the atrium which results in a 2:1 or 3:1 conduction to the
ventricles. Rarely in some cases paroxysmal 1:1 conduction is seen. It
may be either paroxysmal or incessant in nature and is reported to be
associated with fetal hydrops in 7 – 43 % of cases 14, 18, 31, 32. The most
common electrophysiologic mechanism in AF is a re-entry circuit confi-
ned to the atrium. M-mode echocardiography will show typical atrial
contractions that are followed by ventricular contractions every 2 or 3
atrial contractions (Figure 3).
Figure 3
M-mode echocardiography of AF. Flutter contractions of the atrium are indicated by the
small arrows; atrioventricular conduction is 2:1 and ventricular contractions are indicated
by the large arrows. (RA = right atrium, LV = left ventricle)
FMCG will show typical flutter waves (P-waves) followed by QRS com-
plexes every 2-3 P-waves (Figure 4.1).
Figure 4.1
Raw FMCG trace of atrial flutter with 2:1 conduction.
25
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Figure 4.2
Averaged FMCG trace of atrial flutter with 2:1 conduction.
Transplacental pharmacological intervention with digoxin is reported
to be successful in 45 % 31 , with sotalol 63 %, reaching 79 % after the
addition of digoxin 21.
26
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Supraventricular tachycardia
SVT is reported to account for 47 – 68 % of cases of fetal tachycardia 14,
18, 21 and is associated with a low percentage of structural abnormali-
ties in 2 % of cases. It is defined by a 1:1 atrioventricular conduction in
which the atrial contraction precedes the ventricular contraction.
Heart rates in SVT most commonly range from 200-300 bpm, is either
paroxysmal or incessant in nature and associated with fetal hydrops in
36 - 64 % 14, 33. The condition has several different underlying electro-
physiologic mechanisms, such as re-entry using an accessory atrioven-
tricular connection (AVRT), which may be either apparent or concealed.
Other possibilities include primary atrial tachycardias and re-entry
within the AV node 34.
The diagnosis of these specific types of fetal tachycardia is difficult, if
not impossible, with the most widely used current technology, M-mode
echocardiography. As mentioned in the introduction, several studies
have been conducted to allow for a more specified diagnosis using
Doppler and M-mode echocardiography. These techniques are based on
the relationship in time between atrial and ventricular wall excursions
on M-mode, and flow patterns over the AV and semilunar valve orifi-
ces. In most re-entry tachycardias, conduction through the accessory
connection is fast, as in the Wolff-Parkinson-White syndrome (WPW).
This results in a short RP interval on the postnatal ECG, comparable to
a short VA interval on M-mode (Figure 5.1). In several patients, slow
conduction is observed in the accessory pathway, as in Persistent
Junctional Reciprocating Tachycardia (PJRT) resulting in a long RP inter-
val on the ECG, comparable to a long VA interval on M-mode echocar-
diography (Figure 5.2). In the literature there has been one case diagno-
sed as JET by Doppler echocardiography 35. It is extremely rare and we
have not encountered JET in the prenatal situation at our center.
27
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Figure 5.1
M-mode echocardiography of a SVT with a short VA interval. First white line placed on the
peak excursion of the left atrium wall, second line placed on the peak excursion of the right
ventricle wall, third line on the consecutive peak atrial wall excursion. The AV interval is
markedly longer than the VA interval.
Figure 5.2
M-mode echocardiography of a SVT with a long VA interval.
The detailed electrophysiological events however, are irretrievable by M-
mode echocardiography. Specific types of fetal tachycardia have been
detected and published using FMCG 36-38. A more detailed configuration,
comparable to the postnatal ECG is obtained. An example of this category
of fetal SVT’s is shown in Figure 6.
28
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Figure 6
FMCG of a fetal SVT, the RR interval is 260 ms, FHR = 231 bpm
The electrophysiologic events are clearly defined in this situation,
however, a precise diagnosis is still debatable. The SVT shown in Figure
6 for instance, may be AVRT using a concealed accessory pathway, but
could also be attributed to represent a PJRT.
Ventricular Tachycardia
VT in the prenatal situation is rare and has only been reported occa-
sionally in the international literature 5, 16. It is usually paroxysmal in
nature and outcome depends on the electrophysiologic mechanism. Of
the utmost importance is the diagnosis of the congenital Long QT syn-
drome (LQTS). The origin of this arrhythmia lies in malfunctioning myo-
cardial ion channels as a result of mutations in genes encoding these
ion channels. It is characterised by prolongation of the QT interval and
the occurrence of polymorphic ventricular arrhythmia (such as torsade
de pointes). Patients with the LQTS are predisposed to ventricular fibril-
lation and sudden death 39, 40. The prenatal diagnosis is focused on
fetuses of mothers with prolonged QT syndrome to document the pos-
sible presence of this syndrome in the fetus. In addition, in fetuses pre-
29
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senting with (baseline) bradycardia or intermittent ventricular tachy-
cardia of the torsade de pointe type, the diagnosis of LQTS must be
considered as well, as spontaneous mutations have been reported. The
suspicion of fetal LQTS may be raised in case M-mode echocardiogra-
phy shows (baseline) bradycardia varying from 60-110 bpm and inter-
mittent ventricular tachycardia in which there is atrioventricular disso-
ciation. FMCG shows a prolonged QT interval (Figure 7), and the possi-
ble presence of intermittent VT 38.
Figure 7
The QT interval is 319 ms, RR interval is 430 ms, QTc interval is 486 ms.
A prolonged QT interval may be detected during labour with STAN®
(Figure 8) and identify fetuses predisposed to LQTS. A postnatal ECG is
warranted in these cases to confirm these findings during labour.
30
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Figure 8
Fetal ECG during labour. The QT interval at 120 bpm is 357 ms, corresponding to a QTc inter-
val of 504 ms.
Discussion
Fetal tachycardia is a rare disorder, in which difficulties are en-
countered in the diagnosis of the exact underlying electrophysiological
mechanism and is therefore probably underreported.
The spectrum of pathologic symptomatology varies from an infrequent
paroxysmal tachycardia to a persistent form, which may deteriorate in
fetal hydrops, neurological morbidity and even fetal demise. The pre-
sence of fetal tachycardia therefore deserves more attention and requi-
res a specialized evaluation to define its electrophysiologic diagnosis.
Fetal atrial flutter is a frequently encountered form of fetal tachycardia
and can be well diagnosed by either M-mode echocardiography or
FMCG. This type of tachycardia has all the symptomatic properties
described above and therefore deserves pharmacological intervention.
Numerous agents have been described, but in our opinion sotalol
medication seems to provide the best clinical result 21. Fetal SVT
remains the most complicated form of fetal tachycardia, both in diag-
nosis as in treatment. The difficulty in delineating an accurate diagno-
sis of the specific form and the relative therapy resistance of the
various subtypes of this tachycardia, for instance PJRT, makes the deve-
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lopment of an optimal treatment protocol complicated.
The most infrequent encountered form of tachycardia is fetal VT,
however, if present, it has very serious implications for the fetus. In
utero management is complicated and yields a limited success but it is
also predictive for an uncertain future after birth. Improved prenatal
diagnostic techniques may support a better understanding of the
pathophysiology, but does not necessarily result in an improved outco-
me.
Implications of technical developments for prenatal 
diagnosis and treatment
FMCG is still in an ongoing phase of development, but it is clear that
specific subtypes of tachycardias can be diagnosed by the technique
and its development will undoubtedly have a great impact on the clas-
sification of fetal tachycardias. The task ahead contains several
aspects:
• The classification and identification of the characteristics of each spe-
cific subtype of tachycardia in the prenatal period. Important features
are the risk on congestive heart failure, development of fetal hydrops,
response to different antiarrhythmics and outcome. Normal values of
the intervals on the MCG in the fetus will have to be obtained from
large studies, to allow for the accurate diagnosis of for instance the
long QT syndrome.
• Comparative studies on the treatment of specific subtypes of fetal
tachycardia will have to be performed, by preference in the setting of
multicentre trials, in order to identify the optimal antiarrhythmic
agent for each subtype of tachycardia.
• The development of a specific treatment protocol for each specific sub-
type of fetal tachycardia.
In addition to FMCG, the interpretation of the fetal ECG in labour
(STAN® ) may provide the clinician with valuable information on the
electrophysiology of the fetal heart. Besides its purpose in fetal moni-
toring, it may have additional value in identifying fetuses with a pre-
disposition to the LQTS.
Studies on these new techniques will hopefully result in a further
reduction of morbidity and mortality in the field of fetal tachycardia.
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Abstract
Background
Persistent junctional reciprocating tachycardia (PJRT) tends to be a per-
sistent arrhythmia and requires aggressive therapeutic management.
Diagnosis and management of this infrequently occurring tachycardia
in the fetus at an early stage is of importance for the prevention of
congestive heart failure (CHF).
Methods 
A retrospective study of four fetuses with supraventricular tachycardia
(SVT) of the PJRT type was performed.
Results
All had sustained SVT (mean of 228 bpm) at a mean gestational age of
34+5 weeks, with CHF present in two. Three fetuses had prenatal char-
acteristics of PJRT on M-mode echocardiography with a ventriculo-
atrial (VA)/ atrio-ventricular ratio >1 on M-mode echocardiography sug-
gesting a slow conducting accessory pathway. All four fetuses had
postnatal confirmation of the diagnosis. Transplacental treatment with
flecainide was effective in one patient, sotalol as a single drug or in
combination with digoxin was partially effective in the remaining
three. Two developed sinus rhythm, with short intermittent periods of
tachycardia and decreasing signs of CHF, one case showed a minimal
decrease in heart rate. Oral propranolol therapy converted two patients
postnatally, in the remaining two patients radiofrequency ablation was
performed at the age of 5 months and 6 years.
Conclusions
The characteristics of our prenatal PJRT cases include a sustained heart
rate not exceeding 240 bpm with a long VA interval, presence of CHF
and therapy resistance. Transplacental treatment should be initiated,
possibly with a combination of sotalol and digoxin in nonhydropic
cases, or flecainide, especially in case of fetal hydrops. Pharmacological
therapy is to be preferred postnatally, but radiofrequency ablation
seems indicated in therapy resistant cases with CHF, even in the first
months of life.
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Introduction
Persistent or permanent junctional reciprocating tachycardia (PJRT),
originally described by Coumel et al. in 1967 1, is an infrequent form of
re-entrant supraventricular tachycardia (SVT) in which retrograde con-
duction occurs via a slowly, decrementally conducting concealed acces-
sory pathway, frequently located near the coronary sinus orifice. The
electrocardiogram (ECG) is characterized by an often incessant tachy-
cardia at a rate of 120-250 beats per minute (in infancy and adulthood)
with inverted P waves in the inferior leads and a P-R interval shorter
than the R-P interval, consistent with slow retrograde conduction. PJRT
tends to be unresponsive to most antiarrhythmic agents and is asso-
ciated with tachycardia induced cardiomyopathy 2,3. Although the ori-
ginal reports deal with adult patients, it has also been described in the
pediatric age group 3. More recently, techniques have been described to
assist in the prenatal diagnosis of this arrhythmia 4. This technique
allows for a more specific differentiation of the diagnosis of tachycar-
dia in utero by M-mode echocardiography than has been reported pre-
viously 5-11.
Although some reports exist on fetuses diagnosed with supraventricu-
lar tachycardia that proved to be PJRT postnatally 9, 12, 13, little is known
about the characteristics of prenatally diagnosed PJRT. This retrospecti-
ve study reports on 4 fetuses diagnosed with supraventricular tachy-
cardia of the PJRT type. Characteristics and outcomes are reviewed and
suggestions as to management are made.
Methods
This retrospective study includes 4 out of 30 mothers presenting with
fetuses referred for supraventricular tachycardia to the University
Hospital of Utrecht, the Netherlands.
Definitions of supraventricular tachycardia
Supraventricular tachycardia is a condition with several different
underlying mechanisms. The most common mechanism in infancy is
re-entry using an accessory atrioventricular connection, other less com-
mon possibilities include primary atrial tachycardias and re-entry wit-
hin the AV node 14. In most re-entry tachycardias, conduction through
the accessory connection is fast, as in the Wolff-Parkinson White syn-
drome (WPW), resulting in a short RP interval on the ECG and a short
VA interval on the prenatal M-mode echocardiography. However, in a
39
Persistent Junctional Reciprocating Tachycardia in the Fetus
portion of patients slow conduction is observed in the accessory path-
way, such as in PJRT. This results in a long RP interval with a shorter PR
interval on the ECG, consistent with a long VA interval on the prenatal
M-mode echocardiography. In primary atrial tachycardia, such as atrial
ectopic tachycardia (AET), the primary focus of the tachycardia lies
within the atria, resulting in a P wave  preceding the QRS wave and
therefore a short PR interval and a longer RP interval as is observed in
PJRT. In tachycardias with re-entry within the AV-node there is no con-
sistent 1:1 relationship between the atria and ventricles and periods of
AV dissociation are present.
Prenatal situation
The patients underwent echocardiographic monitoring for approxima-
tely 30 minutes, reviewing the mechanism of tachycardia by M-mode
echocardiography, measuring heart rates, reviewing or monitoring
signs of congestive heart failure and evaluating the general condition
of the fetus. Fetal tachycardia was defined as a ventricular heart rate
exceeding 180 beats per minute (bpm). Fetuses with atrial flutter
(defined as an atrial rate > 250 bpm with a fixed or variable AV block,
resulting in a variable ventricular response), or tachycardia with atrio-
ventricular dissociation were excluded from this study. On the M-mode
echocardiography, the ventriculo-atrial (VA) and atrioventricular (AV)
intervals, analogous to the RP and PR intervals of the extrauterine ECG,
were measured at peak atrial and ventricular systolic excursions. Slow
conduction was concluded from a long VA interval and defined by a
VA/AV ratio above 1 as described by Jaeggi et al. 4 (Figure 1). PJRT was
considered a possible cause of the tachycardia in case of 1:1 atrioventri-
cular conduction with slow conduction through the retrograde path-
way. Congestive heart failure was diagnosed if fluid accumulation exis-
ted in the fetal body, such as pericardial effusion, pleural effusion, asci-
tes or skin edema. Fetal hydrops was diagnosed if fluid accumulation
existed in 2 or more of these compartments.
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Figure 1.
Fetal M-mode echocardiography, through the four chamber view.
Above are the contractions of the atrium and below the contractions of the ventricles. The
ventriculo-atrial (VA) and atrioventricular (AV) intervals, analogous to the RP and PR inter-
vals of the extrauterine ECG, are measured at peak atrial and ventricular systolic excur-
sions. Measurements show a short AV interval and a long VA interval, consistent with slow
retrograde conduction through the accessory pathway, as is seen in PJRT.
Prenatal treatment
After establishing the diagnosis of fetal SVT and after evaluation of the
maternal ECG for possible abnormalities, the first fetus was treated
through oral maternal flecainide at a G.A. of 31 weeks initiated in a
dosage of 75 mg 2x/day, which was increased to 100 mg 3x/day. The 3
following fetuses were treated according to a newly installed protocol
with oral maternal sotalol 160 mg 2x/day and the addition of digoxin
in case rhythm control was not achieved 11. Fetuses were regularly
monitored during treatment, varying from two to three times a week.
Postnatal situation
All patients were delivered in the hospital and postnatal ECG’s were
performed. Characteristics of PJRT on the postnatal ECG include an
often incessant tachycardia at a rate of 120-250 beats per minute with
inverted P waves in the inferior leads and a P-R interval shorter than
the R-P interval. The definite diagnosis of PJRT was made by invasive
electrophysiologic study (EPS) 15. Follow-up, consisting of three to six
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monthly out-patient visits with ECG and echocardiographic investiga-
tions, was obtained in all cases. Holter investigations were performed
at least once in every patient.
Results
Case reports
Case 1 
A mother presented with a fetus at 31 weeks of gestation with a
sustained tachycardia at 240 bpm. Upon presentation no signs of con-
gestive heart failure were encountered and treatment was initiated
with oral maternal flecainide 75 mg 2 times per day, but had to be
increased to 100 mg 3 times per day before the heart rate dropped to
150 bpm, 48 hours after the dosage increase. The conversion to sinus
rhythm remained, which allowed a decrease in the dosage of flecainide
to 100 mg 2 times per day until delivery. Tachycardia did not re-occur
during the prenatal period and at 38+3 weeks of gestation, a healthy
boy of 2530 gram was born with good Apgar scores. The postnatal ECG
showed a regular sinus rhythm at 140 bpm and since no recurrences
were noted, no antiarrhythmic prophylaxis was given. Follow-up inclu-
ding ECG’s and echocardiography did not reveal any tachycardias and
the patient was discharged from follow-up, at one year of age.
At 6 years of age, the patient presented with intermittent, long-stan-
ding periods of tachycardia for more than two weeks, with heart rates
up to 150 bpm present in rest. The patient did not seem to notice these
periods and did not show any symptoms or signs. The ECG showed a
narrow QRS tachycardia, with long RP and shorter PR interval, periods
of tachycardia ended abruptly and the QRS complex was not followed
by a retrograde P wave. The echocardiogram showed a dilated left ven-
tricle. Electrophysiologic study (EPS) showed decremental VA conduc-
tion via a posteroseptal pathway and ultimately confirmed the diagno-
sis of PJRT. The accessory pathway was ablated with radiofrequency
ablation and the follow-up ECG showed a sinus rhythm of 72 bpm, with
positive P waves in leads I and II and a normal PR interval. The left ven-
tricular end diastolic diameter as percentage (LVEDD%) before the pro-
cedure was 48 (body weight of 26 kg ~ > p97), compared to 35.5, two
weeks after the procedure, while the left ventricular fractional shorte-
ning as percentage (LVFS%) before the procedure, 23, improved to 39 at
two weeks after the ablation. The patient remains without signs or
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symptoms related to PJRT at 2 years of follow-up and no more periods
of tachycardia were noted. Holter investigations in this period did not
reveal any periods of tachycardia.
Case 2 
A mother presented with a fetus at 36+1 weeks of gestation with a
sustained SVT at 230 bpm and a VA/AV ratio of approximately 5. Upon
presentation no signs of congestive heart failure were noted and treat-
ment was initiated with sotalol 80 mg 3x/day. This resulted in only a
minimal decrease in heart rate to 215 bpm and the dosage was
increased to 160 mg 2x/day three days later without significant result.
The fetus was delivered by caesarean section at a gestational age of 37
weeks. A healthy boy of 3340 gram was born with Apgar scores of 9/9.
Postnatal ECG showed short runs and intermittent periods of tachycar-
dia with heart rates jumping from 110 to 210 bpm (Figure 2). Despite
the initiation of digoxin (7 mcg/kg /day 2x/day) and the addition of fle-
cainide (5 mg 3x/day) to the treatment, short and longer lasting
periods of tachycardia remained. Only after the addition of propranolol
(1 mg 4x/day), the intermittent tachycardia was controlled thirteen
days after delivery. The boy was discharged in sinus rhythm with medi-
cations consisting of digoxin 15 mcg 2x/day, flecainide 5 mg 3x/day and
propranolol 1 mg 4x/day. Despite these medications tachycardia of 180
bpm was noted again at the age of 5 months. Moreover, echocardio-
graphic evaluation showed dilated cardiomyopathy. Invasive EPS
showed decremental VA conduction via a posteroseptal accessory path-
way. Radiofrequency ablation was performed and although the patient
showed a brief transient period of first degree AV block, the patient
was discharged in sinus rhythm without medication. The LVEDD% befo-
re the procedure was 30 (body weight of 6 kg ~ >p97), compared to 20,
one week after the procedure, while the LVFS%, before the procedure,
20%, improved to 45% at one week. Follow-up, consisting of clinical,
holter and telemetry investigations at one week, six weeks, three
months and subsequently every six months after ablation showed no
signs or symptoms of recurring tachycardia. The patient is in sinus
rhythm and doing well at 2,5 years of age.
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Figure 2.
An ECG performed on the first day of life. Sinus rhythm is interrupted by a short run of
tachycardia. Negative P-waves are seen in aVF and a shorter PR than RP interval, consistent
with PJRT.
Case 3 
A mother with a fetus at 35+2 weeks of gestation presented with a
sustained fetal SVT at 232 bpm and a VA/AV ratio of 1,25. There were
signs of developing fetal hydrops, pleural and pericardial effusion were
present. Sotalol was initiated at 80 mg 2x/day, though at 36 weeks G.A.
tachycardia still remained. The maternal level of sotalol at that time
was 0,9 mg/l (therapeutic range of 0,9 – 2,5 mg/l) and sotalol was
increased to 160 mg 2x/day. At 37+3 weeks G.A. the fetus heart rate
showed persisting normal sinus rhythm of 130-132 bpm. Signs of
hydrops disappeared and the sotalol therapy was continued at 160 mg
2x/day. At the beginning of labour at 39+1 weeks gestation the cardio-
tocography recording showed a recurrence of the fetal tachycardia at
230 bpm, interrupted by periods with a sinus rhythm of 130 bpm. A boy
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of 4270 gram was born with Apgar scores of 8/9. A postnatal ECG
showed sinus rhythm of 130 bpm. During the first day of life the
patient developed a tachycardia twice, with heart rates of 220 to 240
bpm, with PJRT characteristics on the surface ECG. These episodes
were terminated by the diving reflex, induced by facial immersion in
cold water, and oral digoxin (5 mcg/kg 2x/day) was initiated. Since no
more periods of tachycardia were noted the patient was discharged on
oral digoxin 5 mcg/kg 2x/day and remained in sinus rhythm, until the
patient was readmitted with a sustained tachycardia at 240 bpm at 7
months of age. The patient regained sustained sinus rhythm after the
addition of propranolol (5 mg 3x/day ~ 2 mg/kg/day). The patient is
doing well on this combined treatment at the age of 1,5 year.
Case 4 
A mother with a fetus at 31+2 weeks of gestation presented with sustai-
ned fetal tachycardia at 210 bpm, a VA/AV ratio of 3,33 (figure 1) and a
small amount of pericardial effusion. Sotalol (160 mg 2x/day) was ini-
tiated and three days later the heart rate dropped to 186 bpm without
pericardial effusion. Sotalol was increased to 160 mg po 3x per day and
digoxin was added at 0,125 mg po 2x per day which resulted in sinus
rhythm at 133 bpm. Sinus rhythm persisted on this medication until
35+5 weeks G.A, at which time the heart rate relapsed into tachycardia
with a rate at 180 bpm. The maternal digoxin level at that time was 0,5
(therapeutic level 0,9-2,0) and the dosage of digoxin was
increased to 0,125 mg 3x/day. Sinus rhythm at 164 bpm was achieved
within one week on this medication. At 39 weeks G.A. a caesarean sec-
tion was performed because of a breech presentation. A girl of 2735
gram was born with good Apgar scores of 9/10. Postnatal ECG showed
a recurrent tachycardia with a long RP interval and a heart rate at 193
bpm. Intravenous adenosine terminated the tachycardia by antero-
grade block in the AV node, confirming the 1:1 AV relationship, and the-
reby excluding atrial ectopic tachycardia as a cause for the tachycardia.
A re-entrant tachycardia with a slowly decrementally conducting
accessory pathway lead therefore to the confirmation of a PJRT. Oral
propranolol therapy (3 mg 3x/day ~ 3 mg/kg/day) was initiated and
increased (4 mg 3x/day), but the tachycardia persisted at rates around
180-190 bpm at 41 days after delivery. The echocardiogram did not
reveal any abnormalities in the first week of life and at day of life 20.
At 41 days after delivery, however, the echocardiogram started to show
a decreasing left ventricular function with a LVEDD of 23 mm (body
weight of 3900 g ~ p97), compared to 19 mm two weeks in advance.
Radiofrequency ablation was therefore considered until the patient
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suddenly converted to sinus rhythm at 132 bpm for the first time post-
natally. The patient remains in sinus rhythm on propranolol 10 mg
2x/day and is currently doing well at 1 year of age.
Discussion
PJRT is a type of tachycardia, that due to its incessant nature, is asso-
ciated with tachycardia induced cardiomyopathy 2, 3, 16. The literature
reports that the tachycardia can be diagnosed in adults, children and
usually can be recognized in early childhood 3, 17. Our data show that
PJRT can be diagnosed during the prenatal period but that therapeutic
pharmacological intervention remains complicated.
Prenatal diagnosis of PJRT 
In the absence of a reliable fetal ECG, M-mode echocardiography is the
most commonly used method of diagnosis in fetal arrhythmias. The
problem with this technique is that the exact nature of the arrhythmia
remains unrevealed, although several methods have been proposed to
increase the accuracy and reliability of M-mode echocardiography to
diagnose fetal arrhythmias 4, 18. These methods are of particular inte-
rest in differentiating re-entry SVT’s through measuring the atrioven-
tricular (AV) and ventriculoatrial (VA) interval. Dividing these intervals
results in a VA/AV ratio, which is a measure of the conduction proper-
ties through eventual retrograde accessory pathways. The finding of a
long VA interval can make the assumption of fetal PJRT, although atrial
ectopic tachycardia can also show a long VA interval. Other types of
supraventricular tachycardia may show a long RP interval, such as junc-
tional ectopic tachycardia (JET), however, in JET there is no constant 1:1
AV association. Sinus tachycardia may also show a long RP interval, but
is excluded in these cases with heart rates exceeding 200 bpm. The
definite diagnosis of PJRT therefore requires additional assessment
techniques, currently only available in the postnatal setting.
A small but persistent and difficult to treat group of fetal tachycardias,
postnatally proven to be PJRT’s, have been described in previous reports
from our center by van Engelen et al. 9 and Oudijk et al. 10. The above
described technique has allowed us to define this group intra-uterine
as probable PJRT’s. Although this is a step in the right direction, future
techniques such as fetal magnetocardiography, in which the magnetic
field produced by electrical currents in the fetal heart is measured in a
noninvasive way 19, may allow even further and more definitive deline-
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ation of the fetal arrhythmic problems 20, 21. This technique possibly
provides a way to define the electrophysiologic mechanism of the
tachycardia in a prenatal setting and is therefore of potential interest
in the detailed diagnosis of fetal arrhythmias.
Characteristics of fetal PJRT
The mean peak fetal heart rates encountered in our PJRT cases, ranging
from 210 –240 bpm, differ from the ones reported previously 9, 10, in
which heart rates ranged from 200-300 bpm with a mean of 260 bpm.
This is consistent with the slow conduction properties of the accessory
pathway of PJRT.
Another characteristic observed in our cases of fetal PJRT is the inces-
sant nature of the tachycardia. In all our cases, the tachycardia was
sustained, whereas in SVT cases with a short VA interval or fetal atrial
flutter, intermittent periods of sinus rhythm are more frequently
observed as we have reported previously 9, 10.
The incessant nature of PJRT makes the heart vulnerable to congestive
heart failure as can be found in children and adults 2, 3. In half of the
cases, signs of congestive heart failure were noted upon presentation
in fetal life, consistent with a publication by Jaeggi et al 4. Congestive
heart failure disappeared in both cases after the administration of
antiarrhythmics, although at this point intermittent periods of tachy-
cardia were still noted, which may suggest a positive role of periods of
sinus rhythm on the diminishment of heart failure.
Therapy and therapy resistance
Data from patients treated with antiarrhythmics in the postnatal
period show a high therapy resistance of this type of SVT 3, 9. Similarly,
prenatal treatment of long VA SVT’s is difficult 4, 11, 12. In case 1 the fetus
was successfully treated with oral maternal flecainide, however, after a
report by Simpson et al. 7 on fetal death possibly caused by flecainide,
we abandoned flecainide from early inclusion in our therapy protocol
and replaced it by sotalol. As reported previously, in some cases, sotalol
has also been associated with fetal demise. However, this was the case
in SVT patients complicated by severe hydrops and we therefore deci-
ded to stay with our protocol with sotalol as drug of first choice, which
has remained successful in most of our patients since our published
results 10, 11. Flecainide however, remains an option in patients with sig-
nificant fetal hydrops.
The following three cases have shown limited success in fetal PJRT,
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with sotalol as single therapy in two cases and additional digoxin in
one case, reaching results ranging from a decrease in heart rate to
achieving periods of sinus rhythm, although recurrence of intermittent
periods of tachycardia occurred in all. Additional data from literature
are scarce, since most centers do not differentiate between short and
long VA SVT. Jaeggi et al. 4 treated three fetuses with long VA tachy-
cardia with digoxin, which failed in all three; addition of sotalol resul-
ted in a conversion into a sinus rhythm in two fetuses. One of the
responders to sotalol died in utero as a result of severe secondary car-
diomyopathy with generalized hydrops indicating the seriousness of
longstanding VA tachycardia. The other two fetuses had postnatal con-
firmation of PJRT.
In summary, data from our cases and those from Jaeggi et al. show
that 2 fetuses were treated with sotalol as a single therapy of whom
one converted to sinus rhythm and 4 fetuses were treated with a com-
bination of sotalol and digoxin of whom 3 converted to sinus rhythm.
One case was treated successfully by flecainide, which makes one won-
der if despite negative reports on this drug 7, 22 the treatment by fle-
cainide in case of fetal PJRT should not be advocated, especially since
congestive heart failure is frequently encountered in fetal PJRT. In cases
not complicated by fetal hydrops, a combination of sotalol and digoxin
might still be useful.
Postnatal period
All 4 patient reverted into the tachycardia after birth sooner or later
and belong to the group of patients requiring significant (more than 1)
postnatal medications. Congestive heart failure is more common at a
younger age, possibly connected to the faster heart rate in PJRT noted
at these ages compared to PJRT in older patients, according to
Dorostkar et al 3. Therefore, our center has opted for antiarrhythmic
drug therapy (propranolol 3 mg/kg/day) in the first instance, but, in
case of developing signs of congestive heart failure despite multiple
antiarrhythmic medications, we consider these patients to be potential
candidates for early ablation of the accessory pathway 16, 23.
Conclusions
The finding of a long VA interval in case of 1:1 AV association on M-
mode echocardiography in the prenatal period is highly suggestive of
fetal PJRT, however, fetal AET is also a possibility, though not observed
at our center. Other characteristics of fetal PJRT observed in our cases
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include a heart rate not exceeding 240 bpm, usually in a sustained
manner, the frequent presence of congestive heart failure and therapy
resistance. Therefore, we feel that in case fetal PJRT is suspected, a
more aggressive approach as to treatment is necessary. It is our opi-
nion that in the absence of congestive heart failure sotalol combined
with digoxin might still be the treatment of choice, but especially in
the presence of congestive heart failure, a more aggressive approach
such as flecainide might be desirable. In the postnatal period, our cen-
ter has opted for antiarrhythmic drug therapy (propranolol 3
mg/kg/day) in the first instance, but, in case of developing signs of
congestive heart failure despite multiple antiarrhythmic medication,
we consider these patients to be potential candidates for early abla-
tion of the accessory pathway.
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Abstract
Background
Fetal tachycardia is a condition associated with congestive heart failu-
re and development of fetal hydrops, which may result in neurological
morbidity and mortality. Limited data exists on the long-term outcome
of hydropic fetuses.
Methods
A retrospective study on cognitive and neurological functioning of 11
infants, aged 0,5 to 12 years, who experienced fetal tachycardia compli-
cated by hydrops.
Results
Seven fetuses had supraventricular tachycardia, 3 had atrial flutter and
1 had ventricular tachycardia. Nine fetuses converted to sinus rhythm
in a mean time of 7,9 days; resolution of hydrops was achieved in 6 of
these patients in a mean time of 7,4 days.
Mean GA at birth was 35 weeks and 4 days. Neonatal cranial ultra-
sound was normal in 7 infants and all but one of these were normal at
follow-up: one infant who initially had no abnormalities developed
multiple cerebral lesions as a result of a malignant LQTS and died at
the age of 2 years. The remaining 4 infants all had flaring on neonatal
cranial ultrasound, one complicated by a pseudocyst and one by a
porencephalic cyst. One of these infants was normal at follow-up, one
died two days after birth and two infants had neurological abnormali-
ties at follow-up, consisting of mild hemiplegia with normal cognitive
function in one, and a cognitive developmental delay in the other.
Conclusions
Fetal tachycardia complicated by hydrops predisposes the unborn child
to neurological damage. However, in this series 8 out of 11 infants were
neurologically normal. Prognosis seems particularly good in case of
successful treatment and delivery at term, and initiation of therapy
should not be withheld or delayed on the assumption of poor neurolo-
gical outcome.
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Introduction
Fetal tachycardia is a serious condition in which the fetus is at risk for
congestive heart failure and subsequent development of hydrops. This
situation is associated with significant morbidity and mortality 1-3.
Neurological morbidity has been linked to fetal tachycardia in several
reports and is probably the result of dysfunction of the cerebrovascular
autoregulation in hemodynamically compromised fetuses 4-10. This
makes the prevention and management of fetal tachycardia complica-
ted by hydrops most important. Intra uterine therapy is to be preferred
over preterm delivery and postnatal treatment, in avoidance of neona-
tal complications of prematurity additional to the arrhythmia. Several
management protocols have been proposed in the last years of which
treatment with flecainide 11-13 or amiodarone and digoxin 14 seem to be
the most successful in SVT, and sotalol the most successful in AF 15.
However, little is known on the neurological follow-up of these
children. We present a retrospective study on 11 cases that were treated
for fetal tachycardia complicated by hydrops, with special focus on
neurological outcome.
Methods
All cases with fetal tachycardia complicated by hydrops and treated at
our hospital from 1991 until 2002 were reviewed. Two of these patients
have been described in a previous study 4.
Fetal tachycardia was defined as a ventricular heart rate exceeding 180
beats per minute (bpm). Supraventricular tachycardia (SVT) was defi-
ned by 1:1 atrioventricular conduction and atrial flutter (AF) was defi-
ned as an atrial rate > 250 bpm with a fixed or variable AV block, resul-
ting in a variable ventricular response. Fetal hydrops was defined by
clear fluid accumulation in 2 or more of the compartments in the fetal
body, such as pericardial effusion, pleural effusion, ascites and skin
edema.
Treatment differed between cases as a result of the time span of this
study and due to the progressing insights on therapy.
Neurological follow-up
All records, both prenatal and postnatal, were reviewed. All 11 neonates
had cranial ultrasounds performed shortly after birth. Neonates who
were diagnosed to have neurological abnormalities were accurately
documented and enrolled in the neurological follow-up. Neonates who
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showed no signs of neurological damage, both at cranial ultrasound
and during the neurological follow-up in the first year of life, were dis-
charged from further neurological follow-up. Further development was
noted at cardiological follow-up.
At the time of this follow-up study, the patients were invited at our
out-patient clinic. They were asked for possible signs and symptoms of
any disease, medication, level of education and participance in sports.
A full standardized neurological investigation was performed by one
neurologist (RHJMG). Normal neurological outcome was defined by
adequate cognitive functioning, as defined by a normal level of educa-
tion and no abnormalities at neurological investigation.
Statistical difference in GA at presentation and delivery between
groups was made by the Mann-Whitney-U test. A p value of 0,05 was
considered significant.
Results
Prenatal situation
Eleven hydropic patients were included in this study. The mean gesta-
tional age at the time of presentation was 30+3 weeks (range 24+4 –
38+4 weeks). Seven patients had SVT, 3 had AF and 1 patient had ventri-
cular tachycardia (VT). Table 1 shows the patient characteristics. In nine
patients, conversion to sustained sinus rhythm was achieved in a mean
time of 7,9 days (SD 6,0). In 6 of these patients, resolution of hydrops
was achieved in a mean time of 7,4 days (SD 3,8) after conversion to
sinus rhythm. Of the remaining three patients that converted to sinus
rhythm, two went into preterm labour before the hydrops was dissol-
ved (case 9 and 10), and one was delivered at 39 weeks after several
days of sinus rhythm (case 5), although still hydropic.
One case that converted to sinus rhytm without treatment was included
in the group that converted to sinus rhythm (case 4). This was a twin
pregnancy presenting at 31 weeks, with one fetus with SVT at 300 bpm
and massive hydrops, and one unaffected twin. In view of the minimal
cardiac output and expected poor neurological prognosis, it was decided
in conjunction with the parents, not to initiate therapy. However, at fol-
low-up at 32+4 weeks, the heart of the affected twin showed a normal
sinus rhythm and signs of decreasing hydrops. Hydrops was completely
resolved at 33+2 weeks and the biophysical profile was satisfying. At 35
weeks, relapse of the tachycardia occurred at 300 bpm, and at this point
we decided to perform a caesarean section (S.C). Two healthy daughters
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were born with good Apgar scores and birth weights of 2500 and 3000
gram.
Two patients did not convert to sinus rhythm. One patient had intermit-
tent VT at 260-280 bpm , and was treated with sotalol and digoxin. As no
conversion to sinus rhythm occurred and hydrops was progressing, it was
decided to perform a S.C. at 31+1 weeks. A daughter was born with an
Apgar score of 5/8 and a birth weight of 2180 gram. She was diagnosed to
have long QT syndrome  (LQTS) type 3 (case 7). The other patient not con-
verting to sinus rhythm had AF at 300:150 bpm and intermittent 1:1 con-
duction at 300 bpm. Although not converted to sinus rhythm, on therapy,
no 1:1 conduction was seen anymore. Hydrops resolved in 14 days (case 8).
Six fetuses were delivered vaginally and 5 by caesarean section (S.C.)
Indications for S.C. included breech presentation (n=2), therapy resistance
(n=1), relapse (n=1) and emergency S.C. (decreased fetal movements and
reduced FHR variability; n=1).
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Case GA Mechanism Int/ FHR Therapy T to conv T to Delivery GA Outcome
(weeks) continuous (days) resolution
(days)
1 31+1 SVT continuous 260 S+D 12 4 nvd 41+2 Good
2 29+3 AF int 360/180 S+D 8 6 nvd 32+6 Hemiplegia
3 25+0 SVT continuous 60-240 F (-), S (+) 14 7 CS 34+2 Delay
4 31+0 SVT continuous 300 None 11 16 CS 35 Good
5 38+4 SVT int 170-200 F 2 - CS 39 Good
6 24+4 SVT int 250-260 S 9 6 nvd 36 Good
7 29+4 VT int 260 S+D - - CS 31+1 Died at 2 years
8 28+0 AF, int. 1:1 continuous 300/150 F+D - 14 nvd 37+1 Good
conduction
9 33+1 AF continuous 460/230 S 1 - nvd 33+3 Died at 2 days
10 31+0 SVT continuous 250 F 1 14 nvd 40+1 Good
11 27+4 SVT continuous 290 F(-), amio+D 16 - CS 31 Good
Table 1
Prenatal characteristics and outcome of all 11 patients. GA, gestational age. SVT, supraventricular tachycardia. AF,
atrial flutter. Int, intermittent. FHR, fetal heart rate. S, sotalol. D, digoxin. F, flecainide. Amio, amiodarone. T to conv,
time to conversion to sinus rhythm in days. T to resolution, time to resolution in days. Nvd, normal vaginal deli-
very. CS, caesarean section. Delay, cognitive developmental delay.
Postnatal situation
Mean G.A. at birth was 35+4 weeks (range 31 – 41+2). Neonatal cranial
ultrasound was normal in 7 infants (group 1) and abnormal in 4 (group
2). The infants of group 1 had a mean GA at presentation of 30,5 weeks
(SD 4,2), as compared to a mean GA of 28,8 weeks (SD 3,4) in group 2
(not significant). However, there was a significant difference between
the groups in gestational age at delivery (mean 37, SD 3,5 vs mean 33,
SD 1,4; p = 0,047).
The infants of group 2 were neurologically abnormal shortly after birth
and another one became neurologically abnormal later on, due to
ongoing cardiac problems. Two of these five infants died. All together
there were 9 survivors, two of whom with neurological sequelae.
Six of the seven infants with a normal neonatal cranial ultrasound
were normal at follow-up. One is at present 8 months old with normal
neurological results and a normal MRI scan. The other 5 infants are 6 to
12 years old at present. The one patient from this group, who developed
abnormally (case 7), had runs of polymorphic tachycardia shortly after
birth and a QTc of 0,51 (prolonged) and she was diagnosed to have con-
genital LQTS. A ventricular pacemaker was implanted and propranolol
therapy was initiated. Convulsions were present in the first two weeks
of life and a repeated cranial ultrasound performed at two weeks of
age showed a small infarction in the left thalamus. A MRI at two
months of age showed a small cyst in the left-sided nucleus lentifor-
mis. Neurological development however, was good up to one year of
age. At this point in time, the cardiac condition was critical with
several periods of ventricle fibrillation and need for resuscitation. A
cardioverter defibrillator was implanted, but repeated shocks were
required and signs of heart of failure developed. The neurological con-
dition deteriorated and the infant died at 2 years of age of intractable
ventricle fibrillation.
There were four infants with an abnormal neonatal cranial ultrasound.
Two infants had severe flaring (case 3 and 9) and the other two had
mild flaring, with a pseudocyst (case 11) and a porencephalic cyst (case
2). Only case 11 did well. This infant is at present 6 months old, has no
abnormalities on repeated cranial scans and is also neurologically
developing normal. The other 3 cases are discussed below.
Case 3 initially developed well, but proved to have psychomotor retar-
dation at the age of 16 months when he was functioning conform the
age of 9-10 months, determined with the Griffiths developmental
assessment scale (63 out of 100). No subsequent follow-up could be
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obtained as a result of emigration shortly after the last visit (described
in a previous study 4).
Case 2 showed signs of dilatation of the left cerebral ventricle and a
shift of the midline at two months of age. These findings were con-
firmed on MRI, and a ventriculoperitoneal drain was placed. At the
time of this study, he is 7,5 years old, has a mild hemiplegia on the
right side and requires physical therapy, although development is well
and quality of life is not hampered by the mild hemiplegia. Cognitive
functioning is normal (described in a previous study 4).
Case 9 was born preterm with massive hydrops at 33 weeks and 3 days
of gestation, as a result of preterm contractions. In addition to the
severe flaring, a precysteus periventricular leucomalacia was seen and
convulsions occurred. In view of the poor prognosis it was decided to
abstain from therapy. The infant died at the second day of life.
Discussion
Fetal tachycardia is a situation in which the fetus is predisposed to
neurological abnormalities probably as a result of hemodynamical
compromise. These abnormalities are only present in hydropic fetuses
and therefore seem to be related to situations in which such a hemo-
dynamical compromise is severe. Hemodynamic compromise as a result
of a disturbance in rhythm predisposes the fetus to cerebral ischemia
in periods of moderate hypotension and to intracranial hemorrhage in
periods of moderate hypertension 4. The gestational age at presenta-
tion of the tachycardia has been proposed as a risk factor for neurolo-
gical complications, but we could not demonstrate this in our study. A
significant difference however, was present in GA at the time of deli-
very between infants with normal and abnormal neonatal brain scan,
probably as a result of the severity of the condition (preterm delivery
as a result of polyhydramnios in three cases and induced preterm deli-
very because of therapy resistance in one case).
Case reports have suggested an association between fetal hydrops due
to tachycardia and neurological abnormalities 6-10, but the outcome of
a consecutive series is not known. Three of the 11 patients of our study
proved to have neurological complications related to the prenatal
tachycardia, and in one of them these complications were severe
enough, to decide to abstain from further treatment. One patient had
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a marked mental retardation and one a mild hemiplegia with a good
quality of life. One further case initially was neurologically normal, but
deteriorated as a result of the critical cardiological condition. Outcome
of the group as a whole was above our expectations and compares
favorably with that of other causes of fetal hydrops. However, publica-
tions on outcome are mostly focused on mortality rates. In severe
immune fetal hydrops a mortality rate of 45 % has been reported 16,
even after intrauterine treatment. Outcome in non-immune fetal
hydrops related to other causes is poor with perinatal mortality rates
of 80 – 100 % 17, 18. In one study, outcome of 126 surviving infants who
had suffered from anemia prenatally, induced by red blood cell-alloim-
munization, has been studied. In 21 % of infants who had been severely
hydropic prenatally, visits to neurology and rehabilitation departments
were reported, suggesting neurological abnormalities. A percentage of
neurological impairment that is comparable to our findings. In addi-
tion, they reported a trend towards behavioural problems in the group
with severe hydrops 19.
Our data indicate that the majority of fetuses apparently seem capable
of handling fetal tachycardia at least for a certain amount of time, and
adequate blood flow to the fetal brain must be assumed in these
cases. Initiation of therapy should therefore never be withheld or
delayed based only on the unfounded assumption of poor neurological
outcome. Even in cases in which it might take several weeks to achieve
a sinus rhythm and a subsequent resolution of hydrops, outcome is not
necessarily poor (case 11). Only in situations in which obvious neurolo-
gical lesions are detected in utero one may opt, in conjunction with the
parents, to abstain from therapy. Our data do not provide a clue as to
which hydropic fetus will develop favorably or otherwise.
Conclusions
Fetal tachycardia complicated by hydrops predisposes the unborn child
to neurological damage. In our population of 11 fetuses, two deaths
occurred, one shortly after birth as a result of the fetal tachycardia and
its complications, and one at 2 years of age related to the arrhythmia.
The neurological abnormalities encountered in this study, were mild
hemiplegia with normal cognitive function in one patient and a cogni-
tive developmental delay in the other. However, neurological outcome
of the hydropic group as a whole was reasonably good with no neuro-
logical abnormalities in 73 % of cases. At long term follow-up, cognitive
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function was normal in all surviving infants. Prognosis seems particu-
larly excellent in case of successful treatment and delivery at term.
Therefore, initiation of therapy should not be withheld or delayed
based only on the assumption of poor neurological outcome.
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Abstract
Background
The pharmacological treatment of fetal tachycardia (FT) has been
described in various publications. We present a study reviewing the
necessity for treatment of FT, the regimens of drugs used in the last
two decades and their mode of administration.
Methods
Review study of the literature regarding FT in the last two decades.
Results
The absence of reliable predictors of fetal hydrops (FH) has led most
centers to initiate treatment as soon as the diagnosis of FT has been
established, although a small minority advocate non-intervention. As
the primary form of pharmacological intervention, oral maternal trans-
placental therapy is generally preferred. Digoxin is the most common
drug used to treat FT; however, effectiveness remains a point of discus-
sion. After digoxin, sotalol seems to be the most promising agent, spe-
cifically in atrial flutter (AF) and nonhydropic supraventricular tachy-
cardia (SVT). Flecainide is a very successful drug in the treatment of
fetal SVT, although concerns about possible pro-arrhythmic effects
have limited its use. Amiodarone has been described favorably, but is
frequently excluded due to its extensive side effects. Conclusions on
other less frequent used drugs cannot be drawn.
In severely hydropic fetuses and/or therapy resistant FT direct fetal
therapy is sometimes initiated. To minimize the number of invasive
procedures, fetal intramuscular or intraperitoneal injections that provi-
de a more sustained release are to be preferred.
Conclusions
Based on these data we propose a drug protocol of sotalol 160 mg
twice daily orally, increased to a maximum of 480 mg daily. Whenever
sinus rhythm is not achieved, the addition of digoxin 0,250 mg three
times daily is recommended, increased to a maximum of 0,5 mg three
times daily. Only in SVT complicated by FH, either maternal digoxin 1 to
2 mg IV in 24 hours and subsequently 0,5 to 1 mg/day IV or flecainide
200 to 400 mg/day orally is proposed. Initiating direct fetal therapy
may follow failure of transplacental therapy.
Chapter 5
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Introduction
Fetal tachycardia is a condition that occurs in 0,4-0,6 % of all pregnan-
cies1.
With the development of Doppler and M-mode echocardiography, the
knowledge on this rhythm disorder and its impact on the condition of
the fetus has greatly improved 2-5. In the last two decades a number of
publications have highlighted views and experiences on the diagnosis
and management of fetal tachycardia. Fetal tachycardia can hemody-
namically compromise the fetus, presenting with signs as ventricular
dysfunction and dilatation, secondary atrioventricular valve regurgita-
tion and fetal hydrops, which may ultimately lead to fetal death.
Several treatment protocols  have been developed, in which different
modes of pharmacological intervention, indirect (transplacental,
through oral or intravenous maternal therapy) or direct (intra-umbili-
cal, intra-amniotic, intra-peritoneal and intra-muscular fetal therapy)
have been proposed. Although prenatal treatment in advanced cases of
fetal tachycardia is widely accepted, the necessity for treatment in mil-
der cases is still a point of discussion 6, 7.
This review article will discuss the various regimens of drugs used in
the treatment of fetal tachycardia over the past two decades, their
mode of administration, necessity for treatment and future prospects.
Definition of Fetal Tachycardia
The normal fetal heart rate ranges are approximately 120-160 bpm at
30 weeks and 110-150 bpm at term 8, 9. Frequencies up to 170 bpm are
considered mildly abnormal, whereas overt tachycardia is usually defi-
ned as a heart rate exceeding 170 bpm 8 or 180 bpm 10. Fetal tachycar-
dia is subdivided in supraventricular tachycardia (SVT, defined by 1:1
atrioventricular conduction), of which permanent junctional reciproca-
ting tachycardia (PJRT) is a particular therapy resistant type; atrial flut-
ter (AF, with atrial rate >250 bpm with fixed or variable AV block, resul-
ting in a variable ventricular response); ventricular tachycardia (VT,
with AV dissociation, lack of a 1:1 relationship between atria and ventri-
cles) and sinus tachycardia 10. Further categorization can be made on
the basis of the percentage of time that the tachycardia is present:
sustained, >50% of time present or intermittent, < 50% of time.
This article focuses on fetal tachycardia as a primary condition, where-
as its presentation as a secondary condition (cardiac structural malfor-
mation, infection, uterine contraction and fetal distress) might require
in a different management protocol.
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Diagnosis
Detection of fetal tachycardia often occurs at routine prenatal visits
after which referral to a specialized center for fetal cardiology is arran-
ged. Fetal electrocardiography is not of clinical significance in the diag-
nosis of FT because its signal-to-noise ratio is low, thereby precluding
the demonstration of atrial activity. The diagnosis is made by M-mode
and sometimes Doppler echocardiography, which enables a differentia-
tion in types of rhythm. The two-dimensional image is used to exclude
structural cardiac malformations and to position the M-mode sampling
line to intercept both the atrial and ventricular walls. The relationship
between atrial and ventricular contraction is sufficient to make a divi-
sion in SVT, AF, VT and sinus tachycardia (see definitions), although the
exact electrophysiologic mechanism of the tachycardia remains undis-
closed. Fetal magnetocardiography allows a more complete evaluation
of the type of arrhythmia but the technique is currently still in an
experimental stage.
Drugs used
All drugs used in the treatment of fetal tachycardia are classified follo-
wing the Vaughan-Williams classification of antiarrhythmics. Table 1
provides a list of antiarrhythmic agents and their recommended use.
Table 2 contains a comparison of  treatment protocols used in the lar-
ger studies published recently.
All information in paragraphs on pharmacokinetics and dose refer to
maternal values and are obtained from women who are not pregnant,
unless otherwise stated. Direct fetal treatment will be discussed in a
separate chapter.
Digoxin
Pharmacodynamics
Digoxin, a digitalis glycoside exerting direct and indirect effects on the
myocardium, conduction system and autonomic nervous system, has
positive inotropic and negative chronotropic properties, resulting in an
increase in cardiac output and a decrease in heart rate, respectively. In
addition, digoxin prolongs the refractoriness of the AV-node, thereby
delaying atrio-ventricular conduction and the ventricular rate in AF or
SVT.
Chapter 5
72
Drug SVT, SVT, AF, AF, Administration schedule 
no hydrops hydrops no hydrops hydrops
Sotalol +++ - +++ +++ PO: 160 mg 2x/day,
max. 480 mg/day
Digoxine +++ +++ + + PO: 0,25 mg 2x/day,
max. 1 mg/day,
IV: 0,5-1 mg/day
Flecainide - + - - PO: 200-400 mg/day
Amiodarone - + - + PO: 800-1200 mg/day,
gradually decrease
Procainamide - + - - PO: 500 mg 8x/day,
IV: 2-6 mg/min maintenance
Dofetilide - - (+) (+) Individualize on creatinine 
clearance
Propranolol - - - - PO: 30 mg 4x/day,
max. 320 mg/day
Adenosine - - - - - Intraumbilical: 0,1-0,2 mg/kg
estimated fetal weight
Disopyramide - - - - - - - - Not relevant
Quinidine - - - - - - - - Not relevant
Verapamil - - - - - - - - Not relevant
Table 1
Figure legends
- - contraindicated; - not recommended; (+) experimental use as drug of last resort;
+ may be used in case of therapy resistance to other drugs, ++ recommended, +++ strong-
ly recommended 
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Pharmacokinetics
Orally administered digoxin is absorbed for 75 %. Elimination half-life
of digoxin is 30 to 40 hours. Therapeutic serum concentration of dig-
oxin is 1 to 2 mg/l. Digoxin has a small therapeutic range with a high
incidence of toxicity. Approximately 57-80 %  of the available digoxin is
excreted unchanged in the urine. The rest is eliminated by non-renal
routes: 6-8 % by biliary excretion, 3-5 % by fecal excretion and approxi-
mately 16 % is metabolized in the liver 11.
During pregnancy renal clearance and maternal blood volume increa-
ses, and this higher doses of digoxin are required to achieve adequate
therapeutic levels in the fetus 12, 13 , although higher digoxin plasma
concentrations in pregnant women due to increased absorption are
reported 14.
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Study # of NFH FH SVT AF Digoxin Flecainide Sotalol Dig + Fl Dig + S Multidrugs IUD
patients
Jaeggi et al. (30) 11 10 1 0 11 5+ / 4- 1- 1- 0
Sonesson et al. (95) 14 6 8 14 0 10+ / 4-  2
Allan et al.* (63) 14 0 14 12 2 12+ 2+ 1
Azancot group 1 (39) 9 5 4 4 5 2+ 2+ / 5- 0
Azancot group 2 (40) 7 2 5 5 2 5+ (i.v. Dig) 2+ (i.v. Dig) 0
Oudijk et al. (90) 20 12 8 10 10 10+ / 3- 6+ / 1- 3
van Engelen et al. (27) 34 19 15 25 9 11+ / 4- 7+ 2+ 8+ / 2- 2
Frohn-Mulder et al. (28) 35 22 13 35 0 13+ / 6- 3+ / 4- 4+ 5- 6
Simpson et al.* (29) 110 63 47 92 18 40+ / 11- 16+ / 5- 4+ 23+ / 11- 15
* These studies may have included similar patients.
Table 2.
Comparison of treatment protocols larger studies.
NFH= No Fetal Hydrops, FH= Fetal Hydrops, SVT= Supraventricular Tachycardia, AF= Atrial Flutter, Dig + Fl= Digoxin and Flecainide
combined treatment.
Dig + S= Digoxin and Sotalol combined treatment, Multidrugs= treatment with a combination of more than two drugs, IUD= intra
uterine death.
i.v.Dig = maternal intra-venous Digoxin, + = successful treatment, - = unsuccessful treatment.
Dose
Loading dose for orally administered digoxin, varies between 0,25 and
1,5 mg, followed by a maintenance dose of 0,125 to 0,5 mg daily. The
relatively long elimination half-life of digoxin results in slower achie-
ved steady-state plasma concentrations. Dosing should be individually
adjusted by combining plasma concentration and clinical effects. Rapid
achievement of adequate levels can be reached by intravenous admini-
stration of 1 to 2 mg digoxin given in multiple doses during the first 24
hours, followed by 0,5 to 1 mg daily for 7 days guided by maternal tole-
rance and fetal echocardiography 10.
Antiarrhythmic drugs like quinidine, amiodarone, propafenone, verapa-
mil and flecainide increase the digoxin plasma concentration. Maternal
plasma concentrations are therefore required to adjust the dosages in
case of combined use of digoxin and these drugs 10, 15. Dose adjust-
ments based on combined maternal and fetal blood levels (by cordo-
centesis) are complicated by the fact that measurement of digoxin
levels within the fetus is hampered by cross reactions with preexisting
fetal digoxin-like immunoreactive substance 16. Therefore, we recom-
mend to adjust the dose solely on maternal blood levels.
Placental transfer
Reported fetal: maternal plasma concentration ratios vary between 0,4
and 0,9 14, 17-19. However, in the hydropic fetus this ratio is  reduced,
which may result in failure of treatment. This lower digoxin concentra-
tion may be caused by altered volume distribution, change in protein
binding or other pharmacokinetic parameters in the hydropic fetus 20-
24.
Adverse effects and precautions
Digoxin does not appear to be teratogenic 25. Maternal adverse effects
mainly concern overdosing. Signs of overdosing, such as anorexia, nau-
sea, vomiting and headache have, however, also been reported at the-
rapeutic plasma concentrations. Frequent cardiac adverse effects are
arrhythmias (especially ventricular extrasystoles) and heart block;
atrial tachycardia with an AV-block is characteristic. Digoxin is con-
traindicated in Wolff-Parkinson-White syndrome.
Dose adjustment is required in case of renal failure, maternal hypoka-
lemia or concomitant administration of digoxin with other antiarrhyth-
mics.
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Clinical experience
Digoxin transplacental therapy  has been the drug of choice in the
treatment of fetal tachycardia since its complications are few and well
known. Six large studies and a great number of small studies and case
reports have been published. The large studies have shown that
digoxin monotherapy is relatively effective in the treatment of fetal
tachycardia not complicated by fetal hydrops with conversion rates
ranging from 32 % to 71 % 26-29. In contrast, disappointing conversion
rates of 10 % to 20% have been reported with digoxin monotherapy in
fetal tachycardia complicated by fetal hydrops, although Kleinman et
al. reached a conversion rate of 43 % in these complicated cases 4. A
study by Jaeggi et al. on the use of digoxin in fetal atrial flutter
showed a moderate success rate of 45 % 30. Several other studies stress
the relative inefficacy of orally administered digoxin in atrial flutter
and fetal SVT complicated by hydrops due to the reduced transplacen-
tal transfer of this drug, with an overall success rate of approximately
50 % in nonhydropic fetuses compared to a disappointing rate of 15-20
% in hydropic cases 31-38. Intravenous administration of digoxin may
avoid problems related to poor absorption of digoxin, and consequent-
ly favors the transplacental transfer of the drug; with such a policy
adequate therapeutic fetal plasma concentrations are rapidly achieved
39-41.
In conclusion, digoxin is a safe drug in the treatment of fetal tachycar-
dia with the advantages of a positive inotropic effect. However, digoxin
is known to act slowly and its therapeutic importance in hydropic fetu-
ses is limited. The maternal intravenous administration of digoxin
seems promising, however, logistically complicated. It should therefore
be reserved for severe cases of tachycardia complicated by hydrops and
possibly in combination with a second line drug as flecainide.
Quinidine
Pharmacodynamics
A class IA antiarrhythmic agent that delays conduction and prolongs
the refractory period. An indirect parasympaticolytic effect neutralizes
the delayed AV conduction and may even enhance conduction. It has a
weak negative inotropic effect.
Pharmacokinetics
Peak plasma concentrations occur after 1-2 hours. Quinidine metaboli-
zes partly in the liver and is eliminated through the urine. The elimina-
tion half-life is 6-8 hours. Therapeutic plasma levels are 2-6 mg/l.
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Dose
The starting dose is 200 mg orally every 3 hours until the desired effect
is reached. The maximum daily dose should not exceed 3 gram.
Placental transfer
Quinidine crosses the placenta, one case report shows a fetal: maternal
plasma ratio of approximately 0,3 42, and another report a ratio of 1,0
43.
Adverse effects and precautions
Quinidine toxicity in the mother can lead to severe nausea and vomi-
ting, diarrhea, light-headedness and tinnitus 42. Cardiac adverse effects
include hypotension, torsade de pointes tachycardia and sudden death.
No reports linking the use of quinidine with congenital defects have
been identified.
Neonatal thrombocytopenia has been reported after maternal use of
quinidine.
Clinical experience
There is limited fetal experience with the use of quinidine in the treat-
ment of fetal tachycardia. We could identify thirteen cases in the inter-
national literature. Five cases were treated successfully with a combi-
nation of digoxin and quinidine 15, 44, five cases did not revert to sinus
rhythm on this combination 19, 45-47, while another case was therapy
resistant to quinidine as a monotherapy 48. Two fetuses required
maternal oral quinidine as additional therapy to a fetal intramuscular
injection of digoxin to sustain sinus rhythm 47.
In conclusion, the present data are too scarce to draw conclusions on
the safety and efficacy of quinidine. Since it is thought to increase
maternal mortality 10, it should not be used in the treatment of fetal
tachycardia.
Procainamide
Pharmacodynamics
Procainamide is a class IA antiarrhythmic agent that delays conduction
in the atria, AV node and ventricles with prolongation of the action
potential and the effective refractory period. It does not have a negati-
ve inotropic effect. Its active metabolite N-acetylprocainamide has
class III antiarrhythmic properties.
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Pharmacokinetics
Procainamide is absorbed rapidly and almost completely, resulting in a
bioavailability of 85 %. It metabolizes in the liver to the active N-ace-
tylprocainamide and is excreted mainly by the kidneys. The elimination
half-life is 3-4 hours. Therapeutic plasma concentrations are 4-8 mg/l.
Dose
Oral administration is hampered by the fast elimination of procainami-
de and it is thus mainly initiated intravenously, with a loading dose of
100 mg over 2 minutes followed by a maintenance dose of 2- 6
mg/min. If administered orally the recommended dose is 1 g followed
by 500 mg 8x/day.
Transplacental transfer
Fetal: maternal ratios vary between 0,28 and 1,1 49, 50. Caution is requi-
red as procainamide could accumulate in the fetus 51.
Adverse effects and precautions
Prolongation of QT interval, hypotension, gastro intestinal symptoms
and agranulocytosis have been reported. Procainamide interacts with
amiodarone. Administration should be carefully monitored by ECG.
Clinical experience
There is limited fetal experience with procainamide and data is mostly
confined to reports on its use as a second or third line drug. Frohn-
Mulder et al. found it to be ineffective in 5 hydropic fetuses in a multi-
drug setting 28, and van Engelen et al. treated 4 hydropic fetuses with
several drugs including procainamide 27. Three of these four fetuses
converted to sinus rhythm. Data from case reports is inconclusive, with
14 fetuses treated and conversion reached in 6, 52-56 . Moreover, most of
these fetuses were treated with a multidrug regimen and the specific
effect of procainamide cannot be determined. A problem encountered
is the high frequency of the doses needed, if administered orally.
In conclusion, data are inconclusive on the efficacy of procainamide
and moreover, the inconvenience of the high frequency of oral dosing
is a major limitation to compliance. Procainamide should therefore not
be considered for early inclusion in the treatment protocol.
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Disopyramide
Pharmacodynamics
Disopyramide is a class IA type antiarrhythmic agent that delays the
conduction throughout the myocardium and lengthens the refractory
period. It has an indirect parasympathicolytic effect and, as a result,
has virtually no effect on the sinus node frequency and conduction
through the AV node. It has a negative inotropic effect.
Pharmacokinetics
Orally administered disopyramide has a bioavailability of approximate-
ly 45- 85 %. Peak plasma concentrations occur 1-2 hours after
administration. Disopyramide is metabolized into the active N- mono-
desalkyl disopyramide and is excreted for 75 % by the kidney and the
remainder through the faeces. The eliminition half-life is 4-9 hours.
Dose
The oral dosage is 100- 150 mg 4x/day. Intravenously, the loading dose
consists of 2 mg/kg in 10 minutes under close ECG monitoring and is
continued by 0,4 mg/kg/hour, up to a maximum of 800 mg/day.
Therapeutic blood levels are 2- 4 mg/l.
Placental transfer
Measured fetal: maternal plasma concentration ratios vary from 0,26
to 0,39 57, 58.
Adverse effects and precautions
Life threatening ventricular arrhythmias induced by prolongation of
the QT interval have been reported, as well as induction of an AV block.
Disopyramide may aggravate heart failure. In late pregnancy, disopyra-
mide may stimulate uterine contractions, causing vaginal hemorrhage
and induction of labor 59, 60.
Clinical experience
Data on the use of disopyramide in the treatment of fetal tachycardia
are non existent. Due to its adverse effects and to its stimulating effect
on the induction of labor in particular, it should not be used in the
treatment of fetal tachycardia.
Flecainide
Pharmacodynamics
Flecainide is a class IC antiarrhythmic agent. Flecainide depresses con-
duction throughout the myocardium, with its greatest effects on the
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His-Purkinje system, and a prolongation of atrial, AV nodal and ventri-
cular refractory periods. Flecainide has been shown to produce
negative inotropic effects and congestive heart failure has been reported.
Pharmacokinetics
The bioavailability of orally administered flecainide is 70 %- 90 %, with
peak plasma concentrations occurring 1,5 to 6 hours after administra-
tion. Plasma protein binding occurs in approximately 40 %. Flecainide
undergoes extensive biotransformation to 2 major metabolites and
several minor metabolites, all of which are inactive. A mean of 86 % is
excreted in the urine as flecainide and metabolites. In patients with
normal renal function, the elimination half-life is 7 to 22 hours, with an
average of 14 hours.
Dose
The recommended daily dose of oral flecainide varies from 200 to 400
mg, given twice to thrice daily without a loading dose. The daily
dosage should not exceed 600 mg. It is recommended to initiate therapy
in a small dose (100 mg 2x/day), and stepwise increase the dosage to
obtain efficacy. Blood levels should not exceed 1 mg/l, as higher serum
levels are associated with a higher incidence of proarrhythmic effects 61.
Placental transfer
Flecainide passes the placental barrier easily, with fetal: maternal plas-
ma concentrations ranging from 0,5- 0,97 39,61-64.
Adverse effects and precautions
Dizziness, headache, visual disturbances, paresthesia, tremors, flus-
hing, nausea and vomiting have been reported. One report describes
conjugated hyperbilirubinemia shortly after birth in an infant that was
treated with flecainide prenatally for fetal SVT. An extensive evaluation
did not disclose a cause and the authors attributed the condition as an
adverse effect of flecainide 65. Flecainide has negative inotropic effects
and development of or worsening of congestive heart failure occurs in
2 % to 5 % of patients 66. Flecainide does generally not prolong the QT
segment 67, however, one report described marked QT segment anoma-
lies in a newborn that was treated with flecainide prenatally 68.
Of concern is the increased mortality reported in the Cardiac
Arrhythmia Suppression Trial (CAST) 69. This placebo controlled trial, in
which flecainide was initiated in patients with ventricular premature
beats after myocardial infarction, was discontinued prematurely becau-
se of excess deaths in the flecainide group. The authors concluded that
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flecainide should be reserved for use in patients with life threatening
arrhythmias. Publications on the safety and efficacy in children
conclude that flecainide appears to be safe and efficacious in children
with SVT. Flecainide may not be safe for children who have structurally
abnormal hearts and atrial flutter or ventricular arrhythmias 70, 71.
Proarrhythmia
Proarrhythmic effects tend to occur in 4 % to 8 % of patients, however,
these effects are not always related to life-threatening ventricular
arrhythmias.
Clinical experience
In 1988, the first report appeared in which flecainide was used to sup-
press fetal tachycardia after digoxin had failed 33. Since then several
successful (case) reports have been published in which flecainide was
used as a second line drug 20, 34, 35, 39, 72. In 1991, Allan et al. published
an article in which flecainide was the drug of first choice in a popula-
tion of 14 fetuses with tachycardia complicated by hydrops 63. Twelve
fetuses converted to sinus rhythm and two other fetuses converted to
sinus rhythm after the addition of digoxin. The authors state that,
though very successful, the use of flecainide should be confined to
patients with SVT complicated by severe hydrops due to the risks of
possible side effects. Another report published by the same group
several years later showed that although flecainide proved to be suc-
cessful in the greater part of patients, rate control was not always
achieved and some intra uterine deaths still occurred 29. Two other lar-
ger studies published success rates of 100% in nonhydropic fetuses and
50 %-80 % in hydropic fetuses 27, 28. In the past years, numerous case
reports have been published in which flecainide proved to be succes-
sful as a single therapy or in combination with digoxin 31, 32, 64, 72-76.
In conclusion, flecainide is a successful drug in the treatment of fetal
SVT. Of concern are the possible adverse effects experienced in the
CAST study, which could affect both mother and fetus 69. However,
most studies on flecainide in the treatment of fetal tachycardias did
not show any adverse effects. Intra uterine deaths while on flecainide
have been described, although these might have been the result of the
seriousness of the presenting condition, as flecainide is mainly used in
severely hydropic fetuses. Flecainide should not be used in fetal AF as it
can increase the ventricular response and therefore increase heart rate
63.
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Propranolol
Pharmacodynamics
Propranolol is a nonselective Bèta-adrenergic blocking agent, devoid of
intrinsic sympathicomimetic activity. It causes a decrease in cardiac
output and oxygen consumption and it increases AV-nodal refractori-
ness.
Pharmacokinetics
Propranolol is completely absorbed after oral administration. Protein
binding in pregnancy is 80 %. Propranolol is metabolized by the liver
with subsequent renal elimination of the polar metabolites thus pro-
duced. The elimination half-life of orally administered propranolol is 3-
6 hours. Therapeutic serum concentrations vary between 0,02 and 1
mg/l. The pharmacokinetics of propranolol and its metabolites are not
significantly altered by pregnancy.
Dose
The recommended oral dose ranges between 30 –320 mg/day divided
in 3-4 doses as the therapeutic concentrations vary widely (0,02 mg/l
to 1 mg/l).
Intravenously, 1-6 mg given slowly is recommended.
Placental transfer
Propranolol, with a high degree of liposolubility, readily crosses the
placenta. Fetal: maternal plasma ratios varying between 0,2-1,3 have
been reported 77-79. Caution must be exercised when interpreting cord
blood propranolol concentrations. Lower plasma protein binding of
propranolol in the cord blood implies that the unbound concentration
of propranolol is similar in the mother and the fetus, even when the
total drug concentration in the fetal plasma is only 50 % of that in the
maternal plasma 80.
Adverse effects and precautions
Maternal adverse effects have been reported as a result of the Bèta-
blocking properties of propranolol such as bronchospasm, bradycardia,
hypotension, dizziness, heart failure, cold and cyanotic extremities 81
The drug is apparently not teratogenic, but fetal and neonatal toxicity
may occur 82. The most consistent observation is intrauterine growth
retardation 83. This occurred in 50% of the 12 cases in the study by
Pruyn et al. 84. A plausible mechanism is a reduced umbilical blood
flow and thus a decreased nutrition after long-term propranolol admi-
nistration, as has been shown in the ewe 84. Other perinatal adverse
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effects described are birth apnea, bradycardia, hypoglycemia, polycyt-
hemia, hyperbilirubinemia, prolonged labor and even fetal death 79, 81-83.
Propranolol should never be given in combination with verapamil,
because both drugs have negative inotropic properties, which may lead
to poor myocardial contractility and function 5.
Clinical experience
In 1978 Teuscher et al. reported a successful cardioversion of fetal
tachycardia with maternal administration of propranolol (160 mg/day)
during the last 20 days of a diabetic pregnancy 77.
Since then a couple of case reports have been published, though the
results are largely disappointing 5, 19, 85.
Dumesic et al. reported only partial improvement of  supraventricular
tachycardia after maternal administration of  propranolol in combina-
tion with digoxin 49.
Ito et al. published a review article in 1994 in which they describe failu-
re of maternal propranolol therapy in 14 of 16 patients 80.
In conclusion, propranolol does not seem to be effective in the treat-
ment of fetal tachycardia, moreover, it has been  associated with intra
uterine growth retardation and other adverse effects. Therefore we
advise not to use propranolol, unless there is no other alternative.
Sotalol
Sotalol hydrochloride is a noncardioselective Bèta-adrenergic-blocking
agent devoid of intrinsic sympathomimetic and membrane-stabilizing
actions. In addition, sotalol prolongs the duration of action potentials
in cardiac tissue and increases the refractory period. Hence, besides the
Bèta-blocking actions, it has additional class III anti arrhythmic proper-
ties. The net hemodynamic effects of sotalol are the result of a balance
between its negative inotropic action caused by Bèta-adrenergic anta-
gonism and its tendency to increase contractility by prolongation of
the action potential duration 86.
Pharmacokinetics
Orally administered sotalol is virtually completely absorbed and does
not undergo first-pass metabolism in the liver, resulting in an absolute
bioavailability of 90-100 %. Peak plasma concentrations generally
occur 2 to 4 hours after administration and a linear relation exists
between the administered dose of sotalol and the plasma concentra-
tion. Sotalol is not bound to plasma proteins and not metabolized but
excreted unchanged in urine. In patients with normal renal function,
the mean (±SD) elimination half-life is 8±3 hours 86.
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Dose
The recommended oral starting dose is 160 mg 2x/day and can be
increased to a maximum of 160 mg per 3x/day.
Placental transfer
Sotalol passes the placental barrier rapidly and almost completely.
Measured fetal: maternal plasma concentration ratios vary from 0,47 to
1,42 61, 87-89 . Current investigations at our center suggest a ratio of  1:1,
with an amniotic fluid level: maternal plasma concentration ratio of
3:1.
Adverse effects and precautions
Some Bèta-blockers may cause intra uterine growth retardation and
reduce placental weight, however, these findings have not been
demonstrated with sotalol.
Maternal adverse effects can result from the Bèta-blocking properties
of sotalol and present as fatigue, dizziness, dyspnoea, chest pain, palpi-
tations, asthenia, bradycardia, nausea and vomiting. In our series this
occurred temporarily in 2/21 patients 90.
Proarrhythmia
Of more concern are the possible proarrhythmic effects of sotalol, both
in the mother as well as in the fetus. The development of  torsade de
pointes tachycardia is always a point of concern with the use of class
III antiarrhythmics and concerns approximately 2,4 % of patients 91. In
general, women are at increased risk for the development of torsade
de pointes while using sotalol. However pregnant women are generally
without heart disease and these complications are likely to be lower.
Precaution should still be taken whenever sotalol therapy is initiated
and a thorough maternal examination, consisting of the exclusion of
preexisting arrhythmias or heart failure and an ECG recording to evalu-
ate the QT interval, should be performed. Unfortunately, it is currently
not possible to measure the fetal QT interval and the possible proar-
rhythmic effects on the immature fetal myocardium can not be mini-
mized, although the development of fetal magnetocardiography may
provide a solution to this problem in the near future (see discussion).
Clinical experience
The experience with sotalol in the treatment of fetal tachycardia, bes-
ides several successful case reports 92-94 confines to two studies. The
study by Sonesson et al. 95 consists of patients with fetal SVT in which
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digoxin as a monotherapy was not successful and sotalol was added to
the treatment. Conversion to sinus rhythm after the addition of sotalol
to the treatment was achieved in almost all fetuses, however, two
severely hydropic fetuses died in utero. The authors conclude that sota-
lol might be considered as the drug of second choice in the treatment
of fetal SVT. In our study of 21 patients, with both SVT and AF, sotalol
was used as drug of first choice with the addition of digoxin in un-
successful cases. The treatment protocol proved to be very successful
in fetal AF with a conversion rate of 80-90 %. A moderate success rate
of 60 % was achieved in fetal SVT. The mortality rate in this study was
19 % and consisted of 3 fetuses with SVT and 1 fetus with AF. We con-
cluded that sotalol should be considered as the drug of first choice in
fetal AF, but that in case of fetal SVT complicated by hydrops, the risks
of sotalol may outweigh its benefits and might therefore be limited in
the treatment of fetal SVT with hydrops 90.
Amiodarone
Pharmacodynamics
Amiodarone is a class III antiarrhythmic agent, with a content of 39 %
iodine, that prolongs the repolarization of the myocardium, without
influencing the rest potential. Additionally, it has Alpha- and Bèta-sym-
pathicolytic and vasodilatating effects.
Pharmacokinetics
Orally administered amiodarone has a bioavailability of 30-80 %. As a
result of tissue affinity, the drug accumulates in muscle and fat tissue
in the first few days. This is followed by elimination, and after two
months a steady state occurs between uptake and elimination. The
iodine is split from amiodarone, the rest is partially metabolized in the
liver. Iodine is eliminated through the urine and the rest of the mole-
cule for 65-75 % through bile and faeces. The elimination half-life is 20-
100 days.
Dose
The recommended oral starting dose is 800-1200 mg daily during 8-10
days. When the effect is achieved the dose can be lowered to a mainte-
nance dose of 400- 800 mg daily.
Placental transfer
Amiodarone and its metabolite, desethylamiodarone, cross the placen-
ta to the fetus. Fetal: maternal ratios vary between 0,10-0,28 96, 97.
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Adverse effects and precautions
Fetal or maternal hypo- or hyperthyroidism has been reported 98-102.
Neonates exposed to amiodarone in utero should have thyroid func-
tion studies performed because of the large proportion of iodine con-
tained in each dose 103, 104. Furthermore gastro-intestinal symptoms,
rash, pruritis, corneal microdeposits, peripheral neuropathy, myopathy,
extrapyramidal tremor, cerebellar ataxia, insomnia and nightmares are
reported. Pulmonary toxicity and hepatic toxicity may occur. Neonates
should have liver functions tested. Intra uterine growth retardation
occurs frequently in infants exposed to amiodarone in utero 99, 104.
Rarely proarrhythmic adverse events such as torsade de pointes tachycar-
dia related to prolonged QT interval occur. Bradycardia is also reported.
Clinical experience
Several case reports have been published on the use of amiodarone,
mostly in the treatment of fetal SVT 26, 36, 100, 105, 106. In most of these
reports, amiodarone was initiated in combination with other drugs of
which the combination with digoxin is most common. Although amio-
darone did not succeed in establishing sinus rhythm in all cases, over
one half of all case reports were successful, and one must bear in mind
that it is mainly used in cases that are refractory to conventional treat-
ment protocols. Direct fetal administration of amiodarone has been
described in 7 cases  101, 105-107 of whom 6 proved to be successful,
twice fetal bradycardia was noted and one fetus died on the second
day postnatally due to renal failure, disseminated intravascular coagu-
lation and intractable SVT 29. Of major concern is the potential to
cause hypothyroidism in the fetus and subsequent neurological abnor-
malities which has been described in several reports. Other adverse
effects as intra uterine growth retardation, prematurity and fetal bra-
dycardia are also reported 104.
In conclusion, amiodarone seems to be a very potent antiarrhythmic
agent in the treatment of therapy resistant fetal tachycardia. However,
amiodarone has been shown to produce substantial fetal adverse
effects and is therefore excluded for early inclusion in the treatment
protocol. It may be used as drug of last resort when other types of the-
rapy fail to restore sinus rhythm. Full neonatal thyroid function tests
are in that case recommended. If pathological, the thyroid function
should be normalized and developmental follow-up is recommended.
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Dofetilide
Pharmacodynamics
Dofetilide is a pure class III antiarrhythmic agent and therefore selecti-
vely prolongs repolarization without affecting conduction velocity.
Pharmacokinetics
The bioavailability of orally administered dofetilide approaches 100 %
and peak serum levels occur within 2,5 hours of administration. It is
metabolized partly in the liver and excreted in the urine and the elimi-
nation half-life is 7-8 hours 108.
Dose
Dosing of dofetilide should be individualized and depends on the QTc
interval and calculated creatinine clearance (CrCl). In patients with a
QTc greater than 440 milliseconds, dofetilide is contraindicated. If the
CrCl > 60 milliliters/minute (mL/min) the recommended dose is 0,5 mg
2x/day. If  CrCl is 40 to 60 mL/min, the oral dose is 0,25 mg 2x/day.
Whenever the  CrCl is 20 to 40 mL/min, the oral dose is 0,125 mg
2x/day. The drug is contraindicated in patients with a CrCl of < 20
mL/min. Patients are to be monitored for a minimum of 3 days.
Transplacental transfer
No data exists on the transplacental transfer of dofetilide.
Adverse effects and precautions
Dofetilide has been well tolerated, although headache, dizziness, and
chest pain are reported 109. It does not appear to have a negative inot-
ropic effect. torsade de pointes occurs in approximately 0,8 %, associa-
ted with higher doses, usually shortly after initiation and in patients
with electrolyte imbalances 110. It is contraindicated in congenital or
acquired long QT syndrome and patients with severe renal impairment.
Concomitant use of dofetilide with cimetidine, ketoconazole or verapa-
mil is contraindicated.
Clinical experience
No reports on the use of dofetilide in the treatment of fetal tachycar-
dia have yet emerged. Our opinion is that dofetilide may prove to be
useful in fetal atrial flutter resistant to conventional therapy.
Verapamil
Pharmacodynamics
Verapamil is a class IV antiarrhythmicum, a calcium channel blocking
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agent that inhibits the slow influx of calcium-ions through the cell
membrane of contractile and conducting cells in the heart and of
smooth muscles of coronary and peripheral arteries. It decreases con-
traction and delays conduction in the sinus node and the AV-node. This
results in an increased coronary blood flow and a decreased peripheral
arterial resistance. The oxygen consumption of the myocardium
decreases and the oxygen supply increases.
Pharmacokinetics
As a result of an extensive first-pass effect, bioavailability after oral
administration is only 10-35 %. Peak plasma levels are achieved after 1-
2 hours, and 4-8 hours after intake of retard tablets. The plasma pro-
tein binding is approximately 80 %. Verapamil is mostly excreted as
metabolites through the urine and faeces. The elimination half-life is
approximately 8 hours.
With repeated admission, accumulation of the active metabolite nor-
verapamil is possible.
Dose
An intravenous loading dose of 5- 10 mg over 60 sec. is recommended.
Oral maintenance dose should be 320- 480 mg daily divided in 3 to 4
doses. The daily dosage should not exceed 720 mg.
Placental transfer
Verapamil has been shown to pass the placenta. Fetal: maternal plas-
ma ratios vary from 0,17- 0,26 16.
Adverse effects and precautions
Hypotension, bradycardia, obstipation, headache, nausea, flushing and
dizziness are reported.
Animal studies have shown verapamil to be embryocidal and cause
retarded fetal growth and development. Hypotension has been obser-
ved in patients after rapid bolus 4, and reduced uterine blood flow with
fetal hypoxia is a potential risk 111 . Verapamil should not be initiated in
combination with propranolol as this could have severe negative
inotropic effects and may induce high-grade AV block 4, 5.
Clinical experience
Verapamil is a drug that has been frequently used, particularly in the
1980’s. Numerous case reports and several larger studies exist in the
international literature in which verapamil was mostly initiated in
combination with digoxin. Both successful and unsuccessful case
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reports have emerged. One large study reports a conversion rate of
10/14 nonhydropic fetuses and 11/17 hydropic fetuses with a combina-
tion of digoxin and verapamil. However, one hydropic fetus was treated
with an intraumbilical injection of 0,2 mg verapamil which immediate-
ly lead to asystoly from which the fetus could not be resuscitated 29.
Another report of 6 cases successfully treated with a combination of
digoxin and verapamil warns for maternal adverse effects as verapamil
caused second degree AV block in one mother 4. One fetus that initially
reverted to sinus rhythm on digoxin and verapamil died spontaneously
in utero and the authors conclude that this could have been the result
of side effects of the drug therapy 112. In addition, verapamil has been
shown to cause fetal bradycardia, heart block, depression of contractili-
ty and hypotension in the fetus 5, 35.
In conclusion, although verapamil, especially in combination with
digoxin, seemed to be a potent drug in fetal tachycardia, major con-
cerns have arisen on its adverse effects and possible increased
mortality. In our opinion, verapamil should, therefore, not be used in
the treatment of fetal tachycardia.
Adenosine
Pharmacodynamics
Adenosine, an endogenous purine-based nucleoside, is found in all
cells of the body. It delays AV-nodal conduction which interrupts re-
entry and restores normal sinus rhythm. Adenosine can be used to con-
firm the diagnosis of re-entrant tachycardia.
Pharmacokinetics
Erythrocytes or vascular endothelial cells eliminate adenosine by
uptake from the plasma. Elimination half-life is very short (<10 sec).
Dose
Adenosine is used for direct treatment of the fetus by intravenous
injection into the umbilical vein in a dose of 0,1-0,2 mg/kg estimated
fetal weight 10.
Adverse effects and precautions
The short elimination half-life limits the maternal adverse effects of
direct fetal treatment and a number of reports have described the saf-
ety of adenosine during all phases of gestation 113.
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Clinical experience
A few case reports are described in which fetal administration was
transiently successful 26, 29, 80. However, tachycardia recurred in all
fetuses and additional therapy was required. One fetus died, presuma-
bly of recurrence of the tachycardia or as a result of proarrhythmic
effects of the drug regimen 114.
In conclusion, adenosine is a potent drug for direct fetal treatment of
SVT with immediate but transient cardioversion, however, in all cases
additional drug therapy is required. In our opinion, if one opts for
direct fetal therapy, a drug with a longer lasting effect has the prefe-
rence.
Discussion
Necessity for treatment
The decision to initiate pharmacological intervention in the case of
fetal tachycardia depends on several factors and must be weighed
against possible maternal and/or fetal adverse effects inherent to the
use of antiarrhythmics (see drugs). The problems encountered with a
premature delivery has lead to the decision of treatment in utero, alt-
hough delivery by cesarean section in case of a gestational age of > 33
weeks may be an option in severe cases with therapy resistant tachy-
cardia. The most important goal of initiation of treatment is the pre-
vention or resolution of hemodynamic compromise with subsequent
development of hydrops. Although conversion to a sinus rhythm is
desirable 7, in case of atrial flutter, an AV-block with a significant
decrease in ventricular rate is acceptable. In cases where signs of
hemodynamic compromise is present, the fetus is at high risk of demi-
se and should therefore be treated immediately 115. However, the opti-
mal treatment protocol of fetuses with isolated tachycardia (without
signs of hemodynamic compromise) remains controversial 6. The
absence of reliable predictors of fetal hydrops and the difficulties in
management of hydropic fetuses lead to the initiation of treatment as
soon as the diagnosis of fetal tachycardia has been established in most
centers 17, 116. The reports on expectant management in fetal tachycar-
dia 6, 7, 53 oppose this regimen and suggest that in cases with isolated
fetal SVT, conservative management in the setting of close surveillance
could prove to be a reasonable alternative, since spontaneous resolu-
tion of the tachycardia has been described 1, 6.
Determining the likelihood of the development of hydrops in a particu-
lar case may be a difficult or impossible task. However, if one contem-
plates to opt for conservative therapy, the following factors play a role:
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• The percentage of time that the tachycardia is present. Sustained
tachycardias are presumed to be at greater risk to develop hydrops
although intermittent tachycardias can lead to hydrops as well 117.
• The ventricular rate may be a predictive factor in the development of
hydrops 7. However, several reports did not found a difference in ventri-
cular rates between hydropic and nonhydropic fetuses 27, 90.
• The site of origin of the tachycardia may play a role in the risk of deve-
lopment of hydrops. When the atrial depolarization arises in the left
atrium, the resulting reversal in the pressure gradient could result in a
volume overload of the right atrium. This could be the first step in a
rise in right atrial and systemic venous pressure 10.
Hemodynamic compromise may occur in less than 24 hours in these
fetuses 4, 118 and the three factors described are not very sensitive. We
therefore prefer to initiate therapy as soon as the diagnosis has been
established. The more so since outcome in hydropic fetuses is poor
with intra uterine death or neurological damage as possible conse-
quences 119.
Place for Direct fetal treatment
Transplacental therapy should be the mode of therapy in nonhydropic
fetuses and first choice in hydropic fetuses. However, when conversion
to sinus rhythm is not achieved with several maternally administered
antiarrhythmic drugs, one may opt for direct fetal therapy.
The relative therapy resistance to transplacental therapy in hydropic
fetuses has lead some centers to pursue direct fetal therapy 21, 26, 29, 47,
105, 106, 114. Several modes of direct fetal therapy have been described,
including intra-umbilical, intra-amniotic, intra-peritoneal, intra-muscu-
lar and intra-cardiac injections. These reports however, show a signifi-
cant mortality, but it is unclear if these deaths are attributable to the
invasive measures or the severity of the underlying condition.
The routes of administration all have their specific characteristics. An
intra-umbilical injection allows direct access to the fetal circulation
and thereby the potential for a quick response to therapy 47 , a charac-
teristic also observed with intra-cardiac injections. However, both of
these invasive measures pose a significant risk to the fetus. Intra-peri-
toneal, intra-amniotic and intra-muscular injections (preferably in the
buttock of the fetus), pose less risk to the fetus and provide a more
sustained release of the medication.
Parilla et al. combined the use of transplacental and direct fetal intra-
muscular therapy with digoxin in 6 fetuses with SVT complicated by
hydrops 47. While some fetuses required additional transplacental
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drugs, the authors saw a reduction in time to cardioversion and resolu-
tion of hydrops compared to a group that was solely treated with
transplacental multi-drug therapy. Hansmann et al. treated fetuses
with SVT complicated by hydrops with IV therapy via the umbilical vein
after failed transplacental therapy 26. A mean of seven injections
(range 2 to 25) was required to achieve sustained sinus rhythm, but
several fetuses died in utero. Simpson et al. reported in 1998 on 4 fetu-
ses that were treated through direct fetal therapy 29. One fetus died
immediately after an intra-umbilical injection of 0,2 mg verapamil. Two
fetuses were successfully converted with intra-umbilical amiodarone
(dosage varying from 10 – 20 mg), while another fetus that was treated
by intra-umbilical amiodarone died 2 days after birth due to multiple
complications. Flack and colleagues took a different approach, a hydro-
pic fetus with atrial flutter at 480 bpm with 2:1 AV-block that was
refractory to transplacental sotalol and flecainide therapy, was treated
by combined intra-umbilical, intra-peritoneal and transplacental amio-
darone therapy 106. While the intra-umbilical route (15 mg) provided a
rapid therapeutic response, the intra-peritoneal injection of 15 mg pro-
vided a maintenance dosage. The oral maternal dosage of 200 mg
3x/day prevented the amiodarone from spreading from the fetal to the
maternal compartment and may even have maintained a therapeutic
level in the fetus. This combined therapy succeeded in controlling the
tachycardia and resolving the hydrops, and maybe even more impor-
tant, succeeded in minimizing the number of invasive procedures.
Other case reports provide us with information that placental transfer
of digoxin in hydropic fetuses is poor and intra-muscular fetal injec-
tions proved to be successful in reaching adequate therapeutic levels
and conversion to sinus rhythm 16, 21. Kohl et al. converted a hydropic
fetus with SVT at 240-280 bpm with intra-umbilical adenosine injec-
tions (0,2 mg/kg); to maintain sinus rhythm, digoxin 0,05 mg/kg and
flecainide 1,0 mg/kg was injected intra-umbilically 114. One week later,
the fetus had died in utero, presumably due to the recurrence of the
pre-existent tachycardia or as a proarrhythmic result of the drug regimen.
If one chooses to opt for direct fetal therapy, one must bear in mind
that the antiarrhythmic drug will probably distribute to the maternal
compartment, unless this compartment is primed with the drug.
Therefore, direct fetal therapy should always be administered as an
adjunct to maternal administration 80. In addition, intra-muscular or
intra-peritoneal injections that provide a more sustained release into
the fetal circulation, as well as an antiarrhythmic drug with a long
half-life are to be preferred as this will minimize the number of invasi-
ve procedures required 106.
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Future prospects 
Fetal magnetocardiography
The lack of the presence of a reliable fetal ECG has hampered our abili-
ty to define the exact electrophysiologic mechanism of the tachycar-
dias encountered in utero. The development of fetal magnetocardio-
graphy, a method that measures in a noninvasive way the magnetic
field produced by electrical currents in the fetal heart, provides a way
to define the electrophysiologic mechanism of the tachycardia 120. This
has resulted in several publications on the diagnosis of the long QT
syndrome in utero 121, 122.
Development of specific therapeutic protocols
Specific types of tachycardia (e.g. WPW syndrome, long QT syndrome),
are sometimes treated with potentially harmful drugs. In addition,
fetuses with a specific condition are probably not always treated with
the optimal drug for that condition. Establishment of the exact elec-
trophysiologic mechanism of the tachycardia as described in the pre-
vious paragraph enables the pharmacological intervention to be speci-
fic for the type of tachycardia. This may result in a more fitting appro-
ach to these specific types of tachycardia, and therefore may result in
higher success rates and decrease the incidence of morbidity and mor-
tality, possibly induced by contraindicated antiarrhythmic agents.
Development of new antiarrhythmics
Much is to be expected form the ongoing development of new drugs
with specific clinical applications and with less adverse effects. A pro-
mising agent is dofetilide, a pure class III antiarrhythmic agent, which
is specifically developed for the treatment of atrial flutter/fibrillation.
Optimal dosing regimen
Transplacental drug therapy requires an adequate dosing schedule as
the antiarrhythmic agent will spread to two compartments with trans-
placental passage playing a crucial part in the eventual outcome.
Currently a prospective study on the pharmacokinetics in transplacen-
tal therapy is performed at our center. The relationship between
maternal, fetal, amniotic and neonatal plasma levels of antiarrhythmic
drugs and the effects of drug therapy may eventually lead to an opti-
mal dosing regimen.
MulticenterTrial
Most treatment protocols found  in the international literature are
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based on a combination of local clinical experience and retrospective
studies. In view of the evidence based medicine, we and Simpson and
Sharland 29 , consider there is a need for a prospective, multicenter,
randomized trial to establish the optimum protocol for the manage-
ment of fetal tachycardias.
Proposed drug protocol
Based on the literature and previous studies at our center in Utrecht
we developed a drug protocol for fetal SVT (figure 1) and for fetal AF
(figure 2).
Figure 1
Utrecht protocol Fetal Supraventricular Tachycardia
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No Fetal Hydrops
Fetal SVT
Sotalol orally
160 mg 2x/day
during 3 days
Increase of Sotalol orally
160 mg 3x/day
during 3 days
No conversion to sinus rhythm
or decrease of ventricular rate
Addition of Digoxin orally
0,250 mg 3x/day
during 3 days
No conversion to sinus rhythm
or decrease of ventricular rate
Increase of Digoxin orally
0,500 mg 2x/day
No conversion to sinus rhythm
or decrease of ventricular rate
Fetal Hydrops
Digoxin intravenous:
1,0-2,0 mg in 24 hours followed 
by 0,5-1,0 mg/day during 3 days
Flecainide orally 
200-400mg/day
during 3 days
No conversion to sinus rhythm
or decrease of ventricular rate
Combination of Digoxin intravenous
and Flecainide orally
during 3 days
Consider 
Direct fetal therapy
No conversion to sinus rhythm
or decrease of ventricular rate
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Figure 2
Utrecht protocol Fetal Atrial Flutter
In the treatment of fetal nonhydropic SVT  we recommend sotalol as
drug of first choice, followed by digoxin as drug of second choice. This
protocol has reached conversion rates of around 60 % with sotalol as a
single therapy, and a conversion rate of 71 % after the addition of dig-
oxin. These results are comparable with the upper range of other treat-
ment protocols.
In case of SVT complicated by hydrops we opt for a more aggressive
approach with maternal IV digoxin or maternal oral flecainide. The
second step is a combination of these drugs.
In fetal AF we prefer the use of sotalol above digoxin. Our center has
been using this protocol for many years now, and has been satisfactory.
We believe that sotalol is superior to digoxin in the treatment of fetal
AF as written in our article 90, with a conversion rate as high as 80 %,
nowhere to be found in the international literature in which conver-
sion rates are mentioned of around 50 %. However, if sotalol as a single
therapy fails to restore sinus rhythm within 6 days, we do add digoxin
Fetal AF
Sotalol orally
160 mg 2x/day
during 3 days
Increase of Sotalol orally
160 mg 3x/day
during 3 days
No conversion to sinus rhythm
or decrease of ventricular rate
Addition of Digoxin orally
0,250 mg 3x/day
during 3 days
No conversion to sinus rhythm
or decrease of ventricular rate
Increase of Digoxin orally
0,500 mg 2x/day
No conversion to sinus rhythm
or decrease of ventricular rate
No Fetal Hydrops Fetal Hydrops
Chapter 5
96
to the treatment. We therefore do value the place of digoxin in the tre-
atment of fetal AF. In our protocol there is no difference in treatment
with regard to the hydropic state.
Conclusions
Fetal tachycardia can lead to fetal hydrops, neurological damage and
fetal death. In the absence of reliable predictors of hemodynamic com-
promise, pharmacological intervention, as soon as the diagnosis has
been established, has our preference. In fetuses with SVT not complica-
ted by hydrops, or AF with/without fetal hydrops, oral maternal trans-
placental therapy is preferred. Sotalol is the drug of first choice, follo-
wed by digoxin as drug of second choice. Fetal SVT complicated by
hydrops should be more aggressively treated, by digoxin administered
intravenously. However, one can opt for oral flecainide therapy as it has
proven to be very successful in hydropic fetuses. The second step in
fetal SVT is a combination of IV digoxin and oral flecainide. In cases
complicated by severe hydrops and/or in case of therapy resistance,
direct fetal therapy may be initiated. Our preference would be to opt
for an approach that will quickly achieve a therapeutic level in the
fetus and thus hopefully conversion to sinus rhythm, for instance
through the umbilical route. Secondly, a more sustained release of the
antiarrhythmic agent into the fetal circulation is desirable and may be
reached through an intramuscular or intraperitoneal fetal injection.
Finally, direct fetal therapy should always be installed in conjunction
with oral maternal therapy.
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Abstract
Background
Maternally administered, intra uterine therapy of fetal tachycardia is
dependent on the transplacental passage of the antiarrhythmic agent.
In this study, the pharmacokinetics and -dynamics of sotalol and
digoxin are therefore investigated.
Methods
A prospective study of patients treated for fetal tachycardia with sota-
lol and/or digoxin. Concentrations of sotalol and/or digoxin were
determined in maternal, umbilical and neonatal blood and in amniotic
fluid and the relationship between these concentrations and the occur-
rence of conversion to sinus rhythm, was investigated.
Results
Nineteen patients were studied, 10 with atrial flutter and 9 with supra-
ventricular tachycardia. Fourteen were treated with sotalol; 13 conver-
ted to sinus rhythm, of whom 2 relapsed. There was one intra uterine
death. Four patients were treated with sotalol and digoxin of whom 2
successfully. One patient was unsuccessfully treated with digoxin and
flecainide. Mean birth weight was 3306 gram.The daily maternal sota-
lol dose was linearly related to the maternal plasma concentration.
The mean fetal/maternal sotalol plasma concentration (F/M ratio) was
1,1 and the mean amniotic fluid/fetal blood ratio of sotalol was 3,2. The
effectiveness of sotalol therapy could not be extrapolated from
maternal blood levels. The sotalol T1/2 in neonates varied from 5,9 to
48 hours. Digoxin passes the placenta partially with a mean F/M ratio
of 0,53.
Conclusions
Sotalol is a potent anti-arrhythmic agent in the treatment of fetal
tachycardia. The placental transfer is excellent. Sotalol accumulates in
amniotic fluid but not in the fetus itself. Therefore it seems that renal
excretion in the fetus is efficient and greater than the oral absorption
by fetal swallowing. The maternal blood level is not a reliable predictor
of the chances of success of therapy. Sotalol is not associated with
fetal growth restriction. Pharmacokinetics in the neonate show that
the renal excretion in the neonate is adequate.
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Introduction
Fetal tachycardia is a condition that occurs in approximately 0,4-0,6%
of all pregnancies 1.
It is associated with congestive heart failure, fetal hydrops, neurologi-
cal morbidity and intra-uterine death 2-5. Most centers have therefore
opted for prenatal intervention in the form of maternal pharmacologi-
cal treatment 6-18. Its success however, depends largely on the amount
of drug that crosses the placenta, which is subject to the altered
maternal pharmacokinetics and pharmacodynamics in pregnancy.
Various physiologic changes during pregnancy influence maternal
pharmacokinetics. In addition, the fetal plasma concentration is also
influenced by changes in the fetus itself. Studies on the maternal-
placental-fetal unit are limited for obvious ethical reasons, however,
the treatment of fetal tachycardia provides us with a unique opportu-
nity to investigate this matter. In the literature, data on the trans-
placental passage of sotalol is confined to two small studies and one
case report 19-21.
We present a study in which we have prospectively investigated drug
levels of the anti-arrhythmics sotalol and digoxin, in maternal blood,
umbilical cord blood after delivery, amniotic fluid and neonatal blood.
A correlation between the success or failure of treatment of maternal-
fetal pharmacotherapy and blood concentrations in both mother and
neonate is presented.
Methods and Materials 
Definitions
Fetal tachycardia, defined as a fetal heart rate exceeding 180 bpm, was
diagnosed by M-mode echocardiography and subdivided in supraven-
tricular tachycardia (SVT; 1:1 atrioventricular conduction) and atrial flut-
ter (AF; atrial rate >250 bpm with a fixed or variable atrioventricular
block).
Congestive heart failure was diagnosed if fluid accumulation existed in
the fetal body, such as pericardial effusion, pleural effusion, ascites or
skin edema. Fetal hydrops was diagnosed if fluid accumulation existed
in 2 or more of these compartments.
Patients
All mothers that were diagnosed with fetal tachycardia at the depart-
ment of Obstetrics, University Medical Center, Utrecht, from 1999 until
2002 were given a detailed description of the study protocol and con-
sented to enter this study. A maternal history was obtained to exclude
preexisting arrhythmias, and a maternal ECG was made to exclude pro-
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longed QT intervals. Therapy was installed according to a previously
published protocol, consisting of sotalol 160 mg 2dd, increased to a
maximum of 160 mg 3dd, and the addition of digoxin in case conver-
sion to sinus rhythm did not occur 18, 22. Patients were regularly sche-
duled (at least once a week) for control visits to evaluate the fetal
heart rhythm and possible signs of congestive heart failure.
All deliveries took place at our institution and neonates were admitted
immediately after birth for at least 48 hours for observation. Postnatal
ECG’s were performed in all neonates.
Blood sampling
At every prenatal visit, a 5 ml blood sample was drawn from a maternal
peripheral vein to measure maternal drug levels. At the time of deli-
very 5 ml maternal blood, 5 ml blood from the umbilical artery and
from the umbilical vein and whenever possible, 10 ml of amniotic fluid
was collected. In three neonates, multiple blood samples of 1,5 ml were
drawn to measure the elimination rate in the newborn.
Drug analysis
Digoxin in plasma was quantified using AxSYM Digoxin II Microparticle
Enzyme Immunoassay (Abbott Laboratory, North Chicago, IL 60064,
USA).
Sotalol concentrations in plasma and amniotic fluid were determined
by a modified ionpair reversed-phase HPLC method, with ultraviolet
detection at 226 nm described by Kärkkäinen 23. The lower limit of
quantification was 0,08 mg/L with an intra day coefficient of variation
(CV) of 4,4% at 0,02 mg/L and an inter-day CV of 2,6% at 0,02 mg/L 24.
Approval
The study was approved by the Medical Ethics Review Committee of
the UMCU, according to the Helsinki protocols.
Results
Nineteen women agreed to participate in this study. Details on diagno-
sis, treatment modalities and outcome are summarized in Figure 1. Out
of 10 patients with AF, one fetus was hydropic; 2 out of 9 fetuses with a
SVT had congestive heart failure. Fourteen patients received sotalol as
single therapy. Of these fourteen patients, 10 converted to sustained
sinus rhythm in a mean time to conversion of 46 hours (SD 32 h). In
one additional patient two weeks were required to reach sustained
sinus rhythm. Two patients, who initially converted to sinus rhythm
within 48 hours, relapsed into tachycardia, after 1 and 5 weeks of sinus
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rhythm, respectively. Since both patients had reached a gestational age
of 37 + weeks at that time, we decided to perform a caesarean section
(S.C.) rather than increasing the dosage or addition of another antiar-
rhythmic agent. One nonhydropic fetus with SVT died unexpectedly 3
days after initiation of therapy with sotalol 160 mg 2dd. Sinus rhythm
had not been achieved. The maternal blood level of sotalol was 1,01
mg/L, which is within the normal range. Autopsy showed significant
dilatation of the heart and minimal signs of hydrops. No structural
abnormalities were present.
In four patients, digoxin was added to the sotalol treatment according
to protocol, because of persistent fetal tachycardia. In two patients this
was successful 24 h and 48 h after the addition of digoxin, respectively.
One patient was delivered by S.C. at 35 weeks and 6 days after mem-
branes had ruptured spontaneously and a prolapsed arm was
diagnosed; sinus rhythm had not been achieved despite longstanding
multiple drug therapy. The other patient was delivered by S.C. at 36
weeks and 6 days because of persistence of tachycardia despite 6 days
of multiple drug treatment.
One patient with AF received both flecainide and digoxin. The addition
of digoxin yielded a decrease in rhythm from 420/220 bpm to 300/150
bpm, however signs of fetal hydrops developed and maternal side
effects consisting of nausea, vomiting and general malaise, probably
due to extensive medication, increased. At 34 weeks and 1 day amnio-
centesis showed adequate fetal lung maturation
(Lecithin/Sphingomyelin ratio > 2) and a S.C. was performed.
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Figure 1
Details on diagnosis, treatment modalities and outcome of all cases. SVT, supraventricular
tachycardia; AF, atrial flutter; SC, caesarean section.
Sotalol and digoxin levels
Maternal sotalol levels measured at the prenatal visits in all patients
increased linearly with increasing dosis (Figure 2).
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Figure 2
Mean interquartile range and overall range of maternal blood levels of sotalol per daily
dosage. Number of women with observations are shown within brackets. A linear
relationship between blood level and increasing dosage is shown.
Umbilical vein samples were obtained in 12 cases. The relationship
between maternal sotalol dosage and umbilical vein concentration is
shown in Figure 3.
Figure 3
Mean interquartile range and overall range of umbilical blood level of sotalol per daily
maternal dosage. Number of observations are shown within brackets.
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Maternal and fetal blood levels were almost equal and the mean
fetal/maternal sotalol ratio was 1,11 (SD 0,63), Table 1.
Data on digoxin dose and maternal and umbilical cord levels are shown
in Table 1. The mean fetal/maternal digoxin ratio was 0,53 (SD 0,21).
Case # F/M sotalol F/M digoxin Amn. fluid/F sotalol  
1 0,83 
2 0,75 0,53  
3 0,75 0,77  4,0
4 1,79 3,15
5 1,02 
6 1,14 0,56  2,57
7 0,85 3,11
8 0,67 2,49
9 0,72 5,8
10 2,87 1,28
11 0,25  
12 0,82 
13 1,1 
Mean 1,11 0,53  3,2
SD 0,63 0,21  1,4
Table 1
The fetal/maternal ratio’s at the time of delivery of sotalol and digoxin. Amn. fluid/F sotalol
= ratio of sotalol in amniotic fluid/fetal blood.
Sotalol was measured in amniotic fluid in 7 cases. The concentration
was higher in amniotic fluid than in fetal cord blood and maternal
blood and the concentration ratio’s were 3,2 and 2,94 respectively.
Correlation between maternal blood levels and 
success of therapy
In figure 4 the maternal sotalol blood concentrations are shown in rela-
tion to the occurrence of conversion to sinus rhythm or otherwise. The
levels at which the drug proved to be effective were only slightly
higher than those that did not result in conversion, indicating a large
difference in sensitivity to the drug. In the 3 individual patients in
which sotalol initially was not effective, an increase in dose from 80
mg 2dd in two patients (blood levels 0,60 and 0,87 mg/L) to 160 mg
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2dd (blood levels 1,27 and 1,63 mg/L) and from 160 mg 2dd in one
patient (blood level of 0,77 mg/L) to 160 mg 3dd (blood level of 1,50
mg/L) was associated with conversion to sinus rhythm, whereas in one
case a decrease in dose (from 160 mg 2dd to 80 mg 3dd) and blood
level ( 1,75 mg/L to 0,6 mg/L) was associated with a relapse of AF.
Figure 4
Maternal blood levels of sotalol in relation to the occurrence of conversion to sinus rhythm
or persistence of tachycardia. No significant difference is noted.
Pharmacokinetics in the neonate
In 3 neonates, 2 to 3 blood samples were available for measurement of
the elimination half-life of sotalol. The results are shown in figure 5.
The T1/2 varied from 5,9 hours to 48 hours, roughly comparable to the 
T1/2 in adulthood (10-20 hrs).
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Figure 5
Blood samples of sotalol of 3 neonates. The calculated elimination half-life is shown on the
right.
Postnatal outcome
One fetus died in utero and one infant with a massive hydrops,
delivered at 33 weeks and 4 days, died two days after delivery. Follow-
up is available for the other 17 infants, varying from 6 months to 30
months after birth. Eight infants (5 had AF and 3 had SVT) had no
rhythm disturbances during the newborn period and no medication
was initiated. None of these patients have developed episodes of
tachycardia and are currently doing well. Four patients showed AF at
birth (three therapy resistant cases and one relapse) and all required
electrical cardioversion to reach sustained sinus rhythm. These four
patients are currently doing well and require no medication. Five
patients showed SVT postnatally, of whom 2 had WPW, 2 had PJRT, and
1 patient showed intermittent periods of SVT of unknown origin. All are
doing well on antiarrhythmic therapy, consisting of digoxin in two
patients, propranolol in one patient, and a combination of these two
agents in two patients.
All surviving infants are in good neurological condition.
Birth weight
The mean birth weight was 3306 gram (SD 814). All infants were
appropriate for dates with one exception. This baby was born at 33+4
weeks of G.A. with a birth weight of 960 gram, which is below 2,3 rd
percentile 25; this infant was only treated for 4 days and the low birth-
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Discussion
Success of therapy
In the patients treated with sotalol as a single agent, results were
favorable, since 13/14 patients converted to sinus rhythm in a relatively
short amount of time. Unfortunately, the one patient who went into
premature labour did not profit long enough of sinus rhythm as this
only lasted for three days and hydrops was still present at the time of
delivery. The other 2 patients who went into relapse clearly profited
from in utero therapy as they reached gestational maturity while on
therapy. Our choice of delivery by S.C. at that time rather than the
increase of dosage or the addition of a second antiarrhythmic agent
was based on our opinion that the possible harmful effects of trans-
placental therapy (adverse effects of mother, and potential proarrhyth-
mic effects for both mother and fetus) outweigh the benefits of 
further in utero maturation. In the case that was treated with both
sotalol and digoxin in which no conversion was reached at 36+6 weeks,
the decision to perform a S.C. was based on the same opinion.
The unexpected intra uterine death, possibly as a result of ventricle
fibrillation raises the possibility of proarrhythmic effects of sotalol in
the fetus. Although we have no evidence that this was indeed the
cause of death, we think that this possible risk should be minimized.
Intra uterine therapy should therefore always be weighed against pos-
sible adverse effects. As proarrhythmia of sotalol is known to be dose
related 26, low initiation doses are preferable and dosage increases
should be stepwise. Close monitoring, especially during the initiation
phase is recommended. We therefore propose a new dosage scheme
with an initiation dose of 80 mg 2dd, stepwise increased with 80 mg
per 3 days to a maximum of 160 mg 3dd. Digoxin may be added as
second line drug.
Dosage and maternal blood levels
Despite high oral sotalol dosages, all maternal blood levels remained
below the ‘toxic’ level of 2,5 mg/L (at which marked QTc prolongation is
noted). This is probably the result of the increased blood volume in
pregnant women. This is important, as maternal adverse effects and
the risk on torsade de pointes tachycardia (as a result of QTc prolonga-
tion) are dose-related. The F/M ratio of 1,11 shows that the fetus also
stays below the ‘toxic’ level.
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Fetal/maternal ratio of plasma concentration
Sotalol passes the placenta easily and completely as can be concluded
from the mean F/M ratio of 1,11. This relates to the publication of
O’Hare et al.19, though differs from the lower ratio found in the study
of Erkkola et al.20. This could be explained by the nature of the study in
which only a single dose was administered 3 h before delivery. The
ratio of 1,11 compares favorably with the F/M ratios of other commonly
used drugs in fetal tachycardia. Apparently sotalol does not accu-
mulate in the fetus, which implies that the excretion of sotalol by the
fetal kidney is efficient close to term. The adequate renal excretion
may explain the relatively high concentration of sotalol in amniotic
fluid. The high amniotic fluid/umbilical venous blood ratio combined
with an almost 1:1 relationship of fetal and maternal blood and the
nature of swallowing of  amniotic fluid by the fetus implies that the
elimination rate of sotalol is greater than the oral reabsorption.
Digoxin passes the placental barrier, though not completely as is
observed by the F/M ratio of 0,62. This is in agreement with other
publications in which ratio’s of 0,4 – 0,9 27-30 have been found.
Therefore high maternal dosages are required to achieve adequate
fetal blood levels. This may induce maternal adverse effects as was
observed by us in one case in which the pregnancy had to be termina-
ted by 34 weeks and 1 day by S.C. because of these adverse effects and
the impossibility to increase the dosage further.
Correlation of maternal blood level and success of therapy
Although in individual cases, the maternal dosage of sotalol was rela-
ted to the success of therapy, statistically a strong relation between
the maternal blood level and the success of therapy was not shown.
The therapy resistant cases required either electrical cardioversion or
multiple drug therapy, wich suggests that the success of therapy may
be more related to the type of arrhythmia.
The maternal blood levels do however, strongly relate to the fetal
blood level and could thus be valuable in preventing the fetus to be
exposed to toxic levels.
Birth weight
Some Bèta blockers like propranolol, have been associated with intra
uterine growth retardation 31. All but one of our patients had birth
weights within the normal range with one exception, even though in
several cases this treatment was continued throughout the whole
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third trimester. Therefore, it seems unlikely that sotalol induces fetal
growth restriction.
Conclusions
We conclude that sotalol is a potent anti-arrhythmic agent in the
treatment of fetal AF with or without hydrops as well as in SVT not
complicated by hydrops. Sotalol passes the placenta quickly and
reaches a steady state level almost identical to the maternal plasma
level. Maternal blood levels can therefore be used as an indicator of
the fetal blood levels. Sotalol accumulates in amniotic fluid but not in
the fetus itself, indicating that renal excretion is efficient, and implying
that the elimination rate of sotalol exceeds oral absorption in term
fetuses. Maternal blood levels are not a reliable predictor of the chan-
ces of success of therapy. Sotalol is not associated with fetal growth
restriction. Pharmacokinetics in the neonate show that the renal excre-
tion in the neonate is adequate and comparable to the excretion in
adults.
Treatment of Fetal Tachycardia with Sotalol:
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Abstract
Background
Fetal tachycardia may cause hydrops fetalis and may lead to fetal
death. No unanimity of opinion exists regarding the optimum treat-
ment. This study evaluates our experience with transplacental sotalol
therapy in the treatment of fetal tachycardias in terms of safety and
efficacy.
Methods and Results
The charts of 21 patients who were treated with sotalol for fetal tachy-
cardia were reviewed. Ten fetuses had atrial flutter (AF), 10 had supra-
ventricular tachycardia (SVT) and 1 had ventricular tachycardia (VT).
Hydrops fetalis was present in 9 fetuses. Drug treatment was
successful in establishing sinus rhythm in 8 of 10 fetuses with AF and
in 6 of 10 fetuses with SVT. The mortality rate in this study was 19%
(4 of 21 fetuses, 3 had SVT, 1 had AF), 3 deaths occurred just days after
initiation of sotalol therapy and 1 occurred after a dosage increase.
At birth, tachycardia was present in 6 infants. Two patients who con-
verted to sinus rhythm in utero were found to suffer from neurologic
pathology postnatally.
Conclusions
Fetal tachycardia is a serious condition in which treatment should be
initiated, especially in the presence of hydrops fetalis. The high success
rate in fetuses with AF suggests that sotalol should be considered a
drug of first choice in fetal AF. The low conversion rate and the fact
that 3 of the 4 deaths in this study occurred in fetuses with SVT
indicate that the risks of sotalol therapy outweigh the benefits in this
group and that sotalol should, therefore, be limited in the treatment of
fetal SVT.
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Introduction
Fetal tachyarrhythmia may cause nonimmune fetal hydrops and lead
to fetal morbidity and mortality 1-6. Several protocols for pharmacologi-
cal therapy to restore sinus rhythm have been proposed 7-18. Digoxin
and flecainide are the most commonly used agents in such therapies.
Digoxin as a single therapy, however, is not successful in restoring
sinus rhythm in all fetuses with atrial flutter (AF) or in hydropic fetuses
8, 11-13, 19-21. The use of flecainide was called into question after a report
regarding the potential proarrhythmic dangers of this drug 9. These
data have lead to a continued search for new and possibly better
drugs.
Sotalol is a potent Bèta-blocking agent with additional class III antiar-
rhythmic properties and a mild or absent negative inotropic effect 22, 23,
that has proven to be safe and efficacious in the treatment of tachy-
cardia in adults 24-26 and infants 27-30. Sotalol passes the placental bar-
rier rapidly and almost completely 31. On the basis of these findings, we
hypothesized that sotalol would be a safe and effective antiarrhythmic
agent for the treatment of various forms of tachycardia in fetuses.
Little is known about the effect of sotalol on fetuses. We present a
multicenter retrospective study reviewing our experience with the use
of sotalol in the treatment of fetal tachycardia.
Methods
Patients
This retrospective study includes 21 fetal patients who were diagnosed
with tachycardia between 1993 and 1999 at the University Hospitals of
Utrecht and Nijmegen, the Netherlands and Yale-New Haven Children’s
Hospital, New Haven, CT, USA. The patients included in the study had
either supraventricular tachycardia (SVT, defined by 1:1 atrioventricular
(AV) conduction with a rate of > 180 beats per minute, bpm) or atrial
flutter with a regular atrial rate of > 250 bpm with fixed or variable AV
block. Ventricular tachycardia (VT) was encountered in 1 patient who
will be described separately. Tachycardia was detected during routine
prenatal visits, and the patients were subsequently referred for further
evaluation. Associated cardiac structural abnormalities and possible
definable causes for tachycardia, such as viral infections, were exclu-
ded. Hydrops fetalis, a sign of fetal cardiac failure, was diagnosed when
two or more fluid collections existed in the fetal body, such as pericar-
dial effusion, pleural effusion, ascites and skin edema, regardless of the
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amount of effusion present. Fetuses were monitored for 30 minutes
and treatment was initiated when during this whole period tachycar-
dia was present or a combination of intermittent tachycardia and
hydrops fetalis existed.
In Utero Management
Oral maternal drug therapy was chosen because of previous positive
experience with this technique 11. Patients received sotalol as their ini-
tial mode of therapy to achieve sinus rhythm or rate control due to
partial AV block. Prior to the initiation of sotalol therapy, preexisting
arrhythmias in the mother were excluded. Mothers were interviewed
to reveal possible histories of arrhythmic events and ECG’s were
performed to evaluate QT-interval to minimize the potential for
maternal proarrhythmic events.
Dosage
The starting dosage used was  80 to 160 mg of sotalol, given orally 2
times a day. The dosage was occasionally increased to a maximum of
160 mg 3 times per day if tachycardia persisted 32. Digoxin was added
to the treatment in patients in whom adequate control could not be
achieved with sotalol as a single therapy.
Variables included in the study were the following: gestational age at
recognition of the tachycardia, heart rate, mechanism of the tachycar-
dia as noted on prenatal M-mode echocardiography, the presence of
hydrops, possible structural malformations, in utero therapy and
results, maternal adverse effects, gestational age at birth, mode of
delivery, Apgar score, mechanism of the tachycardia as noted on post-
natal electrocardiography, postnatal therapy and outcome of these
newborns.
The statistical evaluation of the differences in heart rates and time to
successful conversion was performed by Student t-test. A p-value of
< 0,05 was considered significant.
Results
The 21 fetuses were divided into 3 groups according to their electrophy-
siologic mechanism as noted on prenatal M-mode echocardiography
(Figure 1). SVT was present in 10 fetuses; they had heart rates of 200 to
300 bpm (mean, 237 bpm; mean peak fetal heart rate 260 bpm). AF
existed in 10 fetuses; they had atrial rates of 283 to 550 bpm (mean,
383 bpm; mean peak fetal heart rate 403 bpm) and a variable degree of
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AV block, which resulted in a slower ventricular heart rate (mean, 193
bpm). VT was seen in 1 fetus. A total of 9 fetuses were hydropic at the
time of presentation: 5 had SVT, 3 had AF and 1 had VT. The mean
gestational age at the time of presentation was 31 weeks (SEM, 0,96
weeks).
Figure 1.
Allocation of patients to three groups.
AF= atrial flutter, FH= fetal hydrops, G.A.= average gestational age (in weeks), phfr= avera-
ge peak fetal heart rate (beats per minute), SVT= supraventricular tachycardia, VT= ventri-
cular tachycardia.
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G.A. = 31
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10 SVT
G.A. =31
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p fhr = 280
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In utero management
Figure 2 shows the mode of therapy and results. Regardless of the
mechanism of tachycardia, all but 1 fetus were initially treated with
sotalol.
Figure 2.
Outcome of all fetuses, differentiated in the presence of hydrops and form of therapy.
IUD= intra uterine death.
Nonhydropic fetuses
Twelve fetuses showed no signs of hydrops at the time of presentation:
5 had SVT and 7 had AF. All 12 fetuses had a gestational age of 21 to 37
weeks and were started on sotalol as a single therapy; 7 converted to
normal sinus rhythm and no further tachycardia was encountered.
Relapses
One patient (aged 21 weeks) who had AF at 300 bpm and 3:1 AV block
converted to sinus rhythm on a sotalol dose of 160 mg 2 times per day,
but the patient relapsed into flutter after the initial sotalol dosage was
diminished to 80 mg 3 times per day. This prompted an increase in the
sotalol dosage to 80 mg 4 times per day and the addition of digoxin to
the drug regimen. Stable sinus rhythm was then achieved, and no
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further relapses occurred. A second patient (aged 35 weeks) who had
SVT at 300 bpm initially reverted to sinus rhythm for 2 weeks, after
which a relapse occurred. The original dosage of sotalol had been
decreased from 80 mg 3 times per day to 80 mg 2 times per day; it was
subsequently increased to 160 mg 2 times per day. The fetus died in
utero 1 day later. Autopsy did not establish a cause of death.
One patient with SVT at 240 bpm did not convert to sinus rhythm
although the heart rate slowed to 210 bpm. Despite a dosage increase
from 80 mg 3 times per day to 80 mg 4 times per day, SVT persisted at
210 bpm. After 1 week of  unsuccessful treatment, a caesarean section
was performed at 37 weeks of gestation. Shortly after birth the patient
was diagnosed with a permanent junctional reciprocating tachycardia.
Heart rate persisted at 195 bpm, and intravenous digoxin therapy was
initiated. This was followed by conversion to normal sinus rhythm.
The remaining 2 nonhydropic fetuses, both with AF, did not convert to
sinus rhythm and digoxin was added to their treatment. This combina-
tion succeeded in restoring sinus rhythm in 1 fetus. In the other
patient, sinus rhythm was never achieved but an atrial rate of 220 bpm
and a ventricular rate of 110 bpm was well tolerated. At birth the ECG
showed AF and electrical cardioversion established a normal sinus
rhythm of 130 bpm.
In summary, 75 % of nonhydropic fetuses were successfully converted
to a normal sinus rhythm in a mean period of 7 days (1-28 days), in 1
patient only an adequate block was achieved. Mean gestational age at
birth was 39 weeks.
One fetus with SVT at 300 bpm died suddenly after the dosage of sota-
lol had been increased to 160 mg 2 times per day.
Hydropic fetuses
Eight fetuses were hydropic at the time of presentation (gestational
age ranged from 25 to 33 weeks), 5 had SVT and 3 had AF. Sotalol as a
single therapy successfully converted cardiac rhythm to sinus rhythm
and resolved the hydrops in 2 fetuses. One severely hydropic fetus with
SVT at 240 bpm at 29 weeks of gestation was started on 160 mg of
sotalol 3 times per day, but the fetus died in utero after 2 days of treat-
ment. Autopsy showed signs of chronic anoxia, and an abnormal acces-
sory myocardial AV connection was seen, suggesting a reentry tachy-
cardia mechanism. Another fetus, who had SVT at 260 bpm at 25 weeks
of gestation and signs of ascites was initially treated with multiple
drug combinations, including digoxin, flecainide and propranolol, as
well as direct fetal intra-umbilical therapy with adenosine, which was
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transiently successful for 30 minutes. Tachycardia persisted and hydro-
ps fetalis worsened, therefore, at 29 weeks of gestation, all previous
medication was withdrawn and sotalol was started at a dosage of 120
mg 2 times per day. The heart rate slowed within 2 days to 210 bpm,
with intermittent episodes of sinus rhythm. As hydrops fetalis persis-
ted, the sotalol dosage was gradually increased to 160 mg 2 times per
day. The fetus converted into sinus rhythm with short runs of tachycar-
dia to 220 bpm. Six days after the initiation of sotalol therapy and 2
days after the dosage increase, an ultrasound showed no fetal move-
ments and a fetal heart rate of 90 bpm. On prostaglandin, the mother
went into labour and gave birth to a stillborn infant. The retrospective
nature of this study made it impossible for us to elucidate why induc-
tion of labour was preferred above an emercency caesarean section in
this case. Autopsy was not performed.
In 3 of the remaining 4 fetuses, rhythm control was achieved after the
addition of digoxin, with subsequent resolution of hydrops fetalis. The
fourth fetus had an AF rate of 440 bpm with 2:1 AV-block. Sotalol was
initiated at 80 mg 3 times per day. As rhythm control was not achieved,
digoxin was added to treatment and the sotalol dosage was increased
to 80 mg 4 times per day. Shortly after this change in treatment, the
fetus died in utero at 39 weeks of gestation. Autopsy showed severe
fetal hydrops, stenosis of the venous duct and a hypoplastic placenta.
In the hydropic group, 62,5 % of fetuses were successfully converted to
normal sinus rhythm in a mean period of 7 days and hydrops resolved
in all of these cases in a period ranging from 2 to 21 days (mean 14
days). The time to successful conversion to sinus rhythm was equal to
that in the nonhydropic group (p=0,921). Mean gestational age at birth
was 35 weeks. Three deaths occurred in the hydropic group, all of which
occurred in a period ranging from 2 to 6 days after the initiation of
sotalol.
Ventricular tachycardia
In 1 hydropic fetus, an intermittent tachycardia with a rate of 260 to
280 bpm was diagnosed at the gestational age of 30 weeks. This was
erroneously interpreted as SVT and sotalol therapy was initiated. On
this therapy the tachycardia worsened and became persistent. The
echocardiographic appearance of the heart showed a strange peristal-
tic-like movement suggesting a torsade de pointes mechanism. Sotalol
therapy was withdrawn and replaced by digoxin, which remained
unsuccessful. After birth by caesarean section at 31 weeks, this patient
proved to have prolonged QT syndrome and uncontrollable periods of
ventricular, torsade de pointes tachycardia. Despite extensive and mul-
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this patient died at 2 years of age of uncontrollable VT and secondary
myocardiopathy.
Adverse effects
In 2 cases, maternal adverse effects were encountered. They were only
temporary. One mother experienced nausea, and the other, dizziness
and fatigue.
Unfortunately, we did not recognize fetal VT in 1 patient, and the wor-
sening of the fetal tachycardia was probably because of provocation of
torsade de pointes in this patient.
Supraventricular tachycardia versus atrial flutter
Sotalol therapy was successful in 6 of 10 fetuses with SVT and in 8 of
10 fetuses with AF. Treatment was partially effective in 2 fetuses, 1 with
AF and 1 with SVT. Drug therapy was effective in 60% of cases of SVT
and in 80 % of cases of AF. Three deaths in the SVT group and 1 in the
AF group were encountered.
Management and outcome after birth
Follow-up was possible in 17 cases as there were 4 intra uterine deaths.
No rhythm disturbances were seen in 11 of the 17 surviving patients
with fetal tachyarrhythmias (65 %). Prophylactic drug therapy was
administered for 9 months to 1 year in 5 of these 11 patients; 2 patients
received sotalol, and the other 3 patients received digoxin. None of
these patients have shown recurrent signs of tachycardia and are cur-
rently doing well.
A relapse of tachycardia was seen in 6 of the 17 cases (35 %). Two
patients had AF and 3 patients had SVT. The child with VT had recurrent
VT after birth. Two patients were successfully treated with sotalol, 1
patient was treated with digoxin and 1 patient received a combination
of sotalol and digoxin. The fifth patient had AF and was electrically car-
dioverted to restore sinus rhythm and sotalol was administered. All
newborns were treated till the age of one year.
Morbidity
Two patients with fetal hydrops had significant neurological morbidity
immediately after birth. One had SVT and was treated with sotalol, the
second had AF and was treated with sotalol and digoxin. Before con-
version to persistent sinus rhythm was achieved, these patients expe-
rienced intermittent episodes of tachycardia with long-lasting periods
of normal sinus rhythm. These episodes lasted 10 and 21 days, respecti-
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vely, at gestational ages of 29 and 25 weeks, respectively. Although
control of the tachycardia was achieved and these babies were born
with good Apgar scores, their postnatal evaluation showed neurologic
pathology; this was due to intracranial hemorrhage in one and cerebral
hypoxic ischemia in the other 33.
Discussion
Fetal tachycardia can lead to fetal heart failure and death. This has led
us to treat tachycardic fetuses prenatally, although others have been
reluctant to treat certain forms of tachycardia 34. The patients
described in this study were treated on the basis of the existence of
longstanding or sustained tachycardia with or without fetal hydrops.
Choice of drugs
Sotalol was drug of first choice in this study. Although previously used
agents such as digoxin and flecainide have proven to be successful in
most patients, various reports led us to search for alternative and
hopefully better drugs. High maternal serum digoxin levels are requi-
red to reach therapeutic levels in the fetus, because this drug has slow
and only partial transplacental transfer in the presence of hydrops
fetalis 19-21. Digoxin as a single therapy has had limited success in the
treatment of AF 8, 13. The use of flecainide remains controversial due to
the report by Allan et al. 9 of a fetal death that was possibly induced
by flecainide; however Frohn-Mulder  et al. 12 remain very positive on
the use of this drug.
The safety and efficacy of sotalol has been well established in adults,
children and infants 22-30. A negative inotropic effect, which might be
expected, has not been found in isolated cardiac tissue. On the contra-
ry, sotalol may even increase contractility slightly because its class III
antiarrhythmic properties, which prolong the action potential, may
increase time for calcium influx 22, 23. The use of digoxin as second-line
drug was motivated by the fact that digoxin, besides its antiarrhythmic
properties, may have a positive inotropic effect on the compromised
function of the fetal heart.
Recently, however, a study was published in which the risk of proar-
rhythmic events seemed to be higher in the pediatric age group than
in adults and close monitoring by ECG was recommended during the
initiation of sotalol therapy in children 27. The most serious potential
adverse effect of sotalol, the development of maternal torsade de
pointes/ventricular fibrillation, deserves serious consideration. To mini-
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mize this risk, the possible presence of prolonged maternal QT interval
must be excluded prior to the initiation of sotalol therapy. In addition,
a thorough and in-depth maternal history should be performed to
detect previously existing arrhythmias. While on therapy, the maternal
ECG should be regularly evaluated for changes in QT interval.
Mechanism of tachycardia
The efficacy of sotalol as single therapy was 40 % in the SVT group; in
the AF group, 50 % reverted to sinus rhythm. After the addition of
digoxin another 20 % in the SVT group and 30 % in the AF group rever-
ted to sinus rhythm. The fact that this study was performed retrospec-
tively hampered our ability to elucidate the relationship between the
action mechanism of sotalol and the success rates. Perhaps this would
have been possible in a prospective, randomized study.
The conversion rate in the SVT group (60 %) is dissatisfying when com-
pared with the rates of other studies, which are as high as 88% 11. The
relatively low conversion rate in this study suggests that sotalol is pro-
bably not the optimal drug of first choice for the treatment of fetal
SVT. Moreover, the fact that 3 of the 4 fetal deaths occurred in fetuses
with SVT indicates that the use of sotalol should be restricted to those
cases in which other treatment options have failed.
The rate of success in the AF group (80 %) compares favorably with
previous studies, which have shown success rates ranging from 50 % to
66 % 11, 13. One of 10 fetuses with AF died in utero, probably due to a
combination of severe congestive heart failure, stenosis of the venous
duct and a hypoplastic placenta. The low postnatal recurrence rate (10
%) also favors sotalol therapy. The high success rate and the low recur-
rence rate indicate that sotalol could, in our opinion, be
considered a drug of first choice in the treatment of fetal AF, possibly
with digoxin as second-line drug.
Hydropic versus nonhydropic fetuses
Hydropic fetuses carry a higher risk of an adverse outcome than non-
hydropic fetuses 5, 8, 33. Although our results suggest that hydropic
fetuses can be treated successfully by the maternal administration of
sotalol and/or digoxin, they also indicate, in accordance with other
reports 35, that there is a high mortality risk (3 of 8 hydropic fetuses,
37,5%). In those cases in which conversion to sinus rhythm was achie-
ved (5 of 8 hydropic fetuses, 62,5%), the hydrops resolved in a period
ranging from 2 to 21 days (mean 14 days), which is a shorter period
than that of previous reports 36.
The time to the successful restoration of sinus rhythm was equal in
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both groups (nonhydropic and. hydropic, p=0,921) of fetuses treated
with sotalol, which underscores the drug’s effectiveness, especially  in
the hydropic fetus.
Postpartum medication
No unanimity of opinion exists regarding the need for neonatal pro-
phylaxis in patients who do not have persistent or recurrent arrhyth-
mias. Although 11 live-born patients showed no signs of postpartum
relapse of the tachycardia, only 7 did not receive any further therapy
and are currently doing well, suggesting that postnatal prophylactic
medication might not be necessary. A relapse of tachycardia occurred
in 6 patients; they received sotalol and/or digoxin prophylaxis for a
year, after which it was discontinued without recurrence of symptoms.
Remarkably, 2 of these relapsing patients showed neurological damage
(described under morbidity) which suggests the presence of a therapy-
resistant tachycardia. The patient who had torsade the pointes VT died
after two years of unsuccessful therapy.
Morbidity 
Fetal tachycardia has a good prognosis when conversion to sinus
rhythm has been attained in utero: 82 % of all live-born children in this
study are alive and well. However, 2 of our hydropic patients suffered
from neurologic pathology postnatally. In both of these patients, the
time from actual conversion to persistent normal sinus rhythm was
longer than average (10 and 21 days compared to 7 days average). It
seems likely that in the periods in which the patients reverted back
and forth from tachycardia into sinus rhythm, neurological damage
occurred. These results underline the necessity to initiate drug therapy
as soon as possible in hydropic fetuses.
Mortality 
Table 1 shows the mortality rates of studies performed throughout the
past 13 years 4, 9, 11-13, 15, 37-39. Mortality in this study was 4 of 21 fetuses,
which is high compared to these previous studies. As autopsy did not
establish a cause of death in any of our patients, there is a possibility
that proarrhythmic events at higher sotalol doses may have caused
these deaths. All intra uterine deaths occurred within 1 week after the
initiation of sotalol therapy or a dosage increase to a daily dosage of
more than 320 mg/day. It is in these periods that sotalol may cause
proarrhythmic events 23, 24, 27, 30. The incidence of proarrhythmic side
effects of sotalol in the treatment of pediatric patients varies from 0 %
to 22 % 27-30, but the proarrhythmic impact of sotalol may be more pro-
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nounced in the immature fetal heart than it is in adult hearts. The
study of Houyel et al. showed that sotalol causes a significantly
greater prolongation of the corrected QT interval in the neonatal heart
than in adult hearts 40. In our fetus with VT, torsade de pointes was
confirmed by ECG after birth. This fetus provided evidence that sotalol
can cause proarrhythmic events in the immature fetal heart. Therefore,
if one opts for sotalol treatment, low initiation doses of 80 mg 2 times
per day are preferable and dosage increases should be stepwise and
weighed against possible adverse effects. Close monitoring during the
initiation of therapy and dosage increases is recommended.
Table 1.
Mortality rates of studies done over the past 13 years. * In this study, sotalol was added to
digoxin.
IUD= intra uterine death, SVT= supraventricular tachycardia, AF= atrial flutter, VT= ventricu-
lar tachycardia.
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Study # of Mechanism of Treatment IUD Mortality %
patients tachycardia
SVT AF VT Digoxin Digoxin+… Flecainide Flecainide+...
Bergmans et al. (4) 9 9 - - 5 4 - - 0 0%
Allan et al. (9) 14 12 2 - - - 12 2 1 7%
Engelhardt et al. (39) 9 9 - - 4 5 - - 0 0%
van Engelen et al. (11) 34 25 9 - 15 9 7 3 3 9%
Frohn-Mulder et al. (12) 35 35 - - 19 9 7 - 6 17%
Naumberg et al. (38) 15 0 0%
Zielinsky et al. (37) 17 17 - - 17 - - - 3 18%
Jaeggi et al. (13) 11 - 11 - 11 - - - 0 0%
Sonesson et al. (15)* 14 14 - - - 14 - - 2 14%
Simpson et al. (35) 127 105 22 - 18 14%
Experience at Yale 
University 1994-1998 159 117 34 8 8 5%
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Conclusions
Fetal arrhythmias present serious conditions in which treatment is
necessary, especially in the presence of hydrops. Sotalol and the combi-
nation of sotalol and digoxin were very successful in the AF group,
with a conversion rate as high as 80 % and the advantage of a low
recurrence rate. Therefore, sotalol should be considered as a valuable
treatment option for fetal AF.
The low conversion rate and the fact that 3 out of 4 deaths occurred in
fetuses with SVT indicate that the use of sotalol in the treatment of
fetal SVT may be limited. Sotalol can cause proarrhythmic events in the
fetus and although there is no proof, sotalol may have contributed to
the mortality rate. This calls into question whether sotalol should be
used as a first-line drug to treat fetal SVT, because several other antiar-
rhythmic protocols have shown variable success rates without compa-
rable mortality rates. The evidently present risks should be weighed
against the limited benefits of sotalol therapy for fetal SVT. It is our
belief that the use of sotalol should be restricted to cases with fetal AF
and those cases of fetal SVT in which other treatment options have
failed to be successful.
Chapter 7
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Abstract
Protocols for the treatment of supraventricular tachycar-
dias in the fetus
The protocols mentioned are used by Utrecht University Hospital for
the treatment of fetal supraventricular tachycardias (SVT). In case of
atrial flutters the pregnant woman is treated with sotalol admini-
stered orally and, if no sinus rhythm is obtained nor a reduced ventri-
cular rhythm occurs, subsequently with digoxin. If there is no hydrops
fetalis, the same treatment regimen is used for other forms of fetal
SVT. In the case of hydrops fetalis the treatment is more aggressive:
digoxin intravenously or flecainide orally. If the rhythm does not con-
vert into a sinus rhythm nor a reduced ventricular rhythm occurs then
both of these medications are administered; if that also proves to be
insufficient then direct fetal therapy can be considered.
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Foetaal atriumfladderen reageert in de regel matig tot slecht op orale
maternale digoxine, met name indien er sprake is van foetale hydrops 1, 2.
Een studie naar het orale gebruik van sotalol als middel van eerste
keus, met toevoeging van digoxine in tweede instantie, liet echter een
hoog succespercentage van 80-90 % zien 3. Zowel in de groep foetus-
sen met atriumfladderen zonder hydrops, als in de groep met hydrops
gaf dit een goed resultaat.
De groep foetussen met supraventriculaire tachycardie van andere oor-
sprong dan atriumfladderen, die op het moment van de start van de
therapie niet hydropisch was, reageerde ook goed op de behandeling
volgens het ontworpen protocol (Figuur 1).
Figuur 1
Protocol voor de behandeling van een zwangere bij foetaal atriumfladderen, dat in het
Universitair Medisch Centrum Utrecht wordt gehanteerd
De groep foetussen met supraventriculaire tachycardie met hydrops is
een groep met een hoge morbiditeit en mortaliteit. Een agressievere
therapeutische opstelling is dan ook noodzakelijk. Indien mogelijk ver-
dient het de voorkeur de zwangere in de klinische situatie intraveneus
Protocollen voor de behandeling van supraventriculaire
tachycardieën bij de foetus
Foetaal atriumfladderen
Sotalol 160 mg 2dd oraal
gedurende 3 dagen
Verhoging van sotaloldosering 
160 mg 3dd oraal
indien geen conversie naar
sinus ritme of vertraging 
van ventrikelritme
Toevoeging van digoxine:
0,25 mg 3dd oraal
gedurende 3 dagen
indien geen conversie naar
sinus ritme of vertraging 
van ventrikelritme
Verhoging van digoxinedosering:
0,50 mg 2 dd oraal
indien geen conversie naar
sinus ritme of vertraging 
van ventrikelritme
Geen hydrops foetalis Wel hydrops foetalis
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te behandelen met digoxine om zodoende een snelle en adequate the-
rapeutische digoxinespiegel bij de foetus te verkrijgen. Een tweede
optie, indien een klinische opname niet mogelijk is, is het gebruik van
flecainide per os door de moeder. Bij onvoldoende effect is een combi-
natie van deze twee opties mogelijk (Figuur 2).
Figuur 2
Protocol voor de behandeling van een zwangere bij foetale supraventtriculaire tachycardie,
anders dan atriumfladderen, dat in het Universitair Medisch Centrum Utrecht wordt gehan-
teerd
Mocht er zich in die situatie nog steeds geen verbetering van de tachy-
cardie hebben voorgedaan, dan bestaat er een zeer ernstige en geluk-
kig weinig voorkomende situatie. Het zou dan te overwegen zijn de
foetus direct te gaan behandelen middels intra-umbilicale, intra-mus-
culaire, intra-peritoneale of intra-amniotische injecties, al bestaat daar
in het perinatologisch centrum te Utrecht weinig ervaring mee.
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Geen hydrops foetalis
Foetale supraventriculaire
tachycardie
Sotalol 160 mg 2dd
oraal gedurende 3 dagen
Verhoging van s0taloldosering:
160 mg 3dd oraal
gedurende 3 dagen
Indien geen conversie naar
sinus ritme of vertraging
van ventrikelritme
Toevoeging van digoxine:
0,25 mg 3 dd
oraal gedurende 3 dagen
Indien geen conversie naar
sinus ritme of vertraging
van ventrikelritme
Verhoging van digoxinedosering:
0,50 mg 2dd oraal
Indien geen conversie naar
sinus ritme of vertraging
van ventrikelritme
Wel hydrops foetalis
Digoxine intraveneus:
1,0-2,0 mg in 24 uur en daarna
0,5-1,0 mg/dag gedurende 3 dagen
Flecainide 200-400mg/dag
oraal gedurende 3 dagen
Indien geen conversie naar
sinus ritme of vertraging
van ventrikelritme
Combinatie van Digoxine 
intraveneus en flecainide oraal 
gedurende 3 dagen
Overweeg directe foetale 
therapie
Indien geen conversie naar
sinus ritme of vertraging
van ventrikelritme
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Abstract
Background
The morphology of the fetal ECG complex may provide information on
the fetal condition during labour, such as the ST segment and T wave
configuration. The QT interval is known to react to situations of stress
and exercise and we hypothesized that the fetal QT interval would
react to acute asphyxia and could thus provide information on the
fetal myocardial adaptation.
Methods
The hypothesis was tested on four cases, consisting of prolonged cord
occlusion in three fetal sheep experiments and one human fetus
exposed to severe hypoxia during labour as a result of placental
abruption. The QT interval was measured on the fetal ECG displayed by
the STAN® fetal heart monitor. The QTc was calculated using Bazett’s
formula: QT/√RR.
Results
A shortening of the QT and QTc intervals occurred during the initial
phase of asphyxia. The shortening was associated with a rise in T/QRS
ratio and increase of blood pressure, indicating a maintained cardio-
vascular function. Persisting asphyxia was associated with a return of
the QT interval to pre-asphyxic values.
Conclusions
A marked shortening of the QT and QTc intervals occurs shortly after
the onset of asphyxia. Probably this is the result of a surge in epi-
nephrine and Bèta-adrenoceptor activation. These parameters may be
of additional value in intrapartum fetal monitoring.
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Introduction
Fetal ECG analysis has formed the basis for electronic fetal monitoring
for decades. So far the FECG assessment has been limited to RR interval
measurements only. Among other time constants, the relationship
between PR and RR has also been extensively investigated. The PR
shortening with RR lengthening during fetal heart rate (FHR) decelera-
tions and bradycardia 1 and experimental hypoxia 2, has provided rele-
vant information on fetal cardiac adaptation. Clinically, these measure-
ments are not of additional value 3. However, the morphology of the
FECG including the ST segment and T wave configuration has been
shown to provide specific and clinically useful information of fetal car-
diovascular adaptation to experimental hypoxia and as an adjunct to
standard FHR monitoring in labour 4 .
The QT interval has been the focus of many studies in the neonate and
adult, as a prolonged QT interval, either genetic or acquired, predispo-
ses to ventricular tachycardia and sudden death 5-8. Many studies have
shown changes in its properties in situations of exercise, stress and
infection among others, 9-15. We hypothesized that the QT interval on
the FECG, representive of repolarization, could provide information on
the physiology of the fetal myocardium and on the fetal myocardial
adaptation to the ultimate stress of being born 16. Hitherto, no data
has been published on the dynamics of the QT interval in labour as the
technology was not available until recently. The development of the
STAN® technology, originally designed to perform analysis on the fetal
ST waveform to improve fetal surveillance 4, 17 has provided us with the
means of evaluation of specific features on the fetal ECG, including the
QT interval.
The current report presents the pattern of QT changes noted in three
premature sheep fetuses and one human fetus at term all being
exposed to acute asphyxia.
Methods
The hypothesis was tested on four cases obtained from the STAN®
database, consisting of prolonged cord occlusion in three fetal sheep
experiments and a human fetus with severe hypoxia during labour, all
monitored by the STAN® device (STAN S 21 recorder, Neoventa Medical,
Gothenburg, Sweden).
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Fetal sheep
In the three fetal sheep experiments, aseptic surgery was performed at
90 days of gestation. The fetuses were instrumented with polyvinyl
catheters in each brachial artery, in the left brachial vein and in the
amniotic cavity. ECG electrodes were placed subcutaneously over each
shoulder (the right electrode was used as reference) and one over the
apex of the heart. Antibiotics (garamycin, 5 mg/kg, i.v.) were
administered daily to the ewe during the time span of the study.
Asphyxia was induced 48 hours after placement of the electrodes by
inflation of a vascular occluder (In Vivo Metric, Healdsburg, CA), that
was placed around the umbilical cord. Continuous fetal arterial blood
pressure was recorded on a Grass polygraph. The fetal ECG was conti-
nuously monitored by the STAN fetal heart monitor and QT intervals
were measured off-line. The QT data was obtained from FECG recor-
dings originating from studies approved by the Animal Ethical
Committee of the University of Gothenburg.
The human fetus was monitored throughout labour with the STAN
fetal heart monitor as part of normal fetal surveillance. The fetal ECG
was recorded using a single helix scalp electrode and a maternal skin
electrode, resulting in a unipolar fetal ECG lead.
Fetal ECG and measurement of intervals
The fetal ECG and QT interval was reviewed retrospectively from stored
data using a special software application (STAN Viewer, NM Gbg
Sweden). The FECG data was stored digitally at 500 Hz resolution.
The STAN Viewer displayed the fetal ECG on the computer screen which
is an average ECG consisting of 30 high quality FECG complexes. The
T/QRS ratio and appearance of biphasic ST segments are displayed
automatically. In cases 2 and 4, only trends in QT interval changes
could be obtained, as these were recorded with an older version of
STAN. To allow for more accurate measurements of QT in case 1 and 3,
the software was updated. A specialized tool was developed for the
assessment of FECG time intervals in which markers have to be placed
manually on visual assessment of onset of the P-wave, onset and end
of QRS complex and end of T-wave. The computer calculated the inter-
vals in milliseconds (ms). An example of the fetal ECG and measure-
ments is presented in Figure 1.
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Figure 1
An example of measurement of the QT interval. The markers (vertical lines) are placed
manually on visual assessment of the onset of the Q wave and end of the T wave.
The computer automatically calculates the interval in ms, being 250 ms in this case.
The QTc was calculated using Bazett’s formula: QT/√RR.
Results
All 4 cases are presented separately and illustrated with FHR changes
and changes in T/QRS ratio.
Case 1
Sheep experiment, gestational age of 12 weeks and 6 days.
Fetal sheep experiment with cord occlusion at 05.57, lasting 25 minutes
(Figure 2).
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Figure 2
Illustration of the FHR (bpm) + T/QRS ratio recording (1 cm/min) in relation with mean arte-
rial blood pressure (mmHg) and QT and QTc interval (ms) measurements at the time of cord
occlusion.
After occlusion of the cord an immediate fall in fetal heart rate and a
subsequent rise in T/QRS ratio occurred. An initial rise in mean arterial
blood pressure is followed by a decrease. Measurements of the QT and
QTc interval show an initial lengthening, followed by a 4 minute shor-
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tening followed by a second lengthening.
These ECG samples (Figure 3 and 4) show the QT interval shortly after
the start of asphyxia (243 ms) coinciding with a rise in T/QRS ratio
(0,86; Figure 3),
figure 3
and several minutes later when the T wave decreases (T/QRS 0,32) at
which point the QT is lengthening (300 ms; Figure 4).
figure 4
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Case 2
Sheep experiment, gestational age of 12 weeks and 6 days.
Second fetal sheep experiment with cord occlusion at 10:38 (Figure 5).
Figure 5
Illustration of the FHR (bpm) + T/QRS ratio recording (1 cm/min) in relation with mean arte-
rial blood pressure (mmHg) measurements at the time of cord occlusion.
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After occlusion of the cord an immediate drop in fetal heart rate and a
subsequent rise in T/QRS ratio occurred. An initial rise in mean arterial
blood pressure is followed by a decrease.
Figure 6
Illustration of consecutive fetal ECG’s recorded after cord occlusion. The vertical line is
placed at the end of the shortest T wave in the ECG at time 10:44:27.
Figure 6 shows a QT shortening during the first 2 minutes. This coinci-
ded with an increase of the T wave and an increase in blood pressure.
Three minutes later, the QT interval is lengthening and in the last three
ECG’s, the T wave develops a negative segment, and the QT interval is
markedly lengthening.
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Case 3
Sheep experiment, gestational age of 12 weeks and 6 days.
Third fetal sheep experiment with cord occlusion at 4.54 (Figure 7).
Figure 7
Illustration of the FHR (bpm) + T/QRS ratio recording (1 cm/min) in relation with mean arte-
rial blood pressure (mmHg) and QT and QTc interval (ms) measurements at the time of cord
occlusion.
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After occlusion of the cord an immediate drop in fetal heart rate and a
subsequent rise in T/QRS ratio occurred. An initial rise in mean arterial
blood pressure is followed by a decrease. Measurements of the QT
interval show an initial lengthening, followed by a shortening, until
the T/QRS ratio decreased, at which point the QT is lengthening again.
The QTc interval shows an immediate shortening, lasting until the
T/QRS ratio is decreasing.
These ECG samples show the measurement of the QT interval shortly
after the start of asphyxia (225 ms) coinciding with a rise in T/QRS ratio
(0,68; Figure 8),
Figure 8
and several minutes later when the T wave comes down (T/QRS 0,34) at
which point the QT is lengthening (272 ms; Figure 9)
Figure 9
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Case 4
Human data
A term fetus was monitored with the STAN fetal heart monitor throug-
hout labour and displayed a normal reactive heart rate pattern with a
baseline of approximately 150 bpm. In the second stage of labour
however, a sudden drop in heart rate and subsequent increase in T/QRS
ratio was noted (Figure 10) and an emergency vacuum extraction was
performed. A placental abruption was the reason for the sudden drop
in heart rate and T/QRS rise.
Figure 10
Illustration of FHR (bpm) and T/QRS ratio recording (2 cm/min) at the time of placental
abruption.
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Figure 11
Illustration of consecutive fetal ECG’s recorded at the time of placental abruption. The verti-
cal line is placed at the end of the T waves shortly after the abruption.
In Figure 11 a simultaneous progressive rise in T wave amplitude and
shortening of the QT interval can be clearly seen in the last two ECG’s.
Discussion
In a situation of hypoxia when the energy balance within the myocar-
dial cell threatens to become negative, the fetus reacts with a surge in
epinephrine 18, Bèta-adrenoceptor activation 19 and myocardial glyco-
genolysis 20. This alarm reaction is characterized by an increase in
amplitude of the T wave. The rate of T wave rise is directly related to
the rate of glycogenolysis.
In these four cases, the following observations were made with regard
to QT changes:
• A shortening of the QT and QTc intervals occurring during the initial
phase of a rise in T/QRS during asphyxia.
• An association between the shortening of the QT and QTc intervals and
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an increase in blood pressure (in the three mid-gestational fetal lambs).
• Signs of a subsequent return in QT interval in the sheep experiments
with decreasing T/QRS ratio in association with a decrease in blood
pressure.
The QT interval is a dynamic function of the fetal ECG and is influenced
by asphyxia. It is known that exogenous catecholamines shorten the
QT interval 11, 21 and that Bèta blockers prolong the QT interval 22. The
QT shortening in association with an increase in T/QRS ratio and main-
tained cardiovascular function might therefore be the effect of a surge
in epinephrine and Bèta-adrenoceptor activation enhancing cAMP
activity and ion channel pumping. The shortening of the QT interval
during asphyxia provides us with additional information on the
condition of the fetal myocardium, which is trying to respond to the
stressful situation it is exposed to.
The decreasing T wave, finally progressing in a negative T wave compo-
nent during prolonged asphyxia, is the result of a myocardium that has
used its reserves and is not capable anymore of maintaining its func-
tion, as can also be seen from the decrease in blood pressure. Our
observations indicate that in case of a failing myocardium, the QT
interval is lengthening and returns to prehypoxic values, which is con-
sistent with observations in children and adults with heart failure 13, 23-
25.
Individuals suffering from the Long QT syndrome are at increased risk
for life threatening arrhythmias in periods of physical or psychological
stress 26, 27. They are known to respond differently to catecholamines
as compared to control subjects 28-29. We speculate that in fetuses with
the LQTS, the shortening of QT in the first phase of hypoxia/asphyxia,
possibly as a sign of enhanced ion channel activity being part of a nor-
mal response to hypoxic stress, may not be present.
This study has shown that with a specialized tool it was feasible to
accurately assess changes in QT interval. Such changes may provide
additional information on the condition of the fetus.
Conclusions
A marked shortening of the QT interval, with an increase in T wave
amplitude and an increase in blood pressure was noted during the
onset of asphyxia. As asphyxia continued in the fetal sheep, the QT
returned to pre-asphyxic values. These cases show that the QT interval
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is subject to changes during acute asphyxia and that QT shortening
seems to be related to the ability of the cardiovascular system to
respond with an increase in blood pressure. Intrapartum measure-
ments of the QT interval may therefore provide additional information
on the condition of the fetus, in particular when combining QT
shortening with T/QRS increase. The data also show that QT shortening
may be observed in conjunction with acute intrapartum hypoxia due to
placental abruption.
Changes in the Fetal QT interval in Asphyxia 
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Abstract
Background
The morphology of the fetal ECG complex may provide information on
the fetal condition during labour, such as the ST segment and T wave
configuration. We hypothesized that the intrapartum fetal QT interval
may provide additional information on the condition of the fetus, as it
is known that the QT interval is known to react to situations of stress
and exercise.
Methods
The intrapartum QT interval was measured in 68 fetuses who were aci-
demic at birth (pH < 7,05 and BDecf > 12 mmol/l) and in a control group
of similar size. All of these cases were monitored by STAN.
Measurements were performed at start of the recording at baseline
heart rate, during variable decelerations and at the end of the recor-
ding. The QTc was calculated using Bazett’s formula: QT/√RR. The inter-
vals were compared using the Wilcoxon signed ranks test.
Results
In the acidemic fetuses, there was a significant shortening of the QTc
interval at the end of the recording compared to the start of the recor-
ding (397 at the end vs 359,3 at start; p < 0,001), also, heart rate was
significantly lower (136,3 vs 110,9 bpm, p < 0,001). Measurements of QT
and QTc during variable decelerations at start and end of the recor-
ding, also showed a shortening of the QT interval (301,9 vs 273,3 ms,
p < 0,001) and QTc interval (381,6 vs 340,3, p < 0,001), and this was not
dependent on heart rate. In the control cases, no differences in FHR, QT
and QTc intervals were present.
Conclusions
In severe intrapartum hypoxia, resulting in metabolic acidosis, a signi-
ficant shortening of the fetal QT and QTc is present, irrespective of
changes in heart rate. In control cases, this shortening does not occur.
The intrapartum fetal QT interval may therefore provide additional
information on the condition of the fetus.
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Introduction
A prolonged QT interval, either genetic or acquired, predisposes to ven-
tricular tachycardia and sudden death 1-4. Changes in the QT interval
have also been shown during exercise, stress, infection and heart failu-
re 5-11. Delivery is a stressful event for both the fetus and the mother
and fetal hypoxia is a well known complication causing the fetus to
respond forcefully with signs of cardiovascular and metabolic adapta-
tion.
In an observational study in three preterm fetal lambs exposed to
acute cord occlusion and in one term human fetus who became acutely
asphyxiated due to placental abruption, we found that the fetal ECG
QT interval, provides information on the electro-physiological changes
of the fetal myocardium. A QT shortening was noticed in conjunction
with an increase in T wave amplitude. It seemed logical to assume that
the QT shortening would depend on the ability of the fetal myocardi-
um to enhance its performance in response to the catecholamine surge
and Bèta receptor activation known to elicit the rise in T wave amplitu-
de.
The STAN® technology and clinical database, originally designed to per-
form analysis on the fetal ST waveform to improve fetal surveillance 12-
14, provided us with the means of taking this observation further by
evaluating QT interval changes in association with signs of intrapar-
tum hypoxia.
Methods
Data were collected using the STAN® database which was created
during the European community multi-center trial 12 and Swedish ran-
domized controlled trial 13. All cases with metabolic acidosis as defined
by a cord artery pH < 7,05 and BDecf > 12,0 mmol/l were considered for
inclusion.
The technique of measurement of the intrapartum QT interval is
described in chapter 9.
As it was anticipated that these intervals may change with the dyna-
mic heart rate a healthy fetus will display, measurements were
obtained from at least 5 different points in time at baseline and at
least 2 different points during accelerations and decelerations.
The QTc interval was calculated using Bazett’s formula: QT/√ RR.
171
The effects of Intrapartum Hypoxia on the Fetal QT interval
Inclusion criteria
Cases were included if there was a minimal recording time of 30 minu-
tes of good quality during which ECG’s were recorded > 90 % of time
and during which assessment of the end of the T-wave was feasible.
The end of the recording had to be within 20 minutes of delivery to
ensure that metabolic acidosis was indeed very likely at the time of
recording the FECG.
QT measurement in cases with metabolic acidosis
All cases with metabolic acidosis present in the database and fulfilling
the inclusion criteria were reviewed by one of the authors (MAO).
Two sets of data were collected in these cases: PQ, QRS and QT inter-
vals at baseline heart rate at the start of the recording and in the last
5 minutes of the recording when metabolic acidosis was likely to be
present. As a second part of this study QT intervals were measured
during variable decelerations at onset of the recording and during
decelerations or bradycardia at the end of the recording when metabo-
lic acidosis was present. Measurements were required to be at least
one hour apart to ensure a difference in fetal condition. Cases that did
not fulfil these requirements were excluded from the second part of
the study. The fetal heart rate (FHR), QT and QTc intervals were
compared using the Wilcoxon signed ranks test. Statistical significance
was defined by a p value of < 0,05.
QT measurement in control cases
One control case for each metabolic acidosis case was randomly selec-
ted from the database. General inclusion criteria had to be met and all
had a cord artery pH > 7,05 and BDecf < 12,0 mmol/l. The measure-
ments performed were identical to those described in the cases with
metabolic acidosis.
Results
QT measurement in cases with metabolic acidosis
A total of 68 cases with metabolic acidosis were included in the first
part. The mean and SD of the PQ, QRS and QT interval and FHR at base-
line heart rate at the start and end of the recording are shown in Table 1.
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N Mean SD SE of mean  
FHR At start 68 136,3 12,2 1,5  
At end 68 110,9* 29,9 3,6  
QT interval At start 68 265,2 26,5 3,2  
At end 68 269,2 37,8 4,6  
QTc interval At start 68 397,0 33,6 4,1  
At end 68 359,3* 49,6 6,0  
PQ interval At start 68 113,7 13,2 1,6  
At end 68 96,8* 13,8 1,7  
QRS interval At start 68 60,8 7,1 0,9  
At end 68 61,7 8,6 1,1  
Table 1
Mean, SD and SE values of FHR (fetal heart rate in bpm), PQ, QRS and QT intervals (in ms)
recorded during baseline heart rate at the start and end of the recording in cases born with
metabolic acidosis. *  p value < 0,001.
There was a significant decrease in heart rate (136,3 vs. 110,9 bpm, p
<0,001) and in QTc (397 vs. 359,3, p < 0,001) between the start and end
of the recordings. Data on QTc are also shown in Figure 1. The PQ inter-
val also showed a shortening (113,7 vs. 96,8 ms, p < 0,001). The mean QT
intervals remained the same.
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Figure 1
Mean and 95% confidence intervals of QTc at the start of the recording at baseline heart
rate and at the end of the recording in cases with metabolic acidosis (n=68).
Cases with metabolic acidosis and variable decelerations
A total of 55 cases were included in the second part of the study.
Outcome measures are shown in Table 2.
N Mean SD SE of mean  
FHR At start 55 97,0 15,1 2,0  
At end 55 94,5 22,6 3,0  
QT interval At start 55 301,9 38,3 5,2  
At end 55 273,3* 34,9 4,7  
QTc interval At start 55 381,6 50,1 6,8  
At end 55 340,3* 50,3 6,8  
Table 2
Mean, SD and SE of FHR, QT and QTc during variable decelerations at the start of the recor-
ding (before the development of metabolic acidosis) and during decelerations or bradycar-
dia during metabolic acidosis at the end of the recording. * p value < 0,001.
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In these cases, no difference in FHR was present between the measure-
ments at the start and end of the recordings (97 vs. 94,5  bpm, p =
0,504). However, both QT and QTc were statistically shortened in the
period with metabolic acidosis present (QT, 301,9 vs. 273,3 ms, p < 0,001
; QTc, 381,6 vs. 340,3, p < 0,001). The difference in QTc is shown in 
Figure 2.
Figure 2
Mean and 95% confidence intervals of QTc recorded during variable decelerations or brady-
cardia at the start and at the end of the recording in cases who developed metabolic aci-
dosis (n= 55).
Control cases
A total of 55 control cases were included. All had measurements on QT
interval during variable decelerations at the start of the recording and
during variable decelerations or bradycardia at the end of the recor-
ding. Outcome measures are shown in Table 3.
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N Mean SD SE of mean  
FHR At start 55 88,5 11,0 1,5  
At end 55 92,5 16,7 2,3  
QT interval At start 55 303,0 31,5 4,2  
At end 55 300,1 28,7 3,9  
QTc interval At start 55 366,9 41,6 5,6  
At end 55 370,3 40,7 5,5  
Table 3
Mean, SD and SE of FHR, QT and QTc during variable decelerations at start and during dece-
lerations or bradycardia at end of recording (n= 55).
There were no differences in the measured variables between the start
and end of the recording. Data on the QTc are also shown in Figure 3.
Figure 3
Mean and 95% confidence intervals of QTc during decelerations at the start and during
decelerations or bradycardia at the end of the recording in 55 control cases without meta-
bolic acidosis.
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Discussion
This study has demonstrated that the QT interval is shortened during
intrapartum hypoxia as quantified by umbilical artery metabolic acido-
sis. The observation was generally applicable in cases of metabolic aci-
dosis comparing onset and end of labour. Furthermore, a significant
shortening occurred during variable decelerations recorded during the
final part of labour in cases with metabolic acidosis. The data also
show that the QT shortening is not FHR dependent nor related to the
general stress of labour as fetuses without metabolic acidosis did not
show a QT shortening despite FHR changes indicative of such events. A
QT shortening therefore seems to provide similar information as that
noted with a rise in T wave amplitude and T/QRS ratio. These findings
of a marked shortening of the QT interval during marked hypoxia are
consistent with the observations made previously in three fetal sheep
in which asphyxia/acidosis was induced by cord occlusion and in one
human fetus after occurrence of a placental abruption (chapter 9).
During hypoxia the energy balance within the myocardial cell
threatens to become negative. The fetus reacts to this with a surge in
epinephrine 15, Bèta-adrenoceptor activation 16 and myocardial glycoge-
nolysis 17. A responsive fetal myocardium reacts to these changes with
an increase in T/QRS ratio 15. Exogenous catecholamines shorten the QT
interval 7 and Bèta blockers prolong the QT interval 18. The QT shorte-
ning as described in this paper and the association with an increase
in T/QRS ratio are therefore likely to be mediated through a catechola-
mine surge. The observation of a shortening QT interval during hypoxia
provides us with additional information on the condition of the fetal
myocardium that is trying to respond to the stressful situation it is
exposed to.
Measurements of the intrapartum QT interval may therefore be useful
in providing additional information on the ability of the myocardium
to adapt to intrapartum hypoxia and thus may serve to inform about
the condition of the fetus.
Conclusions
During severe intrapartum hypoxia and metabolic acidosis, there is a
significant shortening of the QT interval. The intrapartum QT interval
may therefore provide additional information on the condition of the
fetus.
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The evaluation of the fetal heart rate provides the obstetrician with
important information on the condition of the fetus. As the primary
goal of obstetric care is the delivery of a healthy newborn, in conjunc-
tion with minimal risks for the mother 1, accurate interpretation of the
fetal heart rhythm and detection of possible arrhytmias is of vital
importance.
This thesis focuses on the diagnosis and treatment of fetal tachyar-
rhythmias. The second part deals with the evaluation of the QT interval
of the fetal ECG during labour and on its possible value with respect to
fetal monitoring.
Part I: Fetal tachyarrhythmias
Diagnosis
Fetal tachycardia may be a life threatening disorder and its occurrence
should be regarded as a serious condition warranting specialized evalu-
ation. In chapter 2, methods of diagnosis of fetal tachycardia are
described, including Doppler and M-mode echocardiography, as well as
the latest addition to the diagnostic armamentarium, fetal magneto-
cardiography (FMCG). Characteristics of specific types of tachycardia
are described with examples of the images detected on M-mode and
FMCG. Decisions regarding treatment and different treatment options
are discussed.
M-mode echocardiography remains a valuable tool to classify the
tachyarrhythmias into subgroups depending on the site of origin of
the arrhythmia. A subdivision in supraventricular tachycardia (SVT),
atrial flutter (AF), and ventricular tachycardia (VT) can be derived from
this documentation but is not sufficient enough for differentiation
according to the electrophysiologic mechanism. A more detailed diag-
nosis of the type of tachycardia enables the physician to develop a spe-
cific treatment. Therefore, several studies have been performed to
enhance the accuracy of M-mode echocardiography 2, 3. The study pre-
sented in chapter 3 describes a method for further delineation in the
classification of fetal SVT in short and long VA tachyarrhythmias. The
relationship of peak excursions of atrial and ventricular wall motions
allows for this division, which, in case of a re-entry tachycardia, is a
measure of the conduction velocity of the accessory pathway. Usually,
conduction through the accessory pathway is fast, as in the Wolff-
Parkinson-White syndrome (WPW), but in some cases, slow conduction
is observed, as in persistent junctional reciprocating tachycardia (PJRT).
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In chapter 3, four fetuses are described in whom a long VA interval was
noted on M-mode echocardiography and in whom the definite diagno-
sis of PJRT was made postnatally. The tachycardia in these fetuses
differed in nature from our observations in cases with a short VA
tachycardia. Characteristics of a long VA tachycardia include a
sustained tachycardia at heart rates not exceeding 240 bpm and with
frequent presence of congestive heart failure and therapy resistence.
Postnatal treatment is complicated and requires either multiple drug
therapy or radiofrequency ablation of the accessory pathway early in
infancy.
An even more detailed examination of the electrophysiological proper-
ties of the fetal myocardium has become possible with the use of fetal
magnetocardiography (FMCG) 4, 5. Observations presented in chapter 2
provide evidence that specific time intervals can be measured and that
the electrophysiological nature of tachyarrhythmias can be revealed
prenatally using FMCG. Images are presented of premature atrial con-
tractions, AF, atrioventricular re-entry tachycardia and a prolonged QT
interval. The application of this method to all cases of fetal arrhyth-
mias may ultimately result in a specialized treatment protocol for all
different types of arrhythmias.
Consequences
Tachyarrhythmia is a situation in which there is an increased demand
of the fetal myocardium to maintain adequate cardiovascular function.
Several factors may play a role in the development of congestive heart
failure and consequent development of fetal hydrops as outlined in
chapter 4 and 5. Predisposing factors for the development of hydrops
seem to be the percentage of time that the tachycardia is present, the
gestational age at which the tachycardia occurs 6, the ventricular rate 7
and the site of origin of the tachycardia 8. However, statistical signifi-
cance of these factors could not be obtained in our series. In case of
fetal tachyarrhythmias complicated by fetal hydrops, the fetus is at risk
for neurological morbidity probably as a result of hemodynamical com-
promise 9-11. The cerebrovascular autoregulation that ensures adequate
cerebral perfusion during infancy and adulthood, does not function
adequately in the distressed newborn and most probably also not in
the distressed fetus. A disturbance in rhythm resulting in hemodyna-
mic compromise predisposes the fetus to cerebral ischemia during
periods of hypotension and to intracranial hemorrhage during periods
of hypertension 12. Case reports have suggested that the prognosis of
individuals with fetal hydrops is generally poor. Therefore, in chapter 4,
we have investigated the outcome of the total group of 11 fetuses with
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hydrops as a result of tachyarrhythmia.
In this group, two deaths occurred, one shortly after birth due to the
tachycardia and its complications, and one at 2 years of age as a result
of the arrhythmia. Seven of the 9 survivors are doing neurologically
well; 1 infant suffers from a mild hemiplegia with a normal cognitive
function, and one infant has a cognitive developmental delay.
Cognitive function is normal in the 5 infants who have been followed
up to 12 years of age. In case of fetal hydrops, initiation of therapy
should therefore not be withheld or delayed based only on the
assumption of poor neurological outcome.
Polyhydramnios is also a well known complication in case of a hydropic
fetus, and may induce preterm uterine contractions. Tocolysis may lead
to further in utero maturation and corticosteriods to enhance fetal
lung development can be administered. However, most tocolytic drugs
have cardiovascular adverse effects that may harm the fetal cardiovas-
cular system. In our opinion, if one opts for tocolysis, the oxytocin
antagonist atosiban is to be preferred above other tocolytica, as this
drug does not have any cardiovascular adverse effects.
Necessity for treatment
The decision to initiate pharmacological intervention in case of fetal
tachycardia depends on several factors and must be weighed against
possible maternal and/or fetal adverse effects inherent to the use of
antiarrhythmics. First, the seriousness of the fetal condition must be
assessed. In the chapters 3, 4, 6 and 7, it is outlined that there is a sig-
nificant predisposition to congestive heart failure, subsequent deve-
lopment of fetal hydrops and even sudden cardiac death. Secondly, the
sensitivity of predictors of congestive heart failure mentioned in chap-
ter 5 is low, and these predictors are therefore clinically not very use-
ful. In addition, hemodynamic compromise may occur in less than 24 -
48 hours as has been shown in the fetal lamb 13 and in tachycardic
fetuses 14, 15. On the other hand, spontaneous resolution of the tachy-
cardia has also been described 16. Thirdly, transplacental management
of fetuses with congestive heart failure or fetal hydrops is difficult 17, 18,
probably as a result of limited transplacental transfer of the antiar-
rhythmic drug 19, 20. In case of fetal hydrops, conversion rates are decre-
ased and time to conversion is increased 21. In our opion, treatment is
therefore to be preferred above expectant management, although
some centers oppose this regimen and suggest that in cases with
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(intermittent) fetal SVT not complicated by congestive heart failure or
fetal hydrops, conservative management and close surveillance might
be a reasonable alternative 22-24.
The most important goal of initiation of treatment is the prevention or
resolution of hemodynamic compromise and therefore the prevention
of fetal hydrops. In case of treatment the question remains whether to
treat prenatally or postnatally, in the latter case after artificial preterm
delivery. Several factors play a role in this decision. In case of trans-
placental treatment, the fetus will be able to thrive in its natural envi-
ronment and the problems encountered with a preterm delivery will be
avoided. One may oppose however, that, with elective preterm delivery
and postnatal treatment, monitoring of the infant might be easier. In
case of an emergency situation, for instance ventricle fibrillation, phy-
sicians may be able to react instantly. But, there is no guarantee of a
favourable outcome of this situation in the postnatal setting. This view
seems to result in a redirection of the problem in responsibility
between different specialties and predisposes the neonate to addition-
al complications of prematurity 25, 26. In addition, an induced preterm
delivery, is likely to result in a caesarean section with increased
maternal risks and possible effects on subsequent pregnancies 27-29.
The decision as to prenatal or postnatal start of treatment mainly
depends on gestational age and it is obvious that at an early gestation
prenatal treatment is the only reasonable choice. At term, physicians
may differ in opinion whether to treat pre- or postnatally. However,
transplacental treatment has proven to be both safe and effective, and
serious maternal adverse effects, although theoretically possible, have
not been described in literature. It seems therefore logical to treat the
fetus in its natural environment through transplacental treatment.
The issue of direct fetal therapy is described in chapter 5. In the inter-
national literature, several modes of administration, intra-umbilical,
intra-amniotic, intra-peritoneal, intra-muscular and intra-cardiac, have
been described. These ways of administration show a significant mor-
tality, but it is unclear if these deaths are attributable to the invasive
nature of the treatment or to the severity of the underlying condition
17, 30. Such approaches should only be used in cases of fetal tachycardia
complicated by hydrops with resistance to transplacental multidrug
therapy.
Treatment
In chapter 5, a review of the literature on the various regimens of drugs
used in the transplacental treatment of fetal tachycardia is presented.
Numerous drugs have been proposed in the treatment of fetal tachy-
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cardia, although only several have proven to be clinically useful.
Digoxin has been the drug of first choice in most centers, with success
rates of approximately 50 % in nonhydropic SVT and of 45% in AF 31-34.
In tachycardia complicated by hydrops, disappointing conversion rates
of 15-20 % have been reported 35, probably as a result of reduced
placental transfer 20. Few adverse effects of digoxin are present in this
population. Flecainide has been proposed as an effective drug in the
treatment of SVT with hydrops either as drug of first choice or in com-
bination with digoxin, with conversion rates ranging from 75 – 92 % 36-
38. Another drug of second choice, amiodarone, had received some
attention in the past 39-41, but has gained much popularity lately 24,
since treatment with digoxin and amiodarone proved to be effective in
15 hydropic fetuses with AVRT, and in 2 with VT and JET respectively 42.
In AF, a conversion rate of 50 % (3 out of 6 fetuses) was achieved. The
adverse effects of amiodarone are of possible concern: in 5 of the 23
fetuses a mild transient biochemical hypothyroidism was detected,
which required treatment in only 1 neonate who received amiodarone
for a prolonged period after birth. In one mother, treatment had to be
stopped because of the development of a photosensitive skin rash and
thrombocytopenia.
In chapter 6 and 7 we present the results of two studies on the treat-
ment of fetal tachycardia with sotalol. This antiarrhythmic drug has
both Bèta-adrenergic blocking properties as class III antiarrhythmic
properties and it was hypothesized that this drug may be of value in
the treatment of fetal tachycardia. Chapter 6 describes the pharmaco-
kinetics and dynamics of sotalol in pregnancy. In 19 patients, levels of
sotalol were prospectively studied in maternal, umbilical and neonatal
blood and in amniotic fluid. The maternal blood level of sotalol was
linearly related to the daily maternal dosage, and strongly related to
the fetal blood level as measured in the umbilical cord. The trans-
placental transfer of sotalol proved to be excellent with a mean
fetal/maternal ratio of 1,11. Sotalol accumulates in amniotic fluid with a
mean amniotic fluid/fetal cord blood ratio of 3,2, but not in the fetus
itself. The maternal blood level can therefore be used as an indicator of
the fetal blood level, although it did not prove to be a reliable predictor
of the chances of success of therapy. Sotalol was not associated with
intra uterine growth restriction. The overall success rate of sotalol as a
single therapy in the treatment of atrial flutter in the studies presen-
ted in chapters 6 and 7, was 63 %, and reached 79 % after the addition
of digoxin. This compares favorably with other reports 34 and it is con-
cluded that sotalol is a superior drug in the treatment of AF. The suc-
cess rate in fetal SVT was 53 % with sotalol as a single drug and
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reached 74 % after the addition of digoxin. These results are compara-
ble with other proposed treatment protocols. In the SVT group, there
were however, four deaths. Two of these fetuses had a severe hydrops
and the occurrence of an intra-uterine death in such a case may be
expected. But in two of these deaths, no hydrops was present and no
cause of death could be established at autopsy. Therefore the question
of proarrhythmia was raised, since ventricle fibrillation might have been
the cause of death. Although we have no evidence that this was indeed
the cause of these deaths, it is proposed that this risk should be minimi-
zed by a low initiation dosage and stepwise dosage increase. In addition,
close monitoring, especially during the initiation phase is recommended.
Protocol in the treatment of fetal tachycardia
In chapter 8, a preliminary treatment protocol is presented for the two
main subgroups of fetal tachycardia, atrial flutter (AF) and supraventri-
cular tachycardia (SVT). They differ in nature and course and therefore
require different therapy. In fetal AF, the results of the study presented
in chapters 6 and 7 are superior to those published in the international
literature and sotalol, with digoxin as a second line drug, should there-
fore be the treatment of choice, both in isolated AF as in the presence
of fetal hydrops (Figure 1).
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Fetal AF
Sotalol orally
80 mg 2x/day
during 3 days
Increase of Sotalol orally
with 80 mg per 3 days
to a maximum of 160 mg 3x/day
No conversion to sinus rhythm
or decrease of ventricular rate
Addition of Digoxin orally
0,250 mg 3x/day
during 3 days
No conversion to sinus rhythm
or decrease of ventricular rate
Increase of Digoxin orally
0,500 mg 2x/day
No conversion to sinus rhythm
or decrease of ventricular rate
No Fetal Hydrops Fetal Hydrops
Figure 1
Treatment protocol Fetal Atrial Flutter
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In nonhydropic fetal SVT, the optimal treatment regimen is more com-
plicated. The success rates of the treatment protocol presented in
chapters 6 and 7 is comparable to that of other treatment protocols,
however, there was a relatively high mortality rate in our series. In
table 1, our results are compared to the results in other studies on non-
hydropic fetuses, treated with different protocols. The differences in
mortality, as measured by the Fischer’s exact test were not statistically
significant (P=0,261). The choice for sotalol was based on the electro-
physiologic properties of this agent, but a definite clinical advantage
could not be proved. This is the reason that the treatment protocol
(figure 2) shows 2 options without a documented preference for either.
Study Drugs used IUD Total # Mortality 
of patients percentage
Oudijk et al. S, D 2 20 10%
Simpson et al. D, F, V 2 75 2,7%
Ebenroth et al. D, F 0 30 0%
Frohn-Mulder et al. D, F 0 22 0%
Jaeggi et al. D 0 15 0%
van Engelen et al. D, F 0 19 0%
Table 1
Mortality rates of nonhydropic tachycardic fetuses.
S = sotalol, D = digoxin, F = flecainide, V = verapamil, IUD = intra uterine death
In fetal SVT complicated by hydrops, a more aggressive approach with
more potent drugs is required. Two options are proposed: flecainide, or
a combination of intravenous digoxin and amiodarone, both of which
have proven to be effective in this serious condition (Figure 3).
In conclusion, as a result of the studies of this thesis and of the latest
international literature, new treatment protocols are proposed and
presented (figure 1-3). As discussed in the beginning of this summary
and discussion, a detailed diagnosis of the specific type of tachycardia
may result in a more specific treatment. Hopefully this will result in a
further reduction of morbidity and mortality in the field of fetal tachy-
cardia.
Chapter 11
Figure 2
Treatment protocol options Fetal SVT not complicated by hydrops
Figure 3
Treatment ptotocol options Fetal SVT complicated by hydrops
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Fetal SVT
No Fetal Hydrops
Digoxin orally
0,250 mg 2x/day
during 3 days
Increase of Digoxin
0,500 mg 2x/day
during 3 days
No conversion to sinus rhythm
or decrease of ventricular rate
Addition of sotalol orally
80 mg 2x/day
during 3 days
No conversion to sinus rhythm
or decrease of ventricular rate
Increase of sotalol orally
with 80 mg per 3 days
Maximum of 160 mg 3x/day
No conversion to sinus rhythm
or decrease of ventricular rate
Fetal SVT
No Fetal Hydrops
Sotalol orally
80 mg 2x/day
during 3 days
Increase of Sotalol orally
with 80 mg per 3 days
to a maximum of 160 mg 3x/day
No conversion to sinus rhythm
or decrease of ventricular rate
Addition of digoxin
0,250 mg 3x/day
during 3 days
No conversion to sinus rhythm
or decrease of ventricular rate
Increase of Digoxin
0,500 mg 2x/day
during 3 days
No conversion to sinus rhythm
or decrease of ventricular rate
Fetal SVT
Fetal Hydrops
No conversion to sinus rhythm
or decrease of ventricular rate
No conversion to sinusrhythm
or decrease of ventricular rate
No conversion to sinusrhythm
or decrease of ventricular rate
after 7 days
No conversion to sinusrhythm
or decrease of ventricular rate
after 7 days
Consider direct fetal treatment Consider direct fetal treatment
Digoxin intravenous
loading dose of 1 mg in 24 hours
followed by 0,5-1,0 mg/day
orally during 3 days
Or Flecainide orally
200-400 mg/day
during 3 days
Decrease Digoxin by 50%
Addition of Amiodarone orally
1200-2400 mg/day 2-7 days
maintenance of 400-800 mg/day
Addition of Digoxin intravenous
loading dose of 1 mg in 24 hours
followed by 0,5-1,0 mg/day
orally during 3 days
Part II: Fetal ECG in labour, aspects of the intra-
partum QT interval 
The Fetal ECG (FECG) has provided clinicians with useful information in
electronic fetal monitoring for decades. The most extensively studied
part of the FECG is the RR interval. Although a normal fetal heart rate
pattern is reassuring with respect to the fetal condition, the predictive
value of an abnormal pattern is low 43, 44. In addition, it increases the
rate of caesarean section 45, without a clear improvement of outcome
46, 47. Other time constants, as the relationship between PR and RR
intervals, have also been extensively investigated, but no clinically use-
ful information could be obtained 48. The morphology of the FECG
including the ST segment and T wave configuration has, however, been
shown to provide specific and clinically useful information of fetal car-
diovascular adaptation to experimental hypoxia and as an adjunct to
standard FHR monitoring in labour 49-51.
In part II of this thesis, a specific part of the fetal ECG, the QT interval,
during labour is investigated. A prolonged QT interval, a measure for
delayed ventricular repolarization, predisposes to episodes of ventricu-
lar tachycardia leading to recurrent (pre-) syncope and sudden cardiac
death 52, 53. As it is of the utmost importance that infants with a pro-
longed QT interval are identified at the earliest possible stage, the
FECG in labour may prove to be of value in the detection of children at
risk. Therefore, we conducted a study, in which the properties of the QT
interval during labour are investigated. The QT interval has been
shown to change in response to different (stressful) situations, cate-
cholamine exposure, exercise, infections and heart failure 54-58, and in
our study, interesting observations were made on the effects of
hypoxia on the QT interval.
In chapter 9, observations on the intrapartum QT interval in three pre-
mature sheep fetuses and one human fetus at term, all being exposed
to acute and severe asphyxia, are presented. A shortening of the QT
interval is present, shortly after the fetus is exposed to asphyxia, in
association with a rise in T/QRS ratio and an increase in blood pressure.
In prolonged asphyxia, the QT interval lengthens again in association
with a decrease in T/QRS ratio and decrease in blood pressure. In chap-
ter 10, these observations were taken further by evaluating changes in
the QT interval in 68 fetuses with signs of intrapartum hypoxia quanti-
fied by umbilical artery metabolic acidosis. The QT interval was
measured at the start of the recording at baseline heart rate and
during variable decelerations in a situation without acidosis and at the
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end of the recording at which point metabolic acidosis was likely to be
present. A significant shortening of the QT interval was present at the
end of the recording in comparison with the start of the recording,
consistent with the observations made in chapter 9.
In a situation of hypoxia or asphyxia, when the energy balance within
the myocardial cell threatens to become negative, the fetus reacts with
a surge in epinephrine 59, Bèta-adrenoceptor activation 60 and myocar-
dial glycogenolysis 61. This alarm reaction of the fetus is characterized
by an increase in T wave amplitude with the rate of T wave rise being
directly related to the rate of glycogenolysis and maintained cardiovas-
cular function. The QT shortening as described in this paper is associa-
ted with an increase in T/QRS ratio and these findings are therefore
likely to be mediated through the same mechanism of catecholamine
surge. We speculate that children suffering from the Long QT syndrome
may not be able to react to hypoxia with the same changes as the
cases displayed in chapters 9 and 10, as it is known they respond diffe-
rently to exogenous catecholamines 62, 63. Studies on the relation
between a long QT interval during labour and the association with
LQTS are ongoing.
In conclusion, the observation of an intrapartum shortening of the QT
interval is a sign of developing metabolic acidosis and may therefore
provide additional information on the condition of the fetus in labour.
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Samenvatting en nabeschouwing
De foetale hartslag is een belangrijke parameter voor het verkrijgen
van inzicht in de conditie van de foetus. Aangezien het, het doel van
verloskundige zorg is om ieder kind zo gezond mogelijk geboren laten
worden met zo min mogelijk schade aan de moeder 1, is adequate
interpretatie van het foetale hartslagpatroon en detectie van eventu-
ele hartritmestoornissen van groot belang.
In dit proefschrift concentreren wij ons op de diagnose en behandeling
van foetale tachycardieën. Een tweede gedeelte behandelt het foetale
QT interval durante partu en de mogelijke bruikbaarheid van deze
parameter bij de foetale bewaking.
Deel I: Foetale tachycardieën
Diagnose
Foetale tachycardie is een aandoening met een reëel risico op compli-
caties, en de bevinding rechtvaardigt nader onderzoek in een daartoe
gespecialiseerd centrum. In hoofdstuk 2 worden verschillende metho-
den van diagnose van foetale tachycardie beschreven, zoals Doppler en
M-mode echocardiografie, alsook de nog in ontwikkeling zijnde foetale
magnetocardiografie (FMCG). De kenmerken van de verschillende
typen tachycardie worden beschreven met karakteristieke echo- en
FMCG beelden.
Met behulp van M-mode echocardiografie is het mogelijk de tachycar-
dieën in subgroepen in te delen. Een classificatie in supraventriculaire
tachycardie (SVT), atrium flutter (AF) en ventriculaire tachycardie (VT)
is echter niet voldoende om te differentiëren volgens het elektrofysio-
logische mechanisme van de tachycardie. Een meer nauwkeurige diag-
nose van het type tachycardie stelt de behandelaar in staat een speci-
fieke behandeling in te stellen. Verschillende onderzoekers hebben
daarom getracht de mogelijkheden van M-mode echocardiografie uit
te breiden 2, 3. In hoofdstuk 3 wordt beschreven hoe foetale SVT kan
worden onderverdeeld op basis van de relatie tussen het atrioventricu-
laire (AV) en ventriculoatriale (VA) interval, in korte en lange VA SVT
tachycardieën. Deze relatie is in geval van een re-entry tachycardie een
maat voor de snelheid van de geleiding over de accessoire bundel.
Normaal gesproken is deze geleiding snel, zoals bij het Wolff-
Parkinson-White syndroom. Echter bij enkele aandoeningen is de gelei-
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ding door de accessoire bundel langzaam, zoals bij Persistent
Junctional Reciprocating Tachycardia (PJRT). In hoofdstuk 3 worden vier
foetussen beschreven bij wie een lang VA interval werd gemeten met
M-mode echocardiografie en de diagnose PJRT postnataal werd beves-
tigd. Het verloop van deze tachycardie bleek anders dan die waarbij
sprake was van een kort VA interval. In geval van een tachycardie met
een lang VA interval was prenataal sprake van een therapieresistente
persisterende tachycardie waarbij de hartfrequentie niet boven de 240
slagen per minuut uitkwam en er een sterke associatie met decompen-
satio bleek te bestaan. De behandeling postnataal was eveneens
gecompliceerd en vereiste diverse anti-arrhythmica combinaties dan-
wel ablatie van de accessoire bundel op vroege kinderleeftijd.
Meer gedetailleerde informatie over de electrofysiologie van het foeta-
le hart kan worden verkregen met behulp van FMCG 4, 5. In hoofdstuk 2
worden de FMCG beelden van premature atriale contracties, AF, atrio-
ventriculaire re-entry tachycardie en een verlengd QT interval getoond.
Deze beelden laten zien dat specifieke intervallen van het foetale ECG
nauwkeurig kunnen worden gemeten en dat de tachycardieën ook pre-
nataal kunnen worden gedifferentieerd op basis van de electrofysiolo-
gische achtergrond. Het toepassen van deze techniek bij alle gevallen
van tachycardie zou uiteindelijk kunnen leiden tot een gespecialiseerd
protocol voor de verschillende typen tachycardie.
Consequenties 
Handhaving van een adequatefoetale circulatie loopt bij hoge hartfre-
quenties gevaar als gevolg van het Frank Starling effect. Dit betekent
dat er bij foetale hartfrequenties boven de 180 slagen per minuut
decompensatie, zich uitend in foetale hydrops, kan optreden. In hoofd-
stuk 4 en 5 worden de factoren beschreven die een rol spelen in de ont-
wikkeling van decompensatio cordis en foetale hydrops, in geval van
een tachycardie. Predisponerende factoren zijn onder andere: de tijd
die de tachycardie aanwezig is, de amenorroeduur ten tijde van het
optreden van de tachycardie 6, de ventriculaire frequentie 7 en de ach-
terliggende oorzaak van de tachycardie 8. Echter in ons onderzoek
bereikten geen van deze veronderstelde factoren statistische signifi-
cantie. Bij een foetale tachycardie die gecompliceerd wordt door hydro-
ps, is er een verhoogde kans op neurologische morbiditeit, waarschijn-
lijk ten gevolge van de gecompromitteerde hemodynamiek 9-11. De
cerebrovasculaire autoregulatie die de cerebrale perfusie reguleert bij
kinderen en volwassenen, werkt nog niet voldoende bij aan stress
blootgestelde pasgeborenen, en zeer waarschijnlijk ook niet bij een
dergelijke situatie vóór de geboorte. Grote veranderingen in hartritme
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kunnen resulteren in een inadequate output van het hart, met een ver-
hoogde kans op cerebrale ischaemie tijdens perioden van (milde) hypo-
tensie en een verhoogde kans op intracraniele bloedingen tijdens
perioden van (milde) hypertensie 12. Enkele casuïstische mededelingen
hebben gesuggereerd dat de prognose van foetussen met hydrops
slecht zou zijn. In hoofdstuk 4 hebben wij daarom de uitkomst onder-
zocht van 11 foetussen die in ons centrum bekend waren met hydrops
op basis van een tachycardie.
Van deze groep zijn twee patiënten overleden, één vlak na de geboorte
ten gevolge van de tachycardie en de daaruit voortvloeiende complica-
ties, en één op de leeftijd van twee jaar ten gevolge van een ernstige
arrhythmie. Zeven van de 9 overlevende kinderen zijn gezond; 1 kind is
bekend met een milde hemiplegie met normale cognitieve functie en 1
kind heeft op een leeftijd van 1,5 jaar een ontwikkelingsachterstand
van enkele maanden. Wij concluderen dat in geval van foetale hydrops
ten gevolge van een tachycardie, het instellen van therapie niet mag
worden weerhouden of vertraagd op basis van een veronderstelde
slechte prognose.
Ernstige hydrops met polydramnion gaat vaak gepaard met preterme
uteriene contracties. Remming van weeën maakt het mogelijk om
corticosteroiden ter longrijping in te laten werken. Echter de meeste
tocolytica hebben cardiovasculaire bijwerkingen die potentieel gevaar-
lijk zijn voor de niet optimaal functionerende foetale circulatie. In
geval voor weeënremming wordt gekozen, gaat onze voorkeur uit naar
atosiban, een oxytocine antagonist, aangezien cardiovasculaire bijwer-
kingen niet zijn beschreven bij dit medicament.
De noodzaak van behandeling
De beslissing om te interveniëren met anti-arrhythmica in geval van
een foetale tachycardie hangt af van verschillende factoren en inter-
ventie moet altijd worden afgewogen tegen mogelijke maternale en
foetale bijwerkingen, die inherent zijn aan het gebruik van anti-
arrhythmica. Bij de afweging al dan niet te behandelen is het van
belang de risico’s van de tachycardie te kennen. In de hoofdstukken 3, 4,
6 en 7 wordt uiteengezet dat er bij foetale tachycardie een significant
verhoogde kans is op congestief hartfalen, de ontwikkeling van foetale
hydrops en zelfs op plotselinge hartdood. De sensitiviteit van de in
hoofdstuk 5 genoemde ‘voorspellende’ parameters voor hartfalen is
helaas laag, en daarom zijn deze in de praktijk niet bruikbaar.
Uit dierexperimenteel onderzoek 13 en uit observaties bij de mens is
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bekend 14, 15, dat tachycardie bij de foetus binnen 24 tot 48 uur kan lei-
den tot hydrops. Daar tegenover staat dat spontane resolutie van foe-
tale tachycardie ook is beschreven 16. De vraag of en wanneer er met de
behandeling van de foetus moet worden begonnen wordt hierdoor dus
niet opgelost. Een punt ten gunste voor het starten van een vroege
behandeling wordt geleverd door het feit dat behandeling van de
tachycarde foetus met hydrops middels transplacentaire therapie
gecompliceerder is dan bij ontbreken van hydrops 17, 18, waarschijnlijk
ten gevolge van de verminderde passage van het anti-arrhythmicum
over de placenta 19, 20. Ook is in geval van hydrops het percentage foe-
tussen dat succesvol wordt behandeld lager, en indien toch conversie
optreedt, dan is de tijd tot conversie langer dan bij nonhydropische
foetussen 21. De combinatie van deze gegevens leiden ons ertoe te stel-
len dat behandeling van de tachycardie te prefereren is boven het aan-
nemen van een afwachtende houding. Echter enkele centra zijn hierop
tegen en propageren in geval van (intermitterende) SVT zonder conges-
tief hartfalen of hydrops, geen medicatie te starten, maar de foetus
met zeer frequent echografische controles te bewaken 22-24.
Het belangrijkste doel van behandeling is de preventie danwel resolu-
tie van hartfalen en daarmee de preventie van hydrops. In de keuze
tussen prenatale of postnatale (na een iatrogene vroeggeboorte)
behandeling spelen meerdere factoren een rol. In het geval van prena-
tale behandeling door middel van transplacentaire therapie, wordt de
foetus in staat gesteld zich te ontwikkelen in zijn natuurlijke omgeving
en worden de problemen van een premature partus voorkomen. Aan de
andere kant echter zou men kunnen stellen dat, in geval van een geïn-
duceerde premature partus en postnatale behandeling, de vitale func-
ties van het kind na de geboorte beter kunnen worden bewaakt. In
geval van een noodsituatie zoals ventrikelfibrilleren, zou men dan
direct kunnen reageren. Echter ook in een dergelijke situatie er is geen
garantie op een goede uitkomst. Het lijkt dan ook eerder een verschui-
ving van het probleem te zijn van de ene naar de andere medische dis-
cipline met als gevolg de risico’s van iatrogene prematuriteit 25, 26.
Tevens zal een geïnduceerde preterme partus vaker resulteren in een
keizersnede, met kans op maternale schade en op mogelijke gevolgen
bij een volgende graviditeit 27-29. Deze beslissing hangt grotendeels af
van de zwangerschapsduur en vroeg in de zwangerschap is het duide-
lijk dat prenatale behandeling de enige optie is en alleen in geval van
een à terme zwangerschap is neonatale behandeling een reële optie.
Transplacentaire behandeling is een veilige en effectieve therapie
vorm, en ernstige maternale bijwerkingen, alhoewel in theorie aanwe-
zig, zijn niet in de literatuur beschreven. Het verdient ons inziens dan
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ook de voorkeur om de foetus in zijn natuurlijke omgeving te behande-
len.
Directe foetale therapie wordt beschreven in hoofdstuk 5. In de interna-
tionale literatuur worden verschillende methoden, intra-umbilicaal,
intra-amniotisch, intra-peritoneaal en intra-cardiaal, beschreven. In
deze studies wordt een significante mortaliteit beschreven. Hierbij is
het echter niet duidelijk of deze het gevolg is van de invasieve behan-
deling, of van de ernst van de conditie van de foetussen 17, 30. Wij zijn
van mening dat invasieve behandeling uitsluitend geïndiceerd is in
geval van foetale hydrops waarbij geen reactie optreedt na trans-
placentaire therapie met meerdere medicamenten.
Behandeling
In hoofdstuk 5 worden de verschillende farmacotherapeutische opties
beschreven, die gebruikt worden bij de behandeling van foetale ritme-
stoornissen. Talloze medicamenten zijn in de loop der jaren gebruikt,
maar slechts enkele zijn in de praktijk bruikbaar gebleken. Digoxine is
in vele centra het middel van eerste keuze, met een succespercentage
van ongeveer 50 % in geval van een nonhydropische SVT en van 45 % in
geval van AF 31-34. Bij tachycardieën gecompliceerd door hydrops zijn de
succespercentages lager en in de orde van 15-20 % 35, waarschijnlijk ten
gevolge van verminderde passage van digoxine door de placenta 20.
Een voordeel van digoxine is het lage percentage bijwerkingen.
Flecainide wordt meer en meer beschreven als middel van eerste keuze
in geval van SVT met hydrops, al of niet gecombineerd met digoxine.
Het succespercentage van een dergelijke behandeling ligt in de orde
van 75-92 % 36-38. Amiodarone, een middel van tweede keuze dat vroe-
ger sporadisch werd gebruikt 39-41, lijkt naar aanleiding van nieuwe
resultaten meer aandacht te verdienen 42. Behandeling met digoxine
en amiodarone bleek effectief te zijn bij 15 hydropische foetussen met
atrioventriculaire re-entry tachycardie  en in twee gevallen met VT en
JET 43. Een dergelijke behandeling was ook effectief bij 3 van de 6 foe-
tussen AF. Dit middel heeft echter een ongewenst effect op de foetale
schildklier en bij 5 van de 23 behandelde patiënten werd na de geboor-
te een milde biochemische hypothyreoidie gevonden, die bij één kind
behandeling vereiste (mogelijk omdat de behandeling neonataal werd
voortgezet). Maternaal was er éénmaal sprake van een lichtgevoelige
huiduitslag en trombocytopenie.
In hoofdstuk 6 en 7 worden de resultaten gepresenteerd van twee stu-
dies over de behandeling van foetale tachycardieën met sotalol. Dit
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anti-arrhythmicum is een Bèta blokker met additionele klasse III anti-
arrhythmische eigenschappen en het was de veronderstelling dat dit
middel van betekenis zou kunnen zijn bij de behandeling van foetale
tachycardieën. In hoofdstuk 6 worden de farmacokinetische en farma-
codynamische eigenschappen van sotalol in de graviditeit beschreven.
De bloedspiegels van sotalol werden bij 19 patiënten prospectief
onderzocht in maternaal, navelstreng en neonataal bloed, alsook in het
vruchtwater. De maternale bloedspiegel van sotalol was lineair gecor-
releerd aan de dagelijkse dosis en er was sprake van een sterke relatie
met de foetale spiegel in navelstrengbloed. De passage van sotalol
door de placenta was uitstekend met een gemiddelde foetale/mater-
nale ratio van 1,1. Sotalol blijkt zich op te hopen in het vruchtwater met
een gemiddelde vruchtwater/foetaal bloed ratio van 3,2. De maternale
bloedspiegel geeft dus een adequate indicatie van de foetale bloed-
spiegel, maar bleek geen goede voorspeller van het succes van behan-
deling te zijn. Bèta-blokkers zijn geassocieerd met intra uteriene groei-
retardatie, maar daar vonden wij met betrekking tot sotalol geen aan-
wijzingen voor. Drieënzestig procent van de foetussen met AF werden
met succes behandeld met sotalol en dit percentage steeg naar 79 %
na toevoeging van digoxine (hoofdstukken 6 en 7). Deze percentages
zijn hoger dan bij andere behandelmodaliteiten 34 en wij concluderen
dan ook dat sotalol superieur is bij de behandeling van foetale AF. In
geval van SVT bleek het succespercentage van sotalol 53 % te bedra-
gen, en na toevoeging van digoxine 74 %. Deze resultaten zijn vergelijk-
baar met andere behandelmodaliteiten. In ons onderzoek was echter
viermaal sprake van een uteriene vruchtdood. Bij twee van deze foetus-
sen kan dit verklaard worden door de ernstige hydrops. Echter bij de
andere twee patiënten was geen sprake van hydrops en kon bij obduc-
tie geen oorzaak voor de sterfte gevonden worden. De mogelijkheid
van een pro-arrhythmische bijwerking met als gevolg ventrikelfibrille-
ren kan dan ook niet uitgesloten worden. Alhoewel wij geen harde
aanwijzingen hebben voor deze hypothese, zijn wij wel van mening dat
een dergelijk risico geminimaliseerd moet worden en adviseren daar-
om met een lage dosis te beginnen met een stapsgewijze verhoging.
Regelmatige controles zijn aangewezen, vooral in de initiatie fase.
Protocollen bij de behandeling van foetale tachycardieën
In hoofdstuk 8 wordt een voorlopig behandelprotocol gepresenteerd
voor de twee belangrijkste groepen foetale tachycardie, de AF en de
SVT. De oorzaak en gevolgen van deze tachycardieën zijn verschillend
en zij vereisen daarom een aparte behandeling. In het geval van AF zijn
wij van mening dat de resultaten van ons onderzoek gepresenteerd in
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de hoofdstukken 6 en 7, superieur zijn aan die van andere behandelmo-
daliteiten. Sotalol, met digoxine als middel van tweede keus, is daarom
bij AF te prefereren als middel van eerste keus; dit geldt zowel voor de
geïsoleerde AF als voor de hydrops (Figure 1, summary and discussion, blz
187).
Bij nonhydropische SVT, is de keuze meer gecompliceerd. De succesper-
centages van sotalol zijn vergelijkbaar met die van andere middelen;
echter in ons onderzoek was sprake van een vrij hoge mortaliteit. In
Tabel 1 (Table 1, summary and discussion, blz 188) wordt het percentage
intra uteriene vruchtdoden vergeleken met die van andere onderzoe-
ken waarin aanzienlijke groepen nonhydropische foetussen met SVT
werden behandeld met andere middelen. De verschillen tussen deze
middelen, bepaald met behulp van de Fisher’s exact test, bleken statis-
tisch niet significant (p= 0,261). Er lijkt echter geen duidelijk klinisch
voordeel van de behandeling van sotalol bij nonhydropische SVT te
bestaan, en om deze reden zijn dan ook twee protocolopties opgeno-
men in deze samenvatting (Figure 2, summary and discussion, blz 189).
In SVT gecompliceerd door hydrops, is een agressievere behandeling
vereist. Op basis van eigen ervaringen en op die gepubliceerd door
anderen, worden twee behandelopties gegeven: flecainide, of een com-
binatie van intraveneuze digoxine en amiodarone. Beide opties bleken
zeer effectief bij de behandeling van deze ernstige aandoening (Figuur 3,
summary and discussion, blz 189).
Naar aanleiding van de resultaten van de studies beschreven in dit
proefschrift en de meest recente publicaties in de literatuur worden
nieuwe behandelprotocollen voorgesteld (Figuur 1-3). Zoals beschreven
aan het begin van deze samenvatting en nabeschouwing zou een meer
gedetailleerde diagnose kunnen leiden tot een meer specifieke behan-
deling voor de verschillende typen van tachycardie. Hopelijk zal dit uit-
eindelijk leiden tot een reductie van morbiditeit en mortaliteit.
Deel II: Foetale ECG durante partu; aspecten
van het intrapartum QT interval
Het foetale ECG (FECG) bevat relevante informatie en wordt sinds tien-
tallen jaren gebruikt voor foetale bewaking. Het meest bestudeerde
deel van het FECG is het RR interval en het daaruit voorkomende hart-
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slagpatroon. Een normaal hartslagpatroon is geruststellend omtrent de
conditie van de foetus. De voorspellende waarde van een abnormaal
patroon is echter laag 44, 45. Tevens is aangetoond dat het aantal kei-
zersneden na introductie van cardiotocografie is toegenomen, zonder
een duidelijk gunstig effect op de uitkomst 46, 47. De relatie tussen het
PR en RR interval is ook onderzocht, maar hieruit kon geen klinisch
relevante informatie worden verkregen 48. Het ST segment en de confi-
guratie van de T top blijken klinisch wel relevant en bevatten naast de
standaard hartslagbewaking durante partu additionele informatie
omtrent het cardiovasculaire aanpassingsvermogen van de foetus 49-51.
In het tweede gedeelte van dit proefschrift onderzoeken wij een ander
specifiek interval van het FECG: het QT interval. Een verlengd QT inter-
val is een maat voor vertraagde ventriculaire depolarisatie en predispo-
neert tot perioden van ventriculaire tachycardie die kunnen leiden tot
wegrakingen en plotselinge hartdood 52, 53. Het is daarom van groot
belang om kinderen met een verlengd QT interval in een zo vroeg
mogelijk stadium te identificeren. Mogelijk kan het FECG gebruikt wor-
den om kinderen met een verhoogd risico reeds tijdens de partus op te
sporen. Het QT interval blijkt te reageren op verschillende fysiologische
processen, zoals stress, verhoogde catecholamine belasting, inspan-
ning, infecties en hartfalen 54-58. Wij hebben de effecten van hypoxie
op het QT interval bestudeerd.
In hoofdstuk 9, worden de resultaten gepresenteerd van het verloop
van het QT interval bij 3 premature schapenfoetussen en bij één huma-
ne foetus, die allen blootgesteld waren aan acute asfyxie.
Kort nadat de foetussen werden blootgesteld aan asfyxie trad een ver-
korting van het QT interval op, tegelijkertijd met een stijging van de
T/QRS ratio en van de bloeddruk. Tijdens het aanhouden van asfyxie
was na verloop van tijd sprake van een verlenging van het QT interval,
tegelijk met een daling van de T/QRS ratio en van de bloeddruk. Naar
aanleiding van deze observaties werd in hoofdstuk 10 het QT interval
van 68 foetussen met tekenen van hypoxie onderzocht. Bij al deze foe-
tussen was na de geboorte sprake van metabole acidose in navel-
strengbloed. Het QT interval werd gemeten aan het begin van de regis-
tratie bij een normale hartfrequentie, tijdens variabele deceleraties in
afwezigheid van acidose en aan het einde van de registratie, in aanwe-
zigheid van metabole acidose. Acidose bleek te leiden tot een signifi-
cante verkorting van het QT interval, vergelijkbaar met de observaties
beschreven in hoofdstuk 9.
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In een situatie van hypoxie, wanneer de energiebalans in het foetale
myocardium negatief dreigt te worden, reageert de foetus met een
plotselinge toename van adrenaline 54 , activatie van bètareceptoren 55
en glycogenolyse in het myocardium 56. Deze ‘alarm reactie’ gaat
gepaard met een toename van de amplitude van de T-top, gerelateerd
aan de bij glycogenolyse vrijkomende kalium ionen. Hierbij wordt de
cardiovasculaire functie gehandhaafd. De verkorting van het QT inter-
val zoals beschreven in dit proefschrift vindt plaats in samenhang met
de toename van de T/QRS ratio en is waarschijnlijk gerelateerd aan
hetzelfde mechanisme. Kinderen met het lange QT syndroom zijn
mogelijk niet in staat om op hypoxie durante partu te reageren vol-
gens het patroon zoals beschreven in hoofdstuk 9 en 10, aangezien zij
anders reageren op exogene catecholamines 57, 58. Onderzoek naar de
relatie tussen een lang QT interval tijdens de bevalling en het ‘lange QT
syndroom’ na de geboorte is nog gaande.
Wij concluderen dat een verkorting van het QT interval tijdens de par-
tus een teken is van metabole acidose en dat dit mogelijk van additio-
nele betekenis is met betrekking tot diagnostiek naar de conditie van
de foetus tijdens de bevalling.
206
Chapter 11
Referenties 
zie References op pagina 192 t/m 196
207
Samenvatting en nabeschouwing
Acknowledgements
Dr. E.J. Meijboom, beste Erik-Jan, na een college kindergeneeskunde in
het oude WKZ liep ik jouw kamer binnen om te vragen of er een onder-
zoek was waaraan ik zou kunnen meewerken. Slechts drie jaar later ligt
dit resultaat er. Dankzij je enorme gedrevenheid en enthousiasme heb-
ben we dit voor elkaar gekregen. Je hebt een hoop mogelijkheden voor
me gecreëerd en als ik die middag niet bij je naar binnen was gelopen
was ik nu vast op een ander punt in mijn leven geweest; een punt
waarop ik vast niet zo gelukkig zou zijn geweest als nu, heel veel dank
daarvoor. Ik hoop dat we in de toekomst kunnen blijven samenwerken
in de foetale cardiologie.
Prof. Dr. G.H.A. Visser, beste Gerard, hoe inspirerend kan iemand zijn? Elke
keer als ik je kamer binnen kwam lopen zonder enige hoop op afron-
ding van dit proefschrift, liep ik naar buiten alsof ik de hele wereld aan
kon. Dankzij jou harde werk en enthousiasme voor het onderzoek werd
het mogelijk dit in deze tijd af te ronden. Ook jij hebt veel mogelijkhe-
den voor me gecreëerd, waarvoor ik je erg dankbaar ben.
Prof.dr. K.G.Rosén, bäste KG, på våra promenader i Göteborgs hamn längs
Barken Viking, under en "tankepipa", introducerade du mig in i en
fysiologisk tanke process somlotsade mig vidare in i nästa steg i min
vetenskapliga karriär. Din aldrig sinande entusiasm har motiverat mig
till ett framtida forskningsarbete, fördetta är jag dig evigt tacksam.
Dr. Ph. Stoutenbeek, beste Philip, onze samenwerking vond met name
plaats op de echo-afdeling, alwaar ik mijn vaardigheden met name van
jou opdeed. Jouw gedetailleerde verslaglegging maakte het voor mij
mogelijk met alle data aan de slag te gaan. Veel dank daarvoor.
Dr. M. Glenshaw, dear Monica, it was at the Murambinda Mission
Hospital that my enthusiasm for Obstetrics arose. You guided me
through my first Caesarean section, a moment I will never forget. I very
much admire your work that has made the MMH to what it is today
and I hope the donation will help you carry on with the work.
Dr. A. Miller, dearest Anna, meeting you in Zimbabwe has been one of
the best things that ever happened to me, we had the best time in
Harare and Murambinda and it probably even got me to where I am
right now. To your example, I created my own little ‘shrine’ to finish
this thesis! Lots of love.
208
Chapter 11
For my time at Yale University:
I would like to thank the Medical School for its hospitality.
Prof. C.S. Kleinman, Dear Charles, thank you for the time and energy
you invested in Maaike and me. The article you have helped us write,
turned out to be the basis of this thesis. It has been an honour to work
with you, as being one of the experts in fetal cardiology.
Also a special thanks to Janice Sanderson and Prof. J.A. Copel at the
department of Obstetrics for the time they both invested.
Lieve Maaike, samen zijn we het onderzoek gestart en hebben we erg
veel lol gehad in de ‘Helen Happy Hall’ in New Haven. De Chinese
gemeenschap daar was erg onder de indruk van ‘die twee
Nederlanders’…Tot snel.
Veel dank ook aan mijn co-auteurs, Jopje Ruskamp, Barbara Ambachtsheer,
Tessa Ververs, Livia Kapusta, dr. R.H.J.M. Gooskens, prof.dr. N. Sreeram, Sofia
Blad, Anneke Kwee en prof. dr. M. Peters, voor alle tijd die zij in de artikelen
hebben gestoken.
Paul Verheijen en Lukas Lisowski, bedankt voor de leuke tijd op Yale en
natuurlijk ook voor alle tips bij de afronding van dit proefschrift. Ik
moet jullie alleen nog steeds bellen…
Tijs van den Nieuwendijk, beste Tijs, enorm bedankt voor de strakke lay-
out. Je regelt alles perfect, wat erg relaxed was!
For my time I spent in Göteborg, I would like to thank all the people at
Neoventa. I felt most welcome, and very much enjoyed staying with
you all. I hope we’ll meet again.
Alle verpleegkundigen en verloskundigen van de afdeling Obstetrie in het
UMCU: bedankt voor alle gezellige diensten, met name in de nacht!
Aan alle collega’s in het UMC, dank voor alle interesse en hulp bij het ver-
zamelen van de patiënten voor deze studies. Met name dank aan
Marion Kollen (voor de zeer leerzame, maar bovenal gezellige tijd) en
Wendy Manten en Jan Paul Roovers (voor het overnemen van klinische
taken tijdens de afronding van mijn proefschrift).
Ook al zat ik er niet erg lang, de onderzoekerskamer in het WKZ was
een supergezellige plek om alles af te ronden. Anneloes, Ayten, Rosa en
Maaike bedankt voor de enorm leuke tijd, ik kom snel weer eens koffie
209
Acknowledgements
drinken…als jullie dit keer nu eens een goede roddel hebben!
Lot Wisman en Joke de Wilde, secretaresses bij de Obstetrie en
Kindercardiologie, enorm bedankt dat jullie altijd tijd hadden om aller-
lei zaken voor mij te regelen.
Beste Barrels, vele borrels en feesten heb ik moeten missen vanwege
stages in het buitenland, nachtdiensten en “nachtdiensten”. Het proef-
schrift is nu klaar, dus ik hoop jullie weer meer te zien, maar de “nacht-
diensten” zullen denk ik blijven…
Lieve Martina en Liesbeth, bedankt voor jullie interesse in het onderzoek
en Liesbeth, dank voor je hulp bij de organisatie omtrent het feest!  
Lieve Gert-Jan, Katja, Tom, Esmaralda, Annemieke en Arno, bedankt voor alle
interesse in dit onderzoek, nu kan ik me eens meer richten op dat wat
ik nog ‘niet heb gehad’…
Lieve Ralph, Lot, Catrien, Simen, Willemijn Vervaat, Rolf, Marije, Els, Jackie,
Swook, Willemijn Wolters and Arnout. Met uitzondering van Ralph heb ik
jullie allemaal zien komen naar de Pleasure Dome. Het wordt nu tijd
om weg te gaan…, iets wat me erg zwaar valt. Samen hebben we vele
legendarische avonden gecreëerd, waarvan enkele misschien de mooi-
ste die we ooit zullen meemaken… Ik hou van jullie.
Mijn Paranimfen Simen en Els,
Lieve Simen, je kwam bij mij in huis als ‘die gekke Noor’, maar vertrok als
beste vriend… Ik hoop dat we elkaar zo vaak kunnen blijven zien als de
afgelopen twee jaar en ik ben blij dat jij vandaag naast me staat bij
mijn verdediging. Stor Klem.
Lieve Elsbeth, de dagen die we samen doorbrachten toen jij in de
Pleasure Dome kwam wonen zijn ontelbaar. Ik geniet elke keer weer
van het borrelen samen, waarmee we absoluut moeten doorgaan na
mijn verhuizen! Ik ben blij dat je me vandaag wilt bijstaan in de verde-
diging van mijn proefschrift.
Lieve Beatrijs, jij hebt met name het begin van dit onderzoek meege-
maakt, gelukkig ben je nu ook bij de afronding. Zo te zien komt alles
met ons wel goed, en ook al is het niet samen, gelukkig zien we elkaar
nog veel, en laten we dat vooral zo houden! 
Chapter 11
210
Jan, bij de afronding van mijn proefschrift is jou aanwezigheid van cru-
ciaal belang geweest; bij jou zijn is superrelaxed en samen halen we
die 10 wel… ‘il sogno ch’io vorrei sempre sognar…’
Lieve pap en mam, altijd hebben jullie mij gesteund, zelfs als dat inhield
dat jullie de Atlantische oceaan moesten overvliegen om te horen hoe
het met jullie jongste zoon ging. Ik ben erg trots op jullie en ik denk
dat jullie dat vandaag ook zijn. Bedankt voor al jullie liefde.
211
Acknowledgements
List of publications
Drs. M.A. Oudijk
Articles
1 ‘Sotalol in the Treatment of Fetal Dysrhythmias’
Oudijk MA, Michon MM, Kleinman CS, Kapusta L, Stoutenbeek Ph,
Visser GHA, Meijboom EJ.
Circulation 2000;101:2721-2726.
2 ‘Drug Treatment of Fetal Tachycardias’
Oudijk MA, Ruskamp JM, Ambachtsheer EB, Ververs FFT,
Stoutenbeek Ph, Visser GHA, Meijboom EJ.
Pediatr drugs 2002;4 (1):49-63
3 ‘Persistent Junctional Reciprocating Tachycardia in the Fetus’
Oudijk MA, Stoutenbeek Ph, Sreeram N, Visser GHA, Meijboom EJ.
J Matern Fetal Neonatal Med 2003;13:1-6
4 ‘Prenatale diagnostiek bij structurele congenitale hartafwijkingen;
effectiviteit en gevolgen’
Verheijen PM, Michon MM, Lisowski LA, Oudijk MA, Stoutenbeek
Ph, Meijboom EJ.
Ned Tijdschr Geneeskd 2002;146(48):2297-302
5 ‘Supraventriculaire tachycardieën en premature atriumcontracties bij
de foetus’
Oudijk MA, Ambachtsheer EB, Stoutenbeek Ph, Meijboom EJ.
Ned Tijdschr Geneeskd 2001;145(25):1218-9
6 ‘Transplacental pharmacokinetics and pharmacodynamics: sotalol in
the treatment of fetal tachycardias’
Oudijk MA, Ruskamp JM, Ververs FFT, Ambachtsheer EB,
Stoutenbeek Ph, Visser GHA, Meijboom EJ.
Accepted, J Am Coll Cardiol
212
Chapter 11
Submitted
7 ‘Neurological outcome of hydropic fetuses as a consequence of fetal
tachycardia’
Oudijk MA, Gooskens RHJM, Stoutenbeek Ph, de Vries LD, Visser
GHA, Meijboom EJ.
Submitted 
8 ‘The effects of intrapartum hypoxia on the fetal QT interval’
Oudijk MA, Kwee A, Visser GHA, Meijboom EJ, Rosen KG.
Submitted
9 ‘Amiodarone therapy for drug refractory fetal tachycardia’
Strasburger JF, Cuneo BF, Michon MM, Gotteiner NL, Meijboom EJ,
Deal BJ, McGregor SN, Oudijk MA, Feinkind L, Hussey M, Parilla BV.
Submitted
Abstracts
10 ‘Sotalol in the treatment of Fetal Tachycardia’
Oudijk MA, Michon MM, Kleinman CS, Kapusta L, Stoutenbeek Ph,
Visser GHA, Meijboom EJ.
Circulation Supplement I, Vol 100, No 18, Abstract 3170, 1999.
11 ‘Is there an indication for the use of sotalol in fetal tachycardia?’
Oudijk MA, Michon MM, Kleinman CS, Kapusta L, Stoutenbeek Ph,
Visser GHA, Meijboom EJ.
JACC Supplement A, Volume 35, No 2, Abstract 1192-162, 518A,
February 2000
12 ‘Sotalol in the treatment of fetal dysrhythmias’
Oudijk MA, Michon MM, Kleinman CS, Kapusta L, Stoutenbeek Ph,
Visser GHA, Meijboom EJ.
Cardiology in the Young, Volume 10, supplement 2, Abstract 26,
June 2000
213
List of publications
13 ‘Sotalol in the treatment of fetal dysrhythmias’
Oudijk MA, Michon MM, Kleinman CS, Kapusta L, Stoutenbeek Ph,
Visser GHA, Meijboom EJ.
European Society of Cardiology, Volume 21, Abstract 3409,
August 2000
14 ‘Drug treatment of fetal tachycardias’
Oudijk MA, Ambachtsheer EB, Ruskamp JM, Ververs FFT,
Stoutenbeek Ph, Visser GHA, Meijboom EJ.
Third world congress of Pediatric Cardiology and Cardiac 
Surgery 2001, Toronto, Abstract 2123, p 677.
214
Chapter 11
List of publications
215
216
Curriculum Vitae
Martijn Alexander Oudijk zag het eerste levenslicht op zaterdag 31
juli1976 `s morgens om 08.07 uur na een hele vlotte bevalling in het
Bleuland ziekenhuis te Gouda. In 1994 behaalde hij aan het Christelijk
Lyceum te Gouda zijn Atheneum diploma. In datzelfde jaar begon hij
met de studie Geneeskunde aan de Universiteit Utrecht. Zijn weten-
schappelijke stage startte hij in 1998 in het oude Wilhelmina
Kinderziekenhuis bij Dr. E.J. Meijboom. Het onderzoek naar foetale rit-
mestoornissen zette hij voort aan Yale University in New Haven, U.S.A.
onder leiding van Prof. Dr. C.S. Kleinman. In 1999 behaalde hij het doc-
toraal examen. Tijdens zijn co-assistentschappen vertrok hij in 2000
voor het Gynaecologie en Obstetrie co-schap naar Zimbabwe, en keer-
de na 1 jaar weer terug naar het Murambinda Mission Hospital te
Zimbabwe voor zijn keuze co-schap. Na zijn artsexamen op 31 augustus
2001 begon hij als arts-assistent op de afdeling Gynaecologie en
Obstetrie in het UMCU. Gedurende deze jaren vervolgde hij tevens zijn
promotieonderzoek naar foetale tachycardieën onder leiding van Dr.
E.J. Meijboom en Prof. Dr. G.H.A. Visser. In het najaar van 2002 vertrok
hij naar Göteborg, Zweden om zijn promotieonderzoek af te ronden bij
Prof. Dr. K.G. Rosén. In augustus 2003 zal hij starten met de opleiding
Gynaecologie en Obstetrie binnen het Utrechtse opleidingscluster in
het Anthonius Ziekenhuis te Nieuwegein.
Chapter 11
217
Curriculum Vitae
